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ABSTRACT

UNDERSTANDING ELEMENTS INVOLVED IN ACTIVE RACIAL AND ETHNIC
MINORITY RECRUITMENT PRACTICES FOR BIOPHARMACEUTICALSPONSORED CLINICAL TRIALS:
A SOCIO-ECOLOGICAL QUALITATIVE INQUIRY
by
REBECCA RAE JOHNSON
Seton Hall University
2020
Dissertation Chair: Terrence Cahill, Ed.D., FACHE
Inequitable participation in clinical trials continues to be a problem, and trial populations
do not always reflect the demographics of the population that the investigational product will
ultimately be treating. Because genetic differences between racial and ethnic groups affect the
safety and efficacy of new treatments, it is important that standard of care decisions are made
based on a representative population. The purpose of this study is to understand the socioecological elements that are involved in the active implementation of racial and ethnic minority
recruitment practices for biopharmaceutical-funded trials in the United States. This general
qualitative study was both descriptive and exploratory in nature and utilized semi-structured, indepth interviews for data collection. The socio-ecological model was utilized as the conceptual
framework guiding this study (McLeroy, Bibeau, Stecker, & Glanz, 1988). The interview guide
was designed to explore the perceptions, practices and experiences of 15 clinical research site
professionals related to recruiting racially and ethnically diverse trial participants. Data analysis
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utilized a coding process in which data were coded inductively. Codes were classified according
to the socio-ecological model. Following data analysis, 20 themes emerged from information
pertaining to the actual implementation of minority recruitment practices. These 20 themes
represent each level of the socio-ecological model and provide explanations for intrapersonal,
interpersonal, organizational, community and policy components. A holistic view that facilitates
a comprehensive understanding of effective minority recruitment practices is offered after
considering the interaction of the components at all levels of the socio-ecological model. These
multi-faceted findings reveal that an ecological perspective offers insight into improving access
to clinical trials by focusing on environmental change initiatives, rather than individual change
on a patient level. This study’s findings offer practical guidance for the implementation of
change initiatives in minority recruitment practices at research sites. The results of this study
demonstrate that environmental change can provide a premise for improving access to clinical
trials among minority populations.
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Chapter I
INTRODUCTION
Currently, racial and ethnic minority populations are underrepresented as participants in
most clinical trials (CISCRP, 2017; Diehl et al., 2011; Duda et al., 2011; Killien et al., 2000;
Martin, Negron, Balbierz, Bickell, & Howell, 2013; Murthy, Krumholz, & Gross, 2004; The
Society for Women’s Health Research & FDA, 2011). Aggravated by the fact that health
disparities also disproportionately affect racial and ethnic minorities (USHHS, Centers for
Disease Control and Prevention [CDC], 2011a; USHHS, CDC, 2011b), clinical trial results need
to be generalizable to a wider population that includes racial and ethnic minority groups, women,
and the elderly. To gain insight into improving health outcomes, it is imperative to have equal
representation of all members of the applicable population subgroups represented in clinical
trials. Many known barriers to minority recruitment into clinical trials contribute to this problem,
yet successful strategies used in biopharmaceutical-sponsored trials to address those barriers are
not documented in the literature. Additionally, it is important to understand how research site
staff and organizational characteristics may play a role in the successful recruitment of these
underrepresented populations. The purpose of this study is to explore the involvement of
physical and social environmental elements when investigator sites actively focus on minority
recruitment when conducting biopharmaceutical sponsored clinical trials.
Background of the Problem
Researchers conduct clinical trials to improve the standard of care for diseases and
survival rates and health outcomes in patients. These trials are designed to evaluate the safety
and efficacy of new therapies and to provide scientific evidence in support of decisions heath
care practitioners must make about the care of all affected patients. This includes how new
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therapies may affect women and members of various minority groups differently. Demographic
profiles of clinical trial participants need to be representative of the disease prevalence in order
for the results to be generalized to demographic subgroups (Diehl et al., 2011; Duda et al., 2011;
USHHS, NIH, 2001; USHHS, NHLBI, 2011). In particular, it is important to test the efficacy
and safety of potential new therapies across all racial and ethnic groups since genetic differences
occur amongst various demographic populations. This leads to variations in drug metabolism and
toxicity within different racial and ethnic groups (Hershman et al., 2003; Rotger, Csajaka, &
Telenti, 2006). For example, while angiotensin-converting enzyme (ACE) inhibitors have been
found to be effective in decreasing blood pressure in both African American and white patients
with hypertension, African Americans respond less well than white patients to such treatments
(Cohn et al., 2004). The first race-specific drug, BiDil® (isosorbide dinitrate and hydralazine
hydrochloride), was approved by the Food and Drug Administration (FDA) in 2005 for the
treatment of heart failure in African American patients when added to standard therapy. When
analyzing data from clinical trials, researchers determined that African American and white
patients had a different response to BiDil, with a treatment effect apparent in African American
patients only (Brody & Hunt, 2006; Temple & Stockbridge, 2007). Additionally, a clinical trial
examining the use of gefitinib in non–small-cell lung cancer was conducted. The investigators
found through racial and ethnic molecular profiling that gefitinib works better than the standard
of care in the treatment of patients with a specific mutation that occurs more frequently in Asian
populations (Chen, Lara, Dang, Paterniti, & Kelly, 2014; Mok et al., 2009; Paez et al., 2004).
Therefore, it is imperative that there is adequate participation in clinical trials of patients from
racial and ethnic minorities so treatment effects are tested outside of adult white males, who
represent the majority of clinical trial participants (CISCRP, 2017; Killien et al., 2000; The
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Society for Women’s Health Research & FDA, 2011). More diverse representation in clinical
trials ensures that study results can be of benefit to a wider population through the use of
evidence-based medicine.
Contributing to the problem.
Drug development process. Several factors contribute to the lack of diversity in clinical
trial participation. One probable contributor is the lengthy drug development process and the cost
of bringing a drug to market (USHHS, OIG, 2000). The drug development process takes
approximately 10 to 15 years from discovery through development (PhRMA, 2016, April). The
average cost for each successful drug that goes to market is approximately $2.6 billion dollars
(DiMasi, Grabowski, & Hansen, 2016). The drug development process is highly regulated. It
begins with a discovery process where scientists choose a molecule to target a disease, find a
drug candidate and conduct extensive laboratory tests and studies on animals to determine if the
potential drug is safe to test in humans. This discovery process typically takes between 3 and 6
years. If during the discovery process the researchers deem the drug safe and effective for testing
in humans, the drug manufacturer must file an Investigational New Drug (IND) application with
the FDA and submit their proposed clinical trial to the Institutional Review Board (IRB). Once
approval is received, the manufacturer can then begin testing the safety and efficacy of the drug
on humans through clinical trials (PhRMA, 2016, April). The drug must be tested in three phases
of clinical trials before the manufacturer is able to submit a New Drug Application (NDA) to the
FDA requesting approval to market the drug. During the Phase I clinical trial, researchers
determine the safety, pharmacokinetics and pharmacodynamics of the drug in a small group
(typically less than 100) of healthy volunteers. If researchers deem the drug safe for humans,
they then conduct a Phase II trial. Researchers administer the drug to a group of 100 to 500
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patients with the disease or condition for which the drug is being developed and gather additional
safety data, examine side effects, determine the dosing strength, as well as determine if the drug
is working by the expected mechanism of action. If the administration of the drug results in
improvements in the condition or disease, the drug is then tested with a larger group of people
with the disease (1,000 to 5,000 patients) to obtain statistically significant data about the safety,
efficacy, and benefit versus risk of use of the drug. The three phases of clinical trials generally
take 6 to 7 years for completion. Once the trials are complete and the drug is determined safe and
effective for use in humans, the manufacturer submits an NDA to the FDA. The FDA takes
between 6 months and 2 years to review the preclinical and clinical findings, proposed labeling,
and manufacturing plans before they approve the drug for use in patients. Oftentimes, the FDA
requires manufacturers to conduct Phase IV studies to evaluate long-term safety or to determine
how the drug affects a certain subgroup of patients (PhRMA, 2016, April; USHHS, NIH, 2013a).
Clinical trials play a key role in bringing new drugs to market (USHHS, OIG, 2000).
Several trends in the biopharmaceutical industry are contributing to the need for completing
clinical trials in the shortest time possible. There’s been an increase in pharmaceutical
manufacturer’s research and development (R&D) activities. Combined with the lengthy and
costly drug development process, biopharmaceutical manufacturers need to get their drugs to
market quickly. Delays in clinical trial completion result in delays in getting the product to
market. Every day that a drug is delayed in getting to market results in more than $1.4 million
dollars of potential loss in future sales (assuming projected annual sales of $500 million).
Further, clinical trial delays increase the cost of clinical development (IMS Health, 2012;
Kermani & Bonacossa, 2003; USHHS, OIG, 2000). One of the critical factors in delaying
clinical trials is not being able to recruit the necessary number of appropriate participants within
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the study timeframe. As a result, 80% of trials are delayed due to difficulties in enrollment
(Clinical Trial Arena, 2012; IOM, 2012). For example, recruitment goals were not met in time
for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT), resulting in the need to double the amount of investigator sites and extend the
recruitment period 1½ years and the follow-up period by an additional year in order to achieve
sufficient power (Pressel et al., 2001). Furthermore, half of all research sites under-perform and
only enroll between 0 and 1 patients: 20% fail to enroll a single patient and another 30% fewer
patients than expected. Overall, the majority of patients (70%) are enrolled by only 30% of
research sites (Clinical Trials Arena; 2012; IOM, 2012; PhRMA, 2015 March). As a result,
sponsors are looking for rapid recruitment and gauge a site’s recruitment ability during the siteselection process to find investigator sites that are high performers and will recruit patients
quickly (USHHS, OIG, 2000). This results in a focus on rapid enrollment and not the
prioritization of enrolling study participants in proportion with the disease prevalence being
studied.
Policy and regulation on clinical trial enrollment. Another factor contributing to the
problem of underrepresentation of minorities in clinical trials is related to policy. In an effort to
address this challenge, the National Institutes of Health (NIH), the largest government funding
body for clinical trials, instituted the Revitalization Act of 1993, which mandates the inclusion of
women and minority participants in clinical trials supported or funded by the NIH. As part of this
policy, the NIH is obligated to conduct or support outreach programs to recruit women and
members of minority groups as participants in clinical research (USHHS, NIH, 2001). The NIH’s
National Heart, Lung, and Blood Institute (NHLBI) further requires investigators to recruit
minorities in the study population in the same proportions as in the U.S. population having the
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disease entity being studied. When the prevalence of the disease being studied is unknown, the
NHLBI mandates that minority groups be represented in proportions equal to their representation
in the total U.S. population. However, the NHLBI does allow principal investigators (PIs)
seeking funding to justify why they have planned for limited diversity when these mandates are
not met (USHHS, NHLBI, 2011). It is also important to note that the majority of governmentfunded trials are epidemiologic and behavioral studies and are not designed to test investigational
treatments (Getz, 2010). Although the NIH has established a policy to enforce diverse
representation in clinical trials supported or funded by the NIH, this policy does not apply to
industry-sponsored studies. The majority of clinical trial sponsors provide details on the
demographic profiles of the participants in their NDAs, but the FDA has recently recognized
improvements are still needed and enacted the Food and Drug Administration Safety and
Innovation Act (FDASIA) in 2012. Section 907 of the FDASIA, “Reporting of Inclusion of
Demographic Subgroups in Clinical Trial and Data Analysis in Applications for Drugs,
Biological Products, and Devices,” sets forth requirements for reporting to Congress the extent to
which clinical trial participation by demographic subgroups, including sex, age, race, and
ethnicity, is included in NDAs that are submitted to the FDA. Section 907 of the FDASIA also
requires an analysis of the extent to which the inclusion of safety and effectiveness data by
demographic subgroups is included in product labeling (Food and Drug Administration Safety
and Innovation Act, 2012). The FDA has developed an action plan as part of the FDASIA to be
rolled out over the next several years in an attempt to encourage diverse participation in
biomedical research (USHHS, FDA, 2014). While the efforts of “The FDA Action Plan to
Enhance the Collection and Availability of Demographic Subgroup Data” encourage inclusion of
minorities in clinical trial research, it is not mandated, though it includes an initiative to improve
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the availability and transparency of reporting to the public the demographic composition by
subgroup in clinical trials for FDA-approved medical products (USHHS, FDA, 2014). Since
2015, this information is publically available in the Center for Drug Evaluation and Research’s
(CDER’s) Drug Trial Snapshots Summary Report (USHHS, FDA, 2019). Unfortunately, posthoc subgroup analyses conducted on clinical trial data to ascertain differential responses to an
investigational medication based on race typically cannot be conducted because the sample size
of the minority participants is often too low to achieve adequate power (Cooper & Psaty, 2005).
The FDA’s August 2013 report, “Collection, Analysis, and Availability of Demographic
Subgroup Data for FDA-Approved Medical Products,” includes an analysis of demographic
subgroup data provided in NDAs during 2011. The report noted that while approximately half of
the applications included race subset data in labeling, only a few included efficacy and safety
subset analyses. Furthermore, the analysis of subgroup data reveals that racial subgroups are
underrepresented and race composition is not always consistent with disease prevalence in the
US population. For example, while more than 13% of African American adults has diabetes,
only 2% of study participants in the type 2 diabetes mellitus (T2DM) studies included in the
report are African American. Similar to the findings by Cooper and Psaty (2005), the inclusion
of patient subgroup data did not provide sufficient data for meaningful analysis or to detect
effects in different subgroups because of low sample size limitations (USHHS, FDA, 2013;
USHHS, FDA, 2014). These findings also are confirmed by a literature review conducted by
Chen, Lara, Dang, Paterniti, and Kelly (2014). Chen et al. (2014) found that between 1.5% and
57% of clinical trial publications report their study sample by race and ethnicity; however, a
much lower percentage include an analysis of results by racial or ethnic subgroups.
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Recent public policy initiatives encourage inclusion of racially and ethnically diverse
populations in industry-funded clinical trials. In 2016, the FDA issued guidance for industry for
the “Collection of Race and Ethnicity Data in Clinical Trials.” Within this guidance, the FDA
states their expectations that “sponsors enroll participants who reflect the demographics for
clinically relevant populations with regard to age, gender, race and ethnicity. A plan to address
inclusion of clinically relevant subpopulations should be submitted for discussion to the Agency
at the earliest phase of development and, for drugs and biologics, no later than the end of the
phase 2 meeting” (USHHS, FDA, 2016, p. 3). For clarity, this guidance by the FDA does not
issue a mandate but does provide expectations regarding trial enrollment. In addition, in
fulfillment of a stipulation within the FDA Reauthorization Act of 2017 (FDARA) regarding
expanded access, in 2019 the FDA issued draft guidance for industry, “Enhancing the Diversity
of Clinical Trial Populations—Eligibility Criteria, Enrollment Practices, and Trial Designs.” The
primary focus of this guidance is to broaden eligibility criteria in clinical trials to better reflect
the population most likely to receive the drug. For example, patients with concomitant illnesses
generally are excluded from participation based on the inclusion and exclusion criteria set forth
by the researchers (USHHS, FDA, 2019 June).
Statement of the Problem
Despite efforts of the NIH Revitalization Act of 1993 (2001) and FDASIA (2012),
disparities exist in clinical trial participation with African Americans, Asian Americans and
Hispanic/Latino Americans underrepresented in most studies (Chen, Lara, Dang, Paterniti, &
Kelly, 2014; CISCRP, 2017; Diehl et al., 2011; Duda et al., 2011; Martin, Negron, Balbierz,
Bickell, & Howell, 2013; The Society for Women’s Health Research & FDA, 2011).
Historically, both non-minority and minority women have been underrepresented in clinical
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research studies (Bennett, 1993; Killien et al., 2000; Murthy, Krumholz, & Gross, 2004). This is
a significant problem because minority women are disproportionately affected by disease
(USHHS, NIH, NCI, 2019; USHHS, Healthy People 2020, 2014). Participation disparities are
evident in both government-funded and industry-funded trials. The literature varies with regards
to minority participation in government-funded clinical trials. Some sources indicate that overall
minority enrollment in NIH-funded studies is closely proportional to the US population
(CISCRP, 2017; NIH, 2013c; The Society for Women’s Health Research & FDA, 2011). In fact,
the NIH (2013c) reports that 36% of minorities were enrolled in government-funded clinical
research in 2012. According to the US Census Bureau (2012), minorities represented 37% of the
US population at that time. However, there are also several examples of government-funded
trials in which minorities are underrepresented, despite the fact that the majority of NHLBI PIs
with active studies believe it is important to include racial and ethnic minority groups as
participants in their research (Corbie-Smith, Durant, & St. George, 2006). For example, in 2005,
Fisher et al. (2005) conducted a government-funded trial to assess the effect of tamoxifen as a
preventive therapy for breast cancer in 13,388 patients. Of these patients, 96.5% of the
participants were white, whereas only 3.5% were African American or an unspecified minority.
Furthermore, in a 2004, Murthy, Krumholz, and Gross (2004) conducted a clinical trial that
analyzed enrollment in National Cancer Institute (NCI)-funded trials. They concluded that fewer
Hispanics and African Americans participate in cancer clinical trials as compared with the
percentage of cancer incidence among those populations in the United States. This is further
confirmed by a 2010 Institute of Medicine (IOM) report, which stated that almost 90% of clinical
trial participants enrolled into publically funded NCI clinical trials prior to 2006 were white
when comparing enrollment by race. Furthermore, 8% of the NCI trial participants were African
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American and less than 3% were Asian American (IOM, 2010). Enrollment by ethnicity prior to
2006 was 94.4% non-Hispanic white and 5.6% Hispanic. Enrollment of minority populations
into NCI clinical trials improved slightly in 2013 with 25% minority participation, yet these trials
are still falling short of enrollment that is representative of the US population (National
Academies of Sciences, Engineering, and Medicine, 2016). Chen et al. (2014) also found that
only 1% of NCI-sponsored clinical trials focus primarily on racial or ethnic minority populations.
Instead, the focus is placed on cancer types and not the populations who are disproportionately
affected by those cancers.
Racial and ethnic minorities are underrepresented in most industry-sponsored studies, as
well. For example, in a 2006 study sponsored by the pharmaceutical manufacturer
GlaxoSmithKline comparing the efficacy of different treatments in recently diagnosed type 2
diabetes patients, 88% of the trial participants were white. Yet, more than 13% of African
American adults as well as 13% of Hispanic adults are diagnosed with diabetes (Viberti et al.,
2006; USHHS, CDC, 2020). Additionally, according to the 2019 CDER Drug Trial Snapshots
Summary Report in which 48 newly approved drugs were reviewed, 72% of the trial participants
on average were white. Of note, these were global trials and only 40% of the demographic data is
based on US participation (USHHS, FDA, 2019). Overall, 83% of domestic industry-funded trial
participants are non-Hispanic white, considerably greater than the proportion of the US
population that they represent (CISCRP, 2017; The Society for Women’s Health Research &
FDA, 2011; US Census Bureau, 2012). Speakers participating in the “Dialogues on Diversifying
Clinical Trials” workshop convened by the Society for Women’s Health Research and the FDA
(2011) highlighted the under-representation of minorities in clinical trials. Clinical trials have
representation from 1% of the Hispanic population, yet 16% of the US population was Hispanic
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at that time. African Americans comprise 5% of clinical trial participants, much less than the
12% of the US population they represented at the time (Coakley et al., 2012; The Society for
Women’s Health Research & FDA, 2011). Asian Americans are also underrepresented in clinical
trials. Kwiatkowski, Coe, Bailar, and Swanson (2013) conducted a systematic review of both
federally funded and industry funded clinical trials and reported that among the cancer treatment
clinical trials that reported on race and ethnicity between 2001 and 2010, 3% of trial participants
were Asian American. This is a dramatic increase from 1990-2000 when only 0.04% of cancer
treatment trial participants were Asian American, yet, according to the US Census Bureau
(2019), 6% of the US population is Asian. These facts indicate that clinical trial participation is
not representative of the US population or the prevalence of the disease being studied.
The biopharmaceutical industry is currently the largest funder of drug R&D, and as of
2008, accounted for 90% of all spending on clinical trial testing of investigational drugs and
devices in the United States (Getz, 2010; PhRMA, 2016 April). Members of Pharmaceutical
Researchers and Manufacturers of America (PhRMA) alone invested nearly $80 billion in R&D
in 2018 (PhRMA, 2019). Since 2006, there has been a 43% increase in industry-sponsored trials,
while at the same time a 24% decrease in NIH-funded studies (Ehrhardt, Appel, & Meinert,
2015; Johns Hopkins Bloomberg School of Public Health, 2015). Industry researchers conducted
more than 6,000 clinical trials in the United States in 2013, whereas the NIH provided funding
for just over 1,000 trials that same year (Ehrhardt, Appel, & Meinert, 2015; PhRMA, 2015
March; USHHS, NIH, 2018, June). Therefore, a significant majority of clinical trials are
sponsored by the biopharmaceutical industry and, as such, investigators are not mandated to
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include participation from diverse populations. Accordingly, this study addresses the
underrepresentation of racial and ethnic minority populations enrolled in clinical trials sponsored
by the biopharmaceutical industry.
Purpose of the Study
While the underrepresentation of racial and ethnic minority participants in industryfunded clinical trials is a problem, historically, there have been occasions of successful
enrollment of diverse populations. Notably, NitroMed, Inc., a privately held pharmaceutical
company that is no longer in existence (businesswire, 2008; Mitchell et al., 2011), successfully
enrolled 1,050 African American participants into their African American Heart Failure Trial (AHeFT). The participating sites actively recruited only African Americans. However, the specific
recruitment strategies leading to the successful recruitment of this minority group are not
discussed in the literature, nor are details on recruitment strategies related to any other industryrelated trial recruiting minority participants discussed in the literature. The purpose of this study
is to understand the socio-ecological elements that are involved in the active implementation of
racial and ethnic minority recruitment practices for biopharmaceutical-funded trials in the United
States.
Conceptual Framework
A conceptual framework to view phenomena enables a systematic exploration of
situations in order to better understand and explain the dynamics of events (USHHS, NIH, NCI,
2005). The conceptual framework used as a lens for this study is the socio-ecological model
(McLeroy, Bibeau, Stecker, & Glanz, 1988). Describing the study of an organization as a system
helps to better understand the applicability of the socio-ecological model for this study. Aristotle
claimed that “the whole was more than the sum of its parts” and that knowledge is derived from
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understanding of “the whole.” This worldview laid the foundation for the organization of general
systems theory by Ludwig von Bertalanffy in which he recognized that investigating single parts
and processes cannot provide a complete explanation of phenomena. Rather, the ensemble of the
components and the relations existing between their interactions must be understood in order to
derive the properties and modes of action of higher levels from their components (von
Bertalanffy, 1950; von Bertalanffy, 1972).
Systems can be defined as either open or closed. In an open system, there is an inflow
and outflow of energy to the environment, resulting in a change to the components. An open
system moves towards a steady state through the continuous inflow and outflow of energy with
the environment. In contrast, there is no energy exchange from the environment in closed
systems and eventually a state of equilibrium is reached. The biggest difference between open
and closed systems is characterized by the concept of equifinality. In an open system, an end
state can be reached by many potential means, meaning that similar results can be achieved with
different initial conditions and in different ways. Whereas closed systems cannot behave
equifinally because the final state of the system is dependent on the initial components, which
lead to the same final result (Katz & Kahn, 1978; von Bertalanffy, 1950).
General systems theory initially was applied to biology but now extends to several other
disciplines, including social sciences. The principles of general systems theory apply to all
systems, defined as “a set of elements standing in interrelation among them and with the
environment” (von Bertalanffy, 1972, p. 417). Systems can be distinguished as being real,
conceptual or abstract. From a social science perspective, organizations are considered systems
(Foster –Fishman, Nowell, & Yang, 2007; Katz & Kahn, 1978). Organizations are categorized as
real systems, that is, entities that can be inferred by observation and exist independently of an
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observer. However, many of the interactions between the component elements of the
environmental landscape that the organization is part of are conceptual constructs. General
systems theory provides a way of seeing this organized whole through the dynamic interaction of
multiple factors, which von Bertalanffy suggests were previously overlooked (1950, 1972). In
fact, according to open systems theory, environmental influences are necessary social system
components. Therefore, to understand an organization, its environmental influences must also be
considered (Katz & Kahn, 1978).
A system can be viewed as a hierarchy composed of the system itself, components of the
system (subsystems) and the larger system surrounding the system (supra-system). Each level of
the system is influenced by and influences other parts of the system within the hierarchy. When
using a systems perspective, it is up to the researcher to define the hierarchy of systems,
considered to be the “whole,” including the relationship between the system, subsystems and
supra-system (Benko & Sarvimaki, 2000). When using a systems perspective, real-world
complexities are viewed as whole entities embedded in context. Thinking holistically of a system
as a whole with both interconnected and interdependent parts is essential with systems theory
because a change in one part leads to changes in other parts and the system itself. As such, a
system as a whole cannot be understood by isolating different parts of the system. Instead,
synthetic thinking is used to better understand the interactions of its parts, not the actions of its
parts taken separately (Patton, 2002). This allows for simultaneous analyses of relationships on
and between different system levels (Benko & Sarvimaki, 2000). The context for human actions
in organizations can be examined and better understood using a systems perspective, since a
system change is necessary to change an individual within the system.
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A system needs to be understood in its natural ecosystem, considering the ecological,
cultural, political, economic and policy environments of which the system is a part.
Organizations are social systems that consist of the patterned activities of individuals and should
be studied in the context of their environment relations, both the social and physical environment
within the organization, as well as the environment the organization is a part of (Katz & Kahn,
1978; McLaren & Hawe, 2005; Patton, 2002). An ecological perspective includes a
comprehensive context of the environment, including physical, social, cultural and historical
aspects, as well as the attributes and behaviors of people within this environment. Social ecology
offers a perspective for understanding these interrelations, stressing the multiple dimensions,
levels and complexity of situations within the corresponding environment. Specifically, a socioecological model uses systems thinking in trying to understand the interacting and
interdependent elements that form a whole (McLaren & Hawe, 2004; Stokols, 1992).
A socio-ecological model is a conceptual framework that focuses on the
interrelationships between individuals and their social and physical environment under the
premise that behavior is both affected by and affects the environmental system of which it is a
part. The ecological environment is a nested arrangement of structures that can affect and be
affected by individual and organizational behavior at multiple levels (Bronfenner, 1977;
McLeroy, Bibeau, Stecker, & Glanz, 1988; Trickett, 2009). These levels of influence are
(McLeroy et al., 1988):
1. Intrapersonal factors: characteristics of an individual such as knowledge, attitudes,
behavior, self-concept and skills
2. Interpersonal factors: social network and social support systems, including family, friends
and work group
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3. Organizational factors: social institutions with organizational characteristics and rules
and regulations for operation
4. Community factors: relationships among organizations, institutions and informal
networks within defined boundaries, including face-to-face primary groups to which an
individual belongs. This includes family, social networks, churches and neighborhoods,
all of which may be sources of social identity and influence the community’s norms and
values, as well as individual beliefs and attitudes. This also includes relationships among
organizations as a means to influence community awareness
5. Public policy: local, state, and national laws, policies and procedures
Application of a socio-ecological model. Grounds for using a socio-ecological model
have been made for developing effective health promotion programs for overcoming public
health problems. Most public health challenges are too complex to be understood using a single
level of analysis and, therefore, require a comprehensive approach that includes individual,
organizational, cultural, community and regulatory levels (Stokols, 1996). Historically, the
socio-ecological model has been used for understanding individual behavior in an effort to
develop behavior change interventions targeted at individuals and delivered through health
promotion programs (ACHA, 2016; Baert, Gorus, Calleeuw, DeBacker, & Bautmans, 2016;
Daley at al., 2011; Holt, Rung, Leon, Firestein, & Krousel-Wood, 2014; Mahadevan et al., 2014;
McLeroy, Bibeau, Stecker, & Glanz, 1988; Sword, 1999). Applications of the socio-ecological
model also have been documented in the clinical trial literature, primarily as a framework for
identifying and addressing barriers to and facilitators of clinical trial participation (Chakrapani,
Newman, Singhal, Jerajani, & Shunmugam, 2012; Elder et al., 2007; Frew et al., 2014; Salihu,
Wilson, King, Marty, & Whiteman, 2015; Wallington et al., 2016; Wells & Zebrack, 2008).
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Healthy People 2020 recognizes that the interrelationships between biological, social, economic
and environmental factors influence the ability of individuals and communities to progress
towards the achievement of meeting the objectives set forth for eliminating health disparities
(USHHS, Healthy People 2020, 2020b).
Much of the wide application of the socio-ecological model used for developing health
promotion programs focuses on analyzing behavior change strategies on an individual level in an
effort to change individuals (Stokols, 1992). However, human behavior is influenced by the
environmental system of which it is a part. Instead of focusing on individual behavior change,
the focus should be on changing the social and physical environment that reinforces unhealthy
behaviors; therefore, change may be needed at the organizational and environmental levels
(McLeroy, Bibeau, Stecker, & Glanz, 1988; Stokols, 1992). Accordingly, the socio-ecological
model also is used to create health promotion initiatives that focus on changing the
environmental system in order to create an environment that promotes healthy behavior (Glanz
& Mullis, 1988; Monahan & Scheirer, 1988; Moore, Murphy, Tapper, & Moore, 2010). One
such program strived to create opportunities for the general population to follow a healthy diet.
While the goal of the program initiatives was population health, the researchers used an
environmental approach to target the multiple levels of an ecological model that would impact
population access to following a healthy diet, rather than targeting individual behavioral factors
(Glanz & Mullis, 1988). Moore, Murphy, Tapper, and Moore (2010) investigated how the
availability of food at lunchtime in primary schools was influenced by different socio-ecological
levels, including national policy, Local Education Authority policy, priorities and practices of
catering staff within each school, as well as the social interactions between the catering staff and
children. Interviews were held at an organizational level with the Local Education Authority and
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primary school catering managers to better understand influencers at multiple levels of the socioecological framework. Monahan and Scheirer (1988) also used a social ecological approach to
demonstrate that by considering a multitude of factors and sources of influence at different
levels, state health department dental offices could successfully act as linking agents in the
adoption of a fluoride mouth rinse program at an organizational level (public schools).
Improving population health by implementing health promotion programs through the
influence of social and environmental changes acting synergistically at multiple levels of a socioecological framework provides a premise for exploring ways to promote participation of
minorities into clinical trials using socio-ecological elements. Hawe, Shiell and Riley (2009)
suggested that a public health prevention program be viewed as an intervention within the
ecological system in which it was introduced. In doing so, the intervention should be viewed in
the context of the setting in which it was introduced (Hawe, Shiell & Riley, 2009). Glanz and
Mullis (1988), Moore, Murphy, Tapper, and Moore (2010) and Monahan and Scheirer (1988) all
shared an alternative approach to improving population health by understanding the multiple
levels of influence that impact providing access to the intervention. Similar to the approaches
described in the literature by these authors, the socio-ecological model could guide a better
understanding of the elements involved in overcoming the problem of underrepresentation of
minorities in clinical trials. Specifically, if we view minority recruitment practices as a health
promotion intervention to improve minority access to participate in clinical trials, clinical
research staff could be viewed as the linking agent providing the vehicle for increasing minority
participation. The socio-ecological model could then be used to explore how the behavior and
practices of individuals involved in clinical research who actively recruit minority participants
into clinical trials are influenced by and influence environmental elements. This would offer a

31
better understanding of the contextual factors that promote an environment inviting clinical trial
participation among minorities. Understanding the multiple levels of influencers on the
successful implementation of minority recruitment practices would help researchers provide
opportunities for minority populations to participate in clinical trials in the future by increasing
access to trials.

Figure 1. Application of a socio-ecological model when viewing minority recruitment practices
as a health promotion intervention. Adapted from McLeroy, Bibeau, Steckler, & Glanz, 1988.
Using a socio-ecological model to explore from a provider perspective the
interrelationships between individuals who are involved in clinical research and who actively
recruit minority participants and environmental elements specific to recruiting minority
participants into clinical trials will help frame an approach to increase minority participation. In
literature reviewed, no studies were found that explored minority participation in clinical trials
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using a socio-ecological model from a provider perspective. Delivery of care from the service
provider viewpoint is determined by multiple factors operating within the socio-ecological
framework. Healthcare utilization is understood more wholly when utilizing a socio-ecological
approach (Daley et al., 2011; Sword, 1999). We can assume from this that similar to
understanding delivery of care from a service provider perspective, we can also understand
minority recruitment from a service provider perspective under the realm of a socio-ecological
model.
Research Question
There is one overarching research question guiding this study:
What are the socio-ecological elements that are involved in the active implementation of
racial and ethnic minority recruitment practices for biopharmaceutical-funded trials in the United
States?
Utilizing the socio-ecological model as a framework, the five sub-questions address
different components of the model to support the overarching research question:
1. How are intrapersonal site staff elements involved in the active implementation of
minority recruitment practices for biopharmaceutical-funded trials in the United
States?
2. How are interpersonal site staff elements involved in the active implementation of
minority recruitment practices for biopharmaceutical-funded trials in the United
States?
3. How are organizational elements involved in the active implementation of minority
recruitment practices for biopharmaceutical-funded trials in the United States?
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4. How are community elements involved in the active implementation of minority
recruitment practices for biopharmaceutical-funded trials in the United States?
5. How are policy elements involved in the active implementation of minority
recruitment practices for biopharmaceutical-funded trials in the United States?
Significance of the Study
The minority population residing in the United States is continually growing, and, in fact,
minorities are expected to be in the majority by 2044. Additionally, the Hispanic population is
expected to grow from 17% of the population in 2014 to 29% of the population by 2060.
Meanwhile, the non-Hispanic white population is projected to drop from 62% in 2014 to 44% by
2060. The African American population is expected to grow from 13% in 2014 to 14% by 2060
and the Asian population will nearly double; it is projected to grow from 5% in 2014 to 9% of
the US population by 2060 (US Census Bureau, 2015). Based on these projections, the
composition of the US population is drastically changing and, if these projections hold true, we
will have two main population groups in 2060 (Hispanic and non-Hispanic white).
The Healthy People 2020 goals include achieving health equity, eliminating disparities,
and improving the health of all population groups (USHHS, Healthy People 2020, 2020b).
Despite the goals of Healthy People 2020 and other such initiatives, health disparities still exist
and disproportionately affect members of racial and ethnic minority populations. In fact,
minorities have the highest rates of incidence and mortality of chronic disease (USHHS, CDC,
2009), and minority women are disproportionately affected by disease (USHHS, CDC, 2011a).
According to the Racial and Ethnic Approaches to Community Health across the U.S. (REACH
U.S.) Risk Factor Survey results, residents of minority communities have a lower socioeconomic
status, more barriers to healthcare access, and greater risks for and burden of diseases compared
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with the general populations living in non-minority communities (USHHS, CDC, 2011a). Health
disparities among minority populations not only apply to differences in disease prevalence, but
also to the severity and rate of progression of disease (Ejiogu et al., 2011; USHHS, CDC,
2013a). Several examples of disease-specific healthcare disparities include:
•

Healthy People 2020 includes objectives to reduce the prevalence of hypertension
among adults to 26.9% and increase blood pressure control among adults with
hypertension to 64.1% (USHHS, Healthy People 2020, 2020c). However, the rate of
controlled blood pressure is lower among Hispanics (34.4%) and non-Hispanic blacks
(42.5%) than non-Hispanic whites (52.6%) (USHHS, CDC, 2013a).

•

When looking at coronary heart disease (CHD), the Morbidity and Mortality Weekly
Report (MMWR) reported that death rates from CHD and stroke are declining, but
there are still disparities in the rate of death from these events in racial and ethnic
groups (USHHS, CDC, 2013a).

•

Cardiovascular disease (CVD) is the leading cause of death in the United States and
non-Hispanic black adults are at least 50% more likely to die prematurely of stroke or
heart disease then non-Hispanic whites (USHHS, CDC, 2013a).

•

Adult diabetes is also higher among Hispanic and non-Hispanic blacks than among
non-Hispanic whites. (USHHS, CDC, 2013a). For example, more than 13% of
Hispanic adults in the United States have type 2 diabetes, compared with 7.9% of
non-Hispanic white adults (USHHS, CDC, 2020).
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•

Older blacks and Hispanics are disproportionately more likely to have Alzheimer’s
disease than whites. In fact, older blacks are twice as likely and older Hispanics are
one and one half times as likely than older whites to suffer from the disease
(Alzheimer’s Association, 2020).

•

Overall cancer incidence is highest among African Americans compared with all
other racial and ethnic groups, and the death rate from cancer is higher for African
Americans than for whites. The higher incidence and death rates of cancer among
African Americans (and Hispanics) can be contributed to lack of medical coverage,
unequal access to healthcare services and cancer treatments, lower socioeconomic
status and barriers to screening (USHHS, NIH, NCI, 2019).
o Although the incidence rate of breast cancer is similar in African American
and white women, African American women are most likely to die from the
disease (USHHS, NIH, NCI, 2019).
o American Indian/Alaska Native and Hispanic women experience the highest
cervical cancer incidence rates, yet African American women have the highest
death rates from cervical cancer compared with all other racial and ethnic
groups (USHHS, NIH, NCI, 2019).
o Similarly, due to genetic factors, African American men are more than twice
as likely than white men to die from prostate cancer (USHHS, NIH, NCI,
2019).
o African American men have the highest incidence and death rates for lung
cancer (USHHS, NIH, NCI, 2019).
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Not only do health disparities cause greater risk for disease, disparities in healthcare
access and quality create an additional cost burden on the system. According to a study by the
Joint Center for Political and Economic Studies, “eliminating health inequalities for minorities
would have reduced indirect costs associated with illness and premature death by more than $1
trillion between 2003 and 2006…and reduced direct medical care expenditures by $229.4 billion
for the years 2003 to 2006 ” (LaVeist, Gaskin, & Richard, 2009).
Despite the fact that the United States has a growing minority population that faces a
disproportionate rate of healthcare disparities, minority populations are significantly
underrepresented in industry-funded clinical trials. As previously discussed, 83% of industryfunded clinical trial participants are non-Hispanic white, leading to a pool of trial participants
who are not representative of the US population or the disease being studied (Bennett, 1993;
CISCRP, 2017; Coakley et al., 2012; Cooper & Psaty, 2005; Diehl et al., 2011; Duda et al.,
2011; Killien et al., 2000; Martin, Negron, Balbierz, Bickell, & Howell, 2013; Murthy,
Krumholz, & Gross, 2004; The Society for Women’s Health Research & FDA, 2011; USHHS,
FDA, 2013; USHHS, FDA, 2014; US Census Bureau, 2015). One reason leading to this problem
is that 90% of clinical trial funding testing investigational medicines and devices in the United
States is through industry and, as such, a significant majority of clinical trials do not mandate
diverse participation (Getz, 2010; PhRMA, 2016 April; USHHS, FDA, 2014).
This is especially important with the implementation of the Affordable Care Act (ACA).
It was expected that many of the 46 million previously uninsured nonelderly Americans would
have access to healthcare and prescription medicines as a result of the ACA, a majority of which
were expected to be minority populations, especially Hispanics (The Henry J. Kaiser Family
Foundation [KFF], 2013a; KFF, 2013b; KFF, 2019). In 2010 when the ACA was signed into
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law, approximately 50 million nonelderly Hispanics were residing in the United States. Prior to
the ACA, 33% of nonelderly Hispanic individuals did not have health insurance, making this
group of more than 15 million people the highest uninsured minority racial or ethnic group
within the United States (KFF, 2020). It was expected that the majority of these uninsured
individuals and families would have access to healthcare as a result of the ACA (KFF, 2013a).
As of 2016, over 19 million uninsured people gained coverage under the ACA. There was a
greater decline in the uninsured rate among African Americans and Hispanics than among whites
(KFF, 2019). The result is that minorities increasingly have access to prescription medications
primarily tested on adult white males (Killien et al., 2000). While significant progress has been
made, there are still healthcare coverage disparities. According to the Kaiser Family Foundation
(2020), 19% of nonelderly Hispanics and 11.5% of nonelderly African Americans remain
uninsured, compared with 7.5% of nonelderly whites.
Given the growing minority population in the United States, coupled with the
disproportionate rate of lack of healthcare access and healthcare disparities, it is important to
understand how new medications may affect various populations. The current rate of minority
participation in clinical trials does not allow for understanding genetic differences in treatment
(Cooper & Psaty, 2005; USHHS, FDA, 2013; USHHS, FDA, 2014; Hershman et al., 2003;
Rotger, Csajaka, & Telenti, 2006). There are differences in drug metabolism and toxicity in
diverse racial and ethnic groups (Brody & Hunt, 2006; Cohn et al., 2004; Hershman et al., 2003;
Rotger, Csajaka, & Telenti, 2006; Temple & Stockbridge). Therefore, there is an unmet need for
evidence-based treatments that are relevant for all applicable populations.
In summary, public health is “the science and art of promoting health, preventing disease
and prolonging life through the organized efforts of society.” This includes creating supportive
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environments for health (WHO, 1998). Sallis, Bauman, & Pratt (1998) recommend
environmental and policy interventions based on ecological models as a potential means to
influence health behavior at a population level. Using the socio-ecological model to structure
public health behavior change initiatives targeting the environmental system in order to create an
environment that promotes healthy behavior have proven successful (Glanz & Mullis, 1988;
Monahan & Scheirer, 1988; Moore, Murphy, Tapper, & Moore, 2010).
To achieve the Healthy People 2020 goals of eliminating health disparities, several
objectives need to be met. One Healthy People 2020 imperative is to improve access to quality
healthcare services, by increasing the proportion of people who receive appropriate evidencebased clinical preventive services (USHHS, Healthy People 2020, 2020d). Without testing
medications on those who ultimately will be prescribed them creates a dilemma in that minority
populations are not receiving quality healthcare or evidence-based services when genetic
differences in drug metabolism are not accounted for. A lack of a diverse representation in
industry-funded trials means that minority populations need to be better represented (USHHS,
FDA, 2014). Given the disparities in minority enrollment into industry-funded trials, it is clear
that industry just has not been able to address this need appropriately. Examples in the literature
of successful recruitment of minorities into NIH-funded studies, which will be discussed in the
next chapter, provide optimism that parity in trial participation can be achieved. Obtaining
perspectives from industry-funded clinical research staff members who specifically focus on
recruiting minorities will provide other researchers with guidance for accruing minority
participants. Therefore, this study will address this significant health problem of
underrepresentation of minorities in clinical trials by facilitating a better understanding of
elements involved with actively recruiting minority participants into industry-funded clinical
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trials. Additionally, this study will provide unique insights from published studies that relate to
minority recruitment factors of success involving NIH-funded trials. To the researcher’s
knowledge, there is no published peer-reviewed data on successful minority recruitment
strategies involving industry-sponsored trials.
Operational Definitions
The following definitions are important to understanding this study:
1. Health disparity is defined as “a particular type of health difference that is closely
linked with social, economic and/or environmental disadvantage. Health disparities
adversely affect groups of people who have systematically experienced greater
obstacles to health based on their racial or ethnic group; religion; socioeconomic
status; gender; age; mental health; cognitive, sensory, or physical disability; sexual
orientation or gender identity; geographic location; or other characteristics
historically linked to discrimination or exclusion” (USHHS, Healthy People 2020,
2020a).
2. Minority is defined as a race and ethnicity other than non-Hispanic white (United
States Census Bureau, 2011).
3. “Hispanic” or “Latino” refers to “a person of Cuban, Mexican, Puerto Rican, South or
Central American, or other Spanish culture or origin regardless of race” (United
States Census Bureau, 2011).
4. Informed consent is defined as a “person’s voluntary agreement, based upon adequate
knowledge and understanding, to participate in human subjects research or undergo a
medical procedure” (USHHS, NIH, 2013b).
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5. Health literacy is defined as “the degree to which an individual has the capacity to
obtain, communicate, process and understand basic health information and services to
make appropriate health decisions” (USHHS, CDC, 2019).
6. Betancourt, Green, Carrillo and Ananeh-Firempong (2003) define cultural
competence in health care as “understanding the importance of social and cultural
influences on patients’ health beliefs and behaviors; considering how these factors
interact at multiple levels of the health care delivery system; and, finally, devising
interventions that take these issues into account to assure quality health care delivery
to diverse patient populations.” Specific to research centers, “cultural competence
requires that they have a defined set of values and principles and demonstrate
policies, structures, practices, behaviors and attitudes that enable them to work
effectively cross-culturally” (Wallington et al., 2016).
7. Clinical trial is defined as “a research study in which one or more human subjects are
prospectively assigned to one or more interventions (which may include placebo or
other control) to evaluate the effects of those interventions on health-related
biomedical or behavioral outcomes.” Biomedical clinical trials of an experimental
drug, treatment, device or behavioral intervention may proceed through four phases:
•

Phase I. Investigators test a new biomedical intervention in a small group of
[healthy volunteers] (e.g., 20-80) for the first time to determine efficacy and
evaluate safety (e.g., determine a safe dosage range and identify side effects).

•

Phase II. Investigators study the biomedical or behavioral intervention in a larger
group of people (several hundred) to determine efficacy and further evaluate
safety.
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•

Phase III. Investigators determine efficacy of the biomedical or behavioral
intervention in large groups of people (from several hundred to several thousand)
by comparing the intervention to other standard or experimental interventions, as
well as monitor adverse effects and collect information that will allow the
interventions to be used safely.

•

Phase IV. These studies are conducted after the intervention has been marketed
and are designed to monitor the effectiveness of the approved intervention in the
general population and to collect information about any adverse effects associated
with widespread use (USHHS, NIH, 2013a).

8. Principal Investigator (PI) is defined as the individual who is responsible and
accountable for conducting the clinical trial. The PI assumes responsibility for
analyzing the research data and reporting results (USHHS, NCI, n.d.).
9. Study Coordinator is defined as a specialized research professional who supports,
facilitates and coordinates the daily clinical trial activities under the direction of the
PI (Washington University in St. Louis, 2009).
10. US biopharmaceutical industry: companies engaged in researching, developing,
manufacturing and marketing drugs and biologics for human or veterinary use. Both
pharmaceutical and biopharmaceutical manufacturers are classified as
biopharmaceutical companies (United States Department of Commerce, 2016; United
States Department of Commerce, 2020).
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11. Health promotion: “the process of enabling people to increase control over, and to
improve their health,” (World Health Organization [WHO], 1998); health promotion
is further defined by WHO, indicating that it moves beyond the focus on individual
behavior towards a wide range of social and environmental interventions.
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Chapter II
LITERATURE REVIEW
Findings from the literature search demonstrate that recruiting a representative number
of racial and ethnic minority participants into clinical trials continues to be a challenge,
especially in biopharmaceutical-sponsored trials (Baquet, Commiskey, Mullins, & Mishra, 2006;
CISCRP, 2017; Diehl et al., 2011; Duda et al., 2011; Killien et al., 2000; Mak, Law, Alvidrez, &
Perez-Stable, 2007; Martin, Negron, Balbierz, Bickell, & Howell, 2013; Murthy, Krumholz, &
Gross, 2004; Simon et al., 2004; The Society for Women’s Health Research & FDA, 2011).
Furthermore, literature discussing minority recruitment from the perspective of industry-funded
trials is not available, further contributing to the uniqueness of this study and the need to share
experiences of those industry researchers who are contributing to minority recruitment with the
wider research community. Several themes emerged from the literature related to clinical trial
recruitment trends that further explain the disparities in minority participation and the gaps in the
literature that this study is addressing. A discussion on the findings from the literature review
follows.
Clinical Trial Recruitment Themes
Clinical trial recruitment disparities. Minorities are not informed of clinical trials or
asked to participate as often as whites (Baquet, Commiskey, Mullins, & Mishra, 2006; Simon et
al., 2004). For example, in an analysis comparing independent predictors of clinical trial
recruitment between respondents who identified themselves as being either African American or
white, Baquet et al. (2006) found that African Americans were significantly less likely to be
recruited to a clinical trial than their white counterparts. Simon et al. (2004) had similar findings.
They found that African American breast cancer patients were half as likely to be offered a
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clinical trial compared with their white American counterparts (21% and 42%, respectively), and
only 22% of minority women from other racial groups were offered participation. In their
analysis, the researchers found that the most common reasons for not being offered clinical trial
participation were PIs’ perceptions that they were “likely to be ineligible,” “lack of available
protocols for disease stage,” and “concern about compliance.” African American patients were
more likely to be considered ineligible than white or other race patients (61% and 53%,
respectively). The most frequent reasons cited by investigators for why African American
patients were considered likely to be ineligible and not offered a trial were poor performance
status and inadequate organ function, whereas white and other race patients were considered
ineligible because of prior or current treatment, or they were seeking a second opinion only.
Adams-Campbell et al. (2004) also found that a major reason for excluding African American
patients from cancer clinical trials was because of existing comorbidities. All of the five patients
listed by Simon et al. (2004) who were not offered enrollment in a trial because the PI considered
them likely to be non-compliant were African American.
The largest magnitude of cancer burden disparities is among racial and ethnic minority
populations (USHHS, NIH, NCI, 2019). In an analysis conducted by Diehl et al. (2011), the
researchers found that studies for early-stage cancers were less likely to recruit African
American and Hispanic American participants. For example, African American and Hispanic
Americans in an early-stage breast cancer study comprised less than 10% of participants. Two
advanced-stage breast cancer studies, however, included larger proportions of African American
and Hispanic American participants (15% and 28%). This suggests a disparity in cancer
screening and early detection efforts in minority populations, which ultimately decreases the
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number of minorities who are considered eligible to participate in studies with early-stage
disease inclusion criteria (Diehl et al., 2011).
While most clinical trial result publications do not specify enrollment by race and
ethnicity, of those that do, the majority do not offer enrollment to minority populations.
Oftentimes, these recruitment disparities lead to a misdirected conclusion that racial and ethnic
minorities are less willing to participate in clinical trials. For example, Wendler et al. (2006)
analyzed consent rates by race and ethnicity of those individuals who were actually invited to
participate in a coronary artery surgery study that enrolled 99% non-Hispanic white patients and
1% minority patients. Although only 1% of the clinical trial participants were minority patients,
individuals from minority groups actually agreed to participate at a significantly higher rate than
non-Hispanic white patients who were asked to participate.
Clinical trial participation disparities. Baquet, Commiskey, Mullins, and Mishra
(2006) utilized telephone interviewing to determine attitudes, awareness, and knowledge of
clinical trials, as well as examine predictors of clinical trial recruitment and participation for
adults residing in Maryland’s underserved geographic areas. The researchers conducted an
analysis that compared respondents who self-identified their race as either African American or
white who were recruited into clinical trials. They looked at nine factors considered as enabling
factors to clinical trial participation, including reimbursement, insurance coverage,
transportation, childcare, greater knowledge, time constraints, anonymity, follow-up care and
additional medical care. For most of these enabling factors, they found that African Americans
were less likely than their white counterparts to be influenced to participate. Factors contributing
to clinical trial participation among African Americans and those self-identifying as “other” for
race included provision of childcare, not having to provide names, and provision of
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transportation. They also found that those who were African American and of middle income
(annual income between $15,000-$50,000, as categorized by the authors) were significantly less
likely to participate in clinical trials. Their findings indicate that the reported low rate of
recruitment and participation in clinical trials may help to explain the health disparities observed
among minorities, underserved and rural communities in Maryland (Baquet, Commiskey,
Mullins, & Mishra, 2006).
Similarly, a study conducted by Simon et al. (2004) resulted in similar findings related to
minority participation in clinical trials. They found that the most common reason for both white
and African American women who were offered participation in a breast cancer trial but didn’t
enroll was because they refused to participate. However, a small percentage of white women did
not enroll because they did not meet the study’s eligibility criteria. Conversely, all of the African
American patients who were offered participation but did not enroll had refused participation. In
a study analyzing factors influencing enrollment into cancer studies among patients with
advanced cancer, Jimenez et al. (2013) found that race/ethnicity predicted trial enrollment, with
white patients more likely to be enrolled.
Minority interest. Though there are participation disparities in clinical trials, the
literature also supports the finding that eligible African American and Hispanic American
patients tend to enroll in clinical trials when given the opportunity (Diehl et al., 2011; Jimenez et
al., 2013; Simon et al., 2004; Wendler et al., 2006). For example, Simon et al. (2004) did not find
race to be a significant factor associated with breast cancer clinical trial enrollment among those
who were offered a clinical trial. This suggests that more minority women may enroll if provided
an opportunity; however, they are not always given the opportunity (Baquet, Commiskey,
Mullins, & Mishra, 2006; Diehl et al., 2011; Simon et al., 2004). Albrecht et al. (2008) found
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that, in general, patients at two NCI centers were not offered a clinical trial 76% of the time,
even though they were referred as being potentially eligible. Of those patients who were offered
a clinical trial, 77% actually enrolled. Although separate enrollment rates were not calculated
based on race, 17% of the study sample was African American patients. Since 13% of the US
population is African American, trial participation at these two centers was representative of the
African American population in the United States (US Census Bureau, 2015). Similarly, AdamsCampbell et al. (2004) found that the enrollment rate among eligible African American cancer
patients at one cancer center was 60%, indicating a high rate of interest in trial participation in
this population. In fact, Markman, Petersen, and Montgomery (2008) studied whether there was
a difference in interest rate among various populations with cancer in learning about cancer
clinical trials. They found that minority respondents (categorized as African American, Hispanic
and Asian American) expressed a greater interest than whites in learning about clinical trials.
Furthermore, Cook, Kosoko-Lasaki, and O’Brien (2005) found that while only 5% of minority
respondents participating in a survey indicated they were ever asked to participate in a healthcare
study, 60% responded that they would participate if they were asked.
While Baquet, Commiskey, Mullins, and Mishra (2006) found that African Americans
who were recruited to clinical trials were significantly less likely to participate, they also found
that males from a race other than white or African American were significantly more likely to
participate in a trial. Diehl et al. (2011) analyzed enrollment data from 10 cancer clinical trials
and found that African American and Hispanic patients were represented across the trials.
However, the extent of their participation was not representative of the US population, especially
among Hispanics. Jimenez et al. (2013) found race and ethnicity to be a significant predictor of
clinical trial enrollment; specifically, patients who were white were significantly more likely to
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enroll. However, after controlling for socioeconomic and clinical factors, race and ethnicity was
no longer associated with trial enrollment. This suggests that minority patients are just as likely
as white patients to enroll in clinical trials. This finding is substantiated by the “Strategies for
Ensuring Diversity, Inclusion, and Meaningful Participation in Clinical Trials” workshop
proceedings in which acclaimed researchers devoted to reducing racial and ethnic disparities in
healthcare indicated that based on their experiences, minorities are actually just as likely as
majority populations to participate in clinical trials when given the opportunity (National
Academies of Sciences, Engineering, and Medicine, 2016). After reviewing records of patient
screening data for more than 4,500 patients who declined to participate in a cancer clinical trial,
Langford et al. (2014) found no differences in enrollment, refusal rates, or “not having a desire to
participate in research” based on race or ethnicity. Based on a study conducted by Wendler et al.
(2006), there is evidence to suggest that individuals from minority groups are actually more
willing to participate in clinical or surgical intervention studies than non-Hispanic white patients.
Wendler et al. (2006) analyzed consent rates of more than 14,000 individuals who were eligible
and invited to participate in clinical and surgical intervention trials and found that consent rates
of minority populations were higher than those of non-Hispanic whites. Hispanics in particular
had statistically significant higher overall consent rates. Additionally, Brooks et al. (2015) found
that up to 83% of minority patients who were eligible for a clinical trial chose to enroll, while
only 45% of eligible white patients enrolled.
Barriers of minority participation. There is an abundance of literature on the barriers
specific to participation for minorities in clinical trials. In a systematic review conducted by Ford
et al. (2008), barriers specific to underrepresented populations in clinical trials were categorized
according to a conceptual model that was used to illustrate factors that were related to enrollment
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in a clinical trial. To make a decision about enrolling, an individual needs to be aware of the trial,
as well as be provided with an opportunity to participate. As previously discussed, minorities are
not made aware of or asked to participate in clinical trials at the same rate as white patients
(Baquet, Commiskey, Mullins, & Mishra, 2006; Simon et al., 2004). This results in minority
patients experiencing a lack of awareness and lack of access to trials. Thus, Ford et al. (2008)
categorized barriers based on awareness, opportunity and decision about participation. The
socio-ecological model also can be used as a framework for categorizing barriers to minority
participation, as previously documented in the clinical trial literature (Frew et al., 2014; Salihu,
Wilson, King, Marty, & Whiteman, 2015; Wells & Zebrack, 2008). It is important to note that
while the categorization of barriers to minority participation in clinical trials using the socioecological model provides insight into multiple levels of influencers on an individual patient
level, this is a different application of the socio-ecological model than that which was used to
guide this study. However, since the utility of this categorization is beneficial for a
comprehensive understanding, the barriers have been categorized according to the socioecological model as follows:
Intrapersonal barriers. Barriers to clinical trial participation on an individual patient
level comprise characteristics of the individual, including demographic characteristics,
knowledge, attitudes, beliefs and skills (Baquet, Commiskey, Mullins, & Mishra, 2006; CorbieSmith, Thomas, Williams, & Moody-Ayers, 1999; Ejiogu et al., 2011; Ford et al., 2008; Ford et
al., 2013; Martin, Negron, Balbierz, Bickell, & Howell, 2013; McLeroy, Bibeau, Stecker, &
Glanz, 1988; Roberson, 1994; Simon et al., 2004; Swanson & Ward, 1995). Examples of these
intrapersonal barriers include:
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•

Demographic characteristics, including being of a racial/ethnic minority descent and
having a lower socioeconomic status. Socioeconomic barriers at an intrapersonal
level include cost of participation, lack of transportation and low levels of education
(Baquet, Commiskey, Mullins, & Mishra, 2006; Ejiogu et al., 2011; Ford et al., 2008;
Ford et al., 2013; Simon et al., 2004; Swanson & Ward, 1995)

•

Misunderstandings due to health illiteracy and misunderstanding the concept of
informed consent (Corbie-Smith, Thomas, Williams, & Moody-Ayers, 1999; Cortes,
Drainoni, Henault, & Paasche-Orlow, 2010; Swanson & Ward, 1995)

•

Awareness barriers, including a lack of knowledge surrounding the need for medical
research and about what clinical trials are and a lack of awareness of clinical trial
opportunities (Ejiogu et al., 2011; Ford et al., 2008; Leiter, Diefenbach, Doucette, Oh,
& Galsky, 2015; Ramirez et al., 2008; Roberson, 1994; Simon et al., 2004)

•

Individual beliefs and attitudes, including:
o Fear of being used as a guinea pig (Corbie-Smith, Thomas, Williams, &
Moody-Ayers, 1999; Ford et al., 2008; Ford et al., 2013; Roberson, 1994)
o Time demands and perceived interference of participation with other personal
responsibilities (Corbie-Smith, Thomas, Williams, & Moody-Ayers, 1999;
Ford et al., 2008; Martin, Negron, Balbierz, Bickell, & Howell, 2013)
o Fear of exportation (Ford et al., 2013)
o Lack of perceived benefit of participation (Corbie-Smith, Thomas, Williams,
& Moody-Ayers, 1999; Ejiogu et al., 2011; Ford et al., 2008)
o Lack of interest (Martin, Negron, Balbierz, Bickell, & Howell, 2013)
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o Skepticism due to uncertainty or negative connotations of clinical trials
(Durant et al., 2014)
o Perceived stresses of burdensome procedures or adverse effects (Ford et al.,
2008)
Interpersonal barriers. Barriers on an interpersonal level include influences of an
individual’s social network and social support system, including family, work and friendship
networks and healthcare providers (McLeroy, Bibeau, Stecker, & Glanz, 1988; Salihu, Wilson,
King, Marty, & Whiteman, 2015). Interpersonal barriers include:
•

Negative experience of a potential participant’s family member with the healthcare
system (Ford et al., 2008; Swanson & Ward, 1995)

•

Family concerns about research trials (Ford et al., 2008)

•

Work obligations and an inability to get the time off of work (Ford et al., 2008)

•

Communication barriers, including misunderstandings due to language barriers and
poor doctor-patient communications (Ford et al., 2008; Ford et al., 2013; Swanson &
Ward, 1995; Williams & Corbie-Smith, 2006). Additionally, skepticism about trial
participation is commonly mistaken by research staff as distrust whereas education on
clinical trials could help to alleviate some concerns of potential participants (Durant
et al., 2014)

•

Patients’ lack of trust in their physicians (Corbie-Smith, Thomas, Williams, &
Moody-Ayers, 1999)

•

Cultural differences between researchers and participants (Ford et al., 2013; Williams
& Corbie-Smith, 2006)
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•

Attitudes of healthcare providers: minority patients are oftentimes not informed of a
study when their primary physician mistrusts research or perceives limited scientific
value, perceives their patients as mistrusting research, doesn’t want to commit the
additional time to explain the study or complete paperwork, and/or objects to
referring their patients to other physicians conducting a study (Howerton et al., 2007;
Ramirez et al., 2008; Ramirez et al., 2012; Salihu, Wilson, King, Marty, &
Whiteman, 2015)

•

Lack of provider awareness about clinical trials (Howerton et al., 2007)

Organizational barriers. An organization is defined as a social institution with
organizational characteristics and rules and regulations for operation. Barriers on an
organizational level include influences of organizations, including the healthcare system, and
how policies and structures in place within organizations and the healthcare system influence an
individual’s behavior (McLeroy, Bibeau, Stecker, & Glanz, 1988; Salihu, Wilson, King, Marty,
& Whiteman, 2015). Organizational barriers include:
•

Lack of access to health care or not having health insurance (IOM, 2003; Swanson &
Ward, 1995; USHHS, CDC, 2011a)
o After controlling for insurance status, Jimenez et al. (2013) found that after
controlling for health insurance, African American, Hispanic and Asian
patients were just as likely as their white counterparts to enroll in an
advanced-stage cancer clinical trial. However, not all health insurers cover the
costs of clinical trial participation. After reviewing data from patients
consented into a cancer clinical trial at the Sidney Kimmel Comprehensive
Cancer Center over a 3-year period, researchers determined that 13.6% of
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consented patients were denied coverage by their insurer (Klamerus et al.,
2010). While federal law now requires health insurers to cover routine costs in
clinical trials under ACA, exceptions to this law may result in coverage gaps.
For example, health plans that existed when the ACA was enacted are not
required to cover routine patient costs in clinical trials (USHHS, NIH, NCI,
2020)
•

Lack of access to research centers: minorities are less likely to have access to research
centers where clinical trials are commonly offered (Boden-Albala et al., 2015; Diehl
et al., 2011; Durant et al., 2014)

•

Organizational barriers related to the clinical research sites, including:
o Lack of access to the study population (Durant et al., 2014; Ejiogu et al.,
2011; Swanson & Ward, 1995; Williams & Corbie-Smith, 2006)
o Lack of experience in recruiting racial and ethnic minorities (Ejiogu et al.,
2011; Williams & Corbie-Smith, 2006)
o Researcher beliefs and biases, which influence the effort researchers exert in
addressing barriers to minority recruitment. For example, a researcher’s
perception of the potential harm or benefit a trial could have to patients, as
well as a researcher’s perception of participants’ distrust of research (Ejiogu et
al., 2011; Ford et al., 2008; Simon et al., 2004; Stone, Mauch, & Steger, 1998;
Swanson & Ward, 1995; Williams & Corbie-Smith, 2006)
o Organizational climate, lack of resources and limited funding to support
minority recruitment efforts (Joseph & Dohan, 2009)
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•

Study design: eligibility criteria precludes minorities from being eligible due to
disproportionate comorbid conditions (Adams-Campbell et al., 2004; Ford et al.,
2008; Swanson & Ward, 1995)
o Adams-Campbell et al. (2004) conducted a study to systematically evaluate
the influence of the study design on the recruitment of African Americans into
cancer clinical trials being conducted at one large cancer center. Of the
African American patient population studied, nearly one-fourth was ineligible
to participate in an existing clinical trial because of comorbidities. Langford et
al. (2014) also found that being of non-Hispanic black race was significantly
associated with not meeting eligibility criteria due to existing comorbidities.
Given that health disparities disproportionately affect racial and ethnic
minorities (USHHS, CDC, 2011a; USHHS, CDC, 2011b), it is likely
minorities also have a disproportionate burden of comorbidities excluded by
study protocols, which results in a lack of opportunity to participate

•

Members of racial and ethnic minority groups are underrepresented in the healthcare
workforce, leading to a shortage of minority physicians involved in clinical research.
Ramirez et al. (2008) found that half of the Latino physicians who participated in
their survey indicated they had never been involved in a clinical trial, compared with
one-third of white physicians. This is an important finding since the inclusion of
minority investigators and research staff is associated with successfully recruiting
minority study participants (Ford et al., 2013; Swanson & Ward, 1995; The Society
for Women’s Health Research & FDA, 2011; Williams & Corbie-Smith, 2006)
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Community barriers. Community is not only defined by individuals sharing common
demographic or geographic characteristics, but also includes mediating structures such as family,
social networks, churches and neighborhoods, all of which may be sources of social identity.
Community is also defined by relationships among organizations within a geographical region.
Community barriers include:
•

Cultural beliefs and attitudes
o Lack of trust in the healthcare system and clinical research, particularly due to
past history of unethical conduct in clinical research involving minorities
(Corbie-Smith, Thomas, Williams, & Moody-Ayers, 1999; Ejiogu et al., 2011;
Ford et al., 2013; Roberson, 1994; Swanson & Ward, 1995; Williams &
Corbie-Smith, 2006)
§

One such example was the Tuskegee Study that started in 1932 with
the US Public Health Service and the Tuskegee Institute and enrolled
poor African American men who were told they were being treated for
‘bad blood.’ The men agreed to be treated for their ‘bad blood’ but
were never properly informed about the study to provide their
informed consent. Instead, they had been misled about the study and
were not informed that they had syphilis in order to allow the
researchers to record the natural history of syphilis in African
American men. Furthermore, once penicillin was found to be
successful in treating syphilis in 1947, it was never offered to the study
participants. The study lasted until 1972, when the US government
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deemed the study to be unethical and announced the end of the study
(USHHS, CDC, 2013b)
§

Another example is known as the Puerto Rican “Tuskegee.” In the
1950s to the early 1960s in a remote farming town in Puerto Rico,
women were given a “magic pill.” They were told the pill would keep
them from having children they could not support. Unbeknownst to
these women, they were actually subjects in research testing of the
world’s first birth control pill. Doctors provided hundreds of women
among Puerto Rico’s poorest agricultural class with these free pills
that contained three times as much hormone as the versions currently
on the market. Although the pills kept the women from getting
pregnant, they also came with a multitude of side effects and, more
importantly, without the informed consent of the women taking the pill
(Quintanilla, 2004).

o Cultural beliefs about illness and disease, such as distinguishing between
“hot” and “cold” diseases and preferences for folk healers and herbal remedies
(Juckett, 2013; Swanson & Ward, 1995)
•

Lack of available public transportation to the research site for attending study visits
(Ejiogu et al., 2011; Ford et al., 2008; Swanson & Ward, 1995)

Public policy barriers. Barriers at a public policy level include local, state, and national
laws and policies, such as:
•

The mandate to include women and members of minority groups as participants in
clinical research applies to NIH-funded trials only (USHHS, NIH, 2001)
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•

The federal law under the ACA requiring health insurers to cover costs for routine
procedures in clinical trials grants an exception to Medicaid plans and grandfathered
health plans that were in existence when the ACA became law (USHHS, NIH, NCI,
2020)

A few of these barriers were found to be specific to Hispanics (Martin, Negron, Balbierz,
Bickell, & Howell, 2013; Roberson, 1994). Roberson (1994) found that ethnic background, lack
of information and mistrust are perceived barriers specific to recruitment among the Hispanic
population. Lack of interest and time commitment were cited as the most common barriers to
recruitment for African American and Hispanic women in a postpartum depression study
(Martin, Negron, Balbierz, Bickell, & Howell, 2013). Ford et al. (2013) found that Spanishspeaking clinicians are crucial to the successful recruitment of Hispanic patients, since they are
more likely to be trusted by their Hispanic patients. Study materials need to be translated into
Spanish, keeping in mind patients with low literacy levels. Researchers also need to reassure
patients that immigration status will not be documented (Ford et al., 2013).
Strategies specific to addressing barriers. Martin, Negron, Balbierz, Bickell, and
Howell (2013) successfully recruited minority women (African American and Latina) into a
postpartum depression prevention study by using a feedback-responsive recruitment strategy.
Their approach involved immediately responding to identified recruitment barriers that evolved
throughout the enrollment period by revising their recruitment messages. This strategy resulted
in a decreased refusal rate to participation of 40% to 19%. Lack of interest and time commitment
were identified as the two most common barriers to participation. The researchers addressed
concerns for time commitment by offering alternative methods for completing follow-up
interviews that better fit within the women’s schedules. To help overcome lack of interest, they
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changed their recruitment message and presented the study to potential participants as a way to
teach them about postpartum mothers’ health so their input could be used to benefit other
African American and Latina women in the future. This shared goal of helping others helped
increase recruitment, which is consistent with research that demonstrates altruism as a main
reason for participating in clinical trials (Bevan, Chee, McGhee, & McInnis, 1993). A study
conducted by Smith et al. (2007) found that African American women are motivated by the
desire to help their community or other people of their color.
In a study conducted by Ejiogu et al. (2011), barriers that disproportionately affect
participation in clinical trials by minorities and the socioeconomically disadvantaged were
targeted in order to overcome recruitment challenges and successfully recruit for a longitudinal
study. The study examined how race and socioeconomic status influence the development of
age-related health disparities. They targeted biracial (African American and non-Hispanic white)
and socioeconomically diverse participants. The researchers identified barriers that were specific
to this study and its targeted participants by meeting with local stakeholders, health
professionals, government officials, as well as establishing a community advisory board that
included church leaders, neighborhood activist leaders and local residents. To address the
barriers, the researchers created a recruitment and retention plan that included deploying mobile
medical research vehicles (MRVs) parked in the participants’ neighborhoods in Baltimore,
Maryland, and offering transportation to the MRVs. They also educated members of the
community advisory boards about health disparities and the need for research in their
communities to gain feedback on the study methods and local barriers, as well as to gain
community support. They coordinated surveillance of the MRVs with the Baltimore Police
Department and developed a cultural proficiency curriculum for site staff. The investigators also
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established active community citizenship through their participation in local festivals and
community social events. Finally, they adapted the study design to include medical benefits as a
means to motivate participants who didn’t have access to healthcare. Their recruitment strategy
paid off. Of the 3,722 participants recruited, 2,200 (59%) were African American and 1,522
(41%) were white (Ejiogu et al., 2011). They designed the study based on the recruitment
strategy, which is an important consideration because this is typically not common practice since
recruitment strategies are often an after-thought. Williams and Corbie-Smith (2006) have found
that recruitment strategies need to be established prior to beginning enrollment in order
maximize their success. When they are altered during the recruitment period, they are less
successful in recruiting minority participants.
Value investigators place on minority recruitment. The literature indicates that
physicians’ attitudes toward participating in clinical trials directly impacts enrollment in general,
likely due to the value and importance they place on clinical trials. Further, those physicians who
have more positive feelings towards clinical trials are more active in enrolling patients (Jacobs et
al., 2014). However, there is an ethnic disparity among physicians in regard to their attitudes
toward clinical trials. Twice as many Latino physicians as white physicians disagree that the
scientific value of clinical research outweighs the risks (18% vs. 9%, respectively) (Ramirez et
al., 2008). This may contribute to the underrepresentation of Latino researchers, as well as the
underrepresentation of minority clinical trial participants, since Latino physicians are more likely
to treat Latino patients. This is important because having Spanish-speaking research staff who
look like the population they are trying to recruit has been successful in recruiting Hispanic
women (National Academies of Sciences, Engineering, and Medicine, 2016). Therefore,
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improving minority physician attitudes towards clinical trials could improve minority
participation.
Results of studies have determined that PI attitudes play a significant role in minority
recruitment. The value investigators place on minority recruitment has been found to be a key
contributor toward the success or failure of recruiting minority participants into clinical studies
(Williams & Corbie-Smith, 2006; Wright et al., 2001). For example, Williams and Corbie-Smith
(2006) found that investigators who valued the inclusion of minority participants in clinical
research were more successful in recruiting minority participants. In their study, Williams and
Corbie-Smith (2006) surveyed PIs to gain their perspectives on recruiting minority participants
into clinical trials to identify factors associated with success in this area. The majority of PI
respondents (90%) were white but the majority of them reported including minorities on their
research team. Notably, 73% of the investigators surveyed self-reported success with recruiting
minority participants into a trial. PIs who considered minority participation in research as
important, who didn’t need to make midstream modifications to their recruitment strategy and
who reported fewer recruitment barriers reported being successful in minority recruitment.
Although including minority recruiters, investigators and/or project managers as part of the site
staff was associated with reported minority recruitment success, the race of the PI was not
associated with reported minority recruitment success. Of the sites that didn’t make midstream
changes to their recruitment strategy, 76% reported success in recruiting minority participants,
whereas only 59% of those sites that made changes midstream to their recruitment strategy were
successful in recruiting minorities.
Durant et al. (2007) conducted a survey of PIs to evaluate the attitudes and experiences of
those who receive federal funding in recruiting minorities and women in clinical trials. The
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purpose of their study was to determine the recruitment goals that investigators set for minority
recruitment, the percentage of PIs that failed to reach their goals, and whether or not PI and study
characteristics and PIs’ perceptions of minority recruitment were associated with their failure to
meet minority recruitment goals. The majority of the PIs surveyed were white males with a mean
age of approximately 50 years. The most common methods of recruitment used among the PI
respondents were clinic or hospital-based recruitment, word of mouth, flyers and physician
referral. The authors found that many PIs did not set recruitment goals for individual minority
groups. Goals were set more frequently for African Americans (91%) and whites (88%); 67% of
PIs self-reported setting recruitment goals for Hispanics and 55% for Asian Americans. Mean
recruitment goals were highest for whites (71%), compared with mean recruitment goals of 33%
for African Americans, 21% for Hispanics and 10% for Asian Americans. Although investigators
who receive federal funding are required to meet minority enrollment targets, this study
reinforces the fact that many of these investigators do not set minority recruitment goals. In
another study that explored researcher strategies to incorporate the NIH’s policy to include a
representative proportion of minorities in NIH-funded clinical trials, only half of the respondents
indicated they proactively set recruitment goals for minority inclusion (Boden-Albala et al.,
2015). Durant et al. (2007) also found that PIs were more likely to fail to meet their racial and
ethnicity demographic-specific recruitment goals set for African Americans (51%), Asian
Americans (55%) and Hispanics (44%) compared with goals set for whites (30%). Failure rates
in meeting recruitment goals were significantly higher for African Americans and Asian
Americans as compared with failure rates in meeting recruitment goals for white participants.
Many factors were found to be associated with failing to meet recruitment goals, but they were
varied, and none were consistently associated with failing to meet recruitment goals across
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different racial and ethnic groups. Sixty percent of PIs had not yet completed study enrollment
for their most recent federally funded trial, which could contribute to not meeting their minority
recruitment goals. The factors found to be associated with failing to meet recruitment goals for
African Americans were related to investigator and study characteristics, as well as PI
perceptions. These factors included PIs conducting an observational study, completed study
enrollment, or the perception of PIs that there would be a large number of barriers to minority
enrollment (Durant et al., 2007). The fact that a perception of recruitment barriers was associated
with failing to meet recruitment goals corroborates the findings of Williams and Corbie-Smith
(2006) who reported fewer perceived recruitment barriers were associated with greater success in
minority recruitment (Willams & Corbie-Smith, 2006).
Durant et al. (2007) also found that having more than 20 years of funding as a PI was
associated with a lower chance of failing to meet recruitment goals for African Americans. This
may be due to greater experience in conducting and recruiting for clinical trials. None of the
factors that were analyzed were independently associated with failing to meet recruitment goals
for Hispanics. The value investigators place on minority recruitment plays a role in successfully
recruiting minority participants (Williams & Corbie-Smith, 2006) but whether or not this value is
associated with setting individual minority recruitment goals is unknown.
Interestingly, sites in the ALLHAT with a large African American patient population
recruited African Americans at the same rate as those sites without a high percentage of African
American patients. Though the reasons behind these similar recruitment rates were not
articulated, the authors speculated that they were due to the motivation and training of
investigators to recruit diverse patients, as well as the existing physician-patient relationship at
those sites that successfully recruited African American participants (Wright et al., 2001). These
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findings demonstrate that recruiting minority participants into clinical studies is achievable when
investigators are motivated and place value on recruiting minorities and suggests that these sites
were specifically focusing on and actively recruiting minority participants. Since more than half
of the ALLHAT participants were minorities (Pressel et al., 2001), the research also suggests that
minorities are willing to participate when given the opportunity, similar to findings from Diehl et
al. (2011), Jimenez et al. (2013) and Simon et al. (2004). This is also important to recognize
because of a sponsor’s focus and priority to expedite trial enrollment in order to conduct a study
in the shortest amount of time possible (Getz, 2012; IMS Health, 2012; USHHS, OIG, 2000).
The findings from Wright et al. (2001) provide evidence that recruiting minority participants
when the right sites are involved is not time-consuming.
African American and Hispanic participants likely will enroll in clinical trials when given
the opportunity (Diehl et al., 2011) and minorities are interested in learning about clinical trials
(Markman, Petersen, & Montgomery, 2008). These findings suggest that minority participation
may increase when value on the importance of including minority participants in clinical
research is instilled in more investigators. Therefore, if guidance or successful experience with
minority recruitment is shared among the research community, it may increase the value that
investigators place on recruiting minority participants and, ultimately, result in an increased
number of minority participants enrolling in clinical trials.
Organizational context. Organization contextual factors can impact the enrollment
success of clinical trials among the general population. Specifically, those organizations that
provide support and offer incentives to physicians to enroll patients, as well as mandate
minimum enrollment targets, accrue more patients. While these organizational contextual factors
increase enrollment, they were not found to directly influence physician attitudes toward clinical
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trials. Physicians’ positive attitudes toward participating in clinical trials did, however, have a
direct positive effect on enrollment (Jacobs et al., 2014). McMullen, Griffiths, Leber, and
Greenhalgh (2015) explored factors related to high-recruiting and low-recruiting practices
(within the general population) and found that high-recruiting practices were innovative and
characterized by strong leadership, good managerial relations, dedicated resources and provision
of staff training. Adams, Caffey, and McKevitt (2015) found that research staff perceived
organizational factors to contribute more to recruitment success than the study itself (in general).
These factors included commitment by the research team, the value of research recognized
within the organization and having sufficient resources. In a systematic literature review
conducted by Fletcher, Gheorghe, Moore, Wilson, and Damery (2012), the researchers found
that providing research-dedicated staff, enrollment incentives and additional training led to
increased recruitment rates. They also found that being part of a practice active in research is
connected with positive recruitment results. These findings relate to clinical trial recruitment in
general, and further studies are needed to determine if the same factors apply when recruiting
minorities. However, there is a small pool of literature on organizational contextual factors
specific to minority recruitment.
When exploring organizational barriers to minority participation in cancer clinical trials,
Joseph and Dohan (2009) found that organizational climate and research infrastructure impacts
minority recruitment. Specifically, a lack of resources created a climate in which clinical trials
were made a low priority, such as providers who are already being stretched to see patients and
having recruitment activities occupying exam rooms that were needed for patient care. Limited
funding for research left providers with a small research staff and a lack of resources to translate
patient-facing materials that described studies that were being conducted to patients.
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Furthermore, the interdisciplinary structure of the clinic was such that patients did not have a
dedicated provider, which resulted in a lack of continuity of care and limited individual provider
awareness of specific trials. These factors led to staff having an unfriendly attitude toward
clinical trials, which shaped the culture of the clinic to prioritize clinical care over research.
These findings by Joseph and Dohan (2009) support other findings that research center
infrastructure and experience impact the successful enrollment of minority participants (Etkin,
Farran, Barnes, & Shah, 2012). PIs’ perceived importance of minority inclusion is also
associated with minority recruitment success rates (Williams & Corbie-Smith, 2006), which
would likely impact organizational climate.
As previously discussed, factors related to the investigator site that negatively impact
minority recruitment include lack of access to the study population, lack of experience in
recruiting racial/ethnic minorities, lack of information about effective strategies and cultural
differences between research staff and participants (Williams & Corbie-Smith, 2006). On the
other hand, several studies suggest that characteristics related to specific research sites may have
contributed to their successful enrollment of minorities into clinical trials. Jimenez et al. (2013)
found that white race was not a significant predictor of clinical trial enrollment after controlling
for recruitment site. One recruitment site in particular in this study was a statistically significant
confounder to predicting enrollment based on race and ethnicity. More than half of the study
participants in the ALLHAT were African American and those sites with a large African
American patient base recruited at the same rate as sites that did not have primarily African
American patients (Wright et al., 2001). These examples suggest that there is something different
about these sites from the other sites in terms of recruiting minority participants and that,
perhaps, they are specifically focusing on minority recruitment. In a study conducted by Duda et
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al. (2011), the lack of consistency with recruitment strategies employed across different research
sites led the researchers to believe that the success specific sites had with recruiting minority
patients was related to characteristics of the investigator sites themselves. More research is
needed in this area to determine the specific organizational characteristics that may contribute to
successful minority recruitment.
Health literacy. Health literacy is defined as “the degree to which an individual has the
capacity to obtain, communicate, process, and understand basic health information and services
to make appropriate health decisions” (USHHS, CDC, 2019). Although general literacy and
health literacy are not the same, even people with strong literacy skills and high education levels
have trouble understanding health information. For instance, 15% of high school graduates have
limited health literacy (US Department of Education, Institute of Education Sciences, 2006).
General literacy is defined by the US Department of Education, Institute of Education Sciences
(2006) as “using printed and written information to function in society, to achieve one’s goals,
and to develop one’s knowledge and potential.” This includes reading, writing and basic
mathematical and speech comprehension skills. Thus, general literacy is the foundation for
health literacy because literacy provides the skills that enable individuals to understand and
communicate information within a health context (IOM, 2004).
On average, Hispanic adults have lower health literacy than any other racial or ethnic
group and white adults have the highest health literacy compared with adults of other races or
ethnicities. Sixty-six percent of Hispanic adults have either below basic or basic health literacy
skills, indicating limited health literacy, and 41% do not have the skills to perform simple
everyday literacy activities. Fifty-eight percent of African American adults have limited health
literacy, compared with 28% of white adults (US Department of Education, Institute of
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Education Sciences, 2006). Individuals with limited health literacy have less knowledge about
their medical conditions and management of their disease (IOM, 2004). For example, Williams,
Baker, Parker and Nurss (1998) found that functional health literacy levels in patients with a
chronic disease were correlated with knowledge and management of their disease—patients with
limited health literacy cannot optimally manage their disease. Patients with limited health
literacy also are less likely to use preventive services, since they are more likely to enter into the
healthcare system at a more advanced stage of their disease (IOM, 2004). Paasche-Orlow and
Wolf (2007) suggest that access and utilization of the healthcare system is decreased in
individuals with limited health literacy due in part to a limited ability to navigate the complexity
of the healthcare system. In a systematic literature review conducted by Koskan, Friedman and
Messias (2010), the researchers found that Hispanics with lower levels of health literacy were
less likely to be screened for the presence of diseases. It is no surprise that limited health literacy
is a barrier to clinical trial participation among minorities (Corbie-Smith, Thomas, Williams, &
Moody-Ayers, 1999; Swanson & Ward, 1995). Barriers with entering the healthcare system as
indicated by the IOM (2004) and Paasche-Orlow and Wolf (2007), as well as the limited
knowledge of chronic disease in individuals with lower health literacy levels, may be part of the
reason behind lower clinical trial participation. Further, Hispanic ethnicity and lower levels of
education have been found to be independently associated with decreased levels of clinical trial
awareness (Leiter, Deifenbach, Doucette, Oh, & Galsky, 2015). In a study conducted by Duda et
al. (2011), the researchers found that the minority participants who enrolled in the National Lung
Screening Trial were disproportionately less well educated and more economically
disadvantaged than whites, both of which are factors contributing to limited literacy (IOM,
2004). Although distinct from general literacy, basic literacy skills are required for health
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literacy, and the percentage of adults with proficient health literacy increases accordingly with
each higher level of educational attainment beyond high school (IOM, 2004; US Department of
Education, Institute of Education Sciences, 2006). In fact, approximately half of US adults lack
the basic literacy skills required for full participation in American society. Since basic literacy
skills are a building block for health literacy, a large proportion of the US population, a
disproportionate amount of which are racial and ethnic minorities, therefore, has limited health
literacy. Both being a member of a racial and ethnic minority and lower education levels have
been found to be associated with limited health literacy (IOM, 2004). This poses a problem with
informed consent when sites need to educate patients with low education or limited health
literacy on study details and requirements and any potential risks of participating in the study.
The readability levels of informed consent documents for clinical trials are higher than the
average reading level of most adults in the United States, and the majority of clinical trial
participants do not fully understand the study information presented to them during the consent
process (Cortes, Drainoni, Henault, & Paasche-Orlow, 2010; Flory & Emanuel, 2004;
Helgesson, Ludvigsson, & Stolt, 2005; IOM, 2004). In fact, after using health literacy principles
to redesign a surgical consent form, the percentage of patients who actually read the form
increased from 25% to 91% (Lorenzen, Melby, & Earles, 2008). Even so, following industry
recommendations for improving comprehension of a consent form for a hypothetical study did
not always result in comprehension among Spanish-speaking individuals with low literacy or
lack of familiarity with research. Researchers should incorporate interactive consent discussions
into their consent processes to better ensure comprehension by all potential research participants
(Cortes, Drainoni, Henault, & Paasche-Orlow, 2010; Flory & Emanuel, 2004). Additionally, the
teach-back method can help the researcher determine the patient’s understanding of the
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information being presented (Lorenzen, Melby, & Earles, 2008). Furthermore, individuals with
limited health literacy are less likely to ask questions of their provider and admit that they have a
poor understanding of the discussion. Physicians are often unaware of any misunderstandings
(IOM, 2004). This could result in patients not taking their study medication or performing any
at-home study requirements as instructed, since patients with limited health literacy remember
and understand less than half of what they are told by their physicians (IOM, 2004).
The skill of healthcare professionals in communicating health information also
contributes to health literacy (IOM, 2004). The Agency for Healthcare Research and Quality
(AHRQ) has recognized that in order to address the needs of patients with limited health literacy,
organizations need to become health literate. Ways to promote health literacy within a healthcare
practice include improving communication (spoken and written), providing patients with
empowerment to control their disease and implementing patient support systems (AHRQ, 2010).
According to the participants of an IOM roundtable on health literacy, a health literate
organization is “an organization that makes it easier for people to navigate, understand, and use
information and services to take care of their health” (Brach et al., 2012). Livaudais-Toman,
Burke, Napoles, and Kaplan (2014) conducted a study to assess the organizational health literacy
of clinical trial sites and characteristics associated with health literate behaviors, measured by
communication (written and verbal) and outreach efforts. Less than half of the sites surveyed
offered supplemental information about clinical trials (such as frequently asked question sheets
to help potential participants better understand clinical trials), and only 22% of sites offered
supplemental materials in languages other than English. Only one-fourth of sites offered
translated materials to facilitate recruitment and patient navigation to trials. The provision of
translated materials does not, however, solely fulfill health literacy requirements, since
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individuals with limited English proficiency may have limited health literacy (IOM, 2004).
Sixty-five percent of sites offered professional interpretation services, a finding that is
disappointing given the National Standards on Culturally and Linguistically Appropriate
Services (CLAS) in Health Care policy that healthcare organizations must offer and provide
language assistance services, at no cost, to each patient with limited English proficiency
(Livaudais-Toman, Burke, Napoles, and Kaplan; USHHS, Office of Minority Health, 2018).
Additionally, less than half of the sites engaged in community outreach efforts, a strategy that the
authors categorized as an organizational health literate characteristic and that others have found
to be successful in recruiting minority participants (Etkin, Farran, Barnes, & Shah, 2012;
Livaudais-Toman, Burke, Napoles, and Kaplan). Findings by Livaudais-Toman et al. (2014)
suggest that clinical research sites are not addressing the health literacy needs of their patients.
It is also important to note that culture influences how individuals interact with the health
care system. Cultural differences may have an effect on the communication and understanding of
health information, and an individual’s ability to make appropriate healthcare decisions is based
on their cultural beliefs (Ingram, 2012; IOM, 2004). As a result, culture is a component
influencing the health literacy skills of an individual. As such, cultural competence skills and
knowledge are required for healthcare professionals to be able to provide care as part of a health
literate organization (IOM, 2004).
Cultural competence. Cultural competence is a required skill set among physicians for
them to deliver high quality care to patients successfully, helping to reduce racial and ethnic
disparities in healthcare (Betancourt, 2004; Betancourt, Green, Carrillo, & Ananeh-Firempong,
2003). Cultural competency requires that organizations have a congruent set of values,
behaviors, attitudes, practices, policies and structures that enable them to adapt to diversity and
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deliver services in order to work effectively cross-culturally (Cross, Bazron, Dennis, & Isaacs,
1989). In order to be culturally competent, healthcare professionals must be aware of the values
and belief systems of different cultures, have knowledge of cultural world views, possess the
skills to collect health information in a culturally sensitive manner and encounter patients from
culturally diverse backgrounds with cross-cultural interactions. Lastly, they need to have a desire
to engage in the process of cultural competence (Campinha-Bacote & Campinha-Bacote, 1999;
IOM, 2004). A culturally competent healthcare system is one that acknowledges and
incorporates the importance of culture and adapts services to meet specific cultural needs based
not only on health beliefs and behaviors but also on social factors (Betancourt et al., 2003).
Purnell et al. (2011) published guidance for assessing an organization’s cultural competence in
the delivery of culturally competent healthcare, of which the key components are administration
and governance, education, language services and staff competencies. For example, a culturally
competent healthcare organization has a mission statement and philosophy that address diversity;
they partner with ethnic community agencies to engage the local community in activities, such as
community health screenings; advertisements and health promotion campaigns are representative
of the diversity and languages of patients and placed where they will reach patients in the local
community; resources are allocated to diversity training for all levels within the organization;
recruitment of staff reflects the diversity of the community; and staff are knowledgeable of their
patients’ cultures. Further, Brach and Fraserirector (2000) suggest that if an organization exhibits
cultural competency techniques they could effectively change both physician and patient
behavior, resulting in improved communication, a better understanding of patients’ cultural
behaviors, increased trust and improved patient education on their disease and treatment options.
This would ultimately yield greater access to appropriate healthcare services among minorities.
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Poor doctor-patient communications, cultural differences between researchers and participants,
mistrust, lack of patient knowledge about clinical research as a potential treatment option and
limited access to healthcare services are all barriers to minority recruitment (Baquet,
Commiskey, Mullins, & Mishra, 2006; Corbie-Smith, Thomas, Williams, & Moody-Ayers,
1999; Ejiogu et al., 2011; Ford et al., 2008; Ford et al., 2013; IOM, 2003; Leiter, Diefenbach,
Doucette, Oh, & Galsky, 2015; Roberson, 1994; Simon et al., 2004; Swanson & Ward, 1995;
USHHS, CDC, 2011a; Williams & Corbie-Smith, 2006). These findings, therefore, suggest that a
healthcare organization employing cultural competency techniques also would yield greater
access to clinical trials among minority populations.
Cultural competence also needs to be prevalent in protocol design and study initiation
(Diehl et al., 2011). For example, Adams et al. (2004) found that exclusion criteria prohibited the
eligibility of many African Americans from cancer trials due to the disproportionate incidence of
comorbidities in that population. Characteristics of African Americans and other minorities must
be taken into consideration when developing study designs and eligibility criteria. The capacity
to acquire cultural knowledge about patients is a crucial component of cultural competence
attributed to recruiting minority populations into clinical trials (O’Brien et al., 2006). Examples
in the literature describe successful recruitment of diverse patients into clinical trials by
acquiring cultural knowledge about patients they are targeting and incorporating that knowledge
into the study design and recruitment plan (Ejiogu et al., 2011; Wallington et al., 2016).
Wallington et al. (2016) used a cultural competence conceptual framework to integrate culturally
competent strategies into the study design, such as using diverse staff from the local community,
ensuring all staff were trained on the elements of cultural competence, as well as reviewing all
study procedures, consent documents, data collection tools and recruitment materials for health
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literacy and cultural suitability. Additionally, Ejiogu et al. (2011) found that culturally sensitive
researchers, support of the local community, and designing their study to overcome known
barriers to minority participation in clinical research all contributed to the successful recruitment
of minorities. As part of their recruitment plan, cultural proficiency training was instituted to
help researchers and site staff recognize how their personal biases could influence their
interactions with potential patients who were of a different culture. As a result of these
considerations, the recruitment success in the study was partly credited to the diverse research
staff and the cultural proficiency training program that provided continuous training to the
researchers throughout the study.
Cultural competency also plays an invaluable role in the informed consent process with a
multicultural audience, as evidenced by Simon and Kodish (2005). In reviewing a series of
informed consent discussions for participation in clinical trials for pediatric leukemia, Simon and
Kodish found that information quality and the disclosure process regarding the clinical trial was
significantly better for white parents than it was for minority parents. This included informing
parents about the right to withdraw from the trial, details about the benefits and risks, as well as
details about any expected pain or discomfort that may result from the investigational
medication. Simon and Kodish attributed the disparity in clinical trial information communicated
to the parents of minority patients to assumptions made by the researchers about these parents’
information needs and preferences based on their race or ethnicity and socioeconomic status.
The ACA includes provisions for recruiting and thorough training of the healthcare
professional workforce in an effort to improve access to and delivery of care for all individuals,
especially those who face healthcare disparities, such as minorities (KFF, 2013a; KFF, 2013b;
Sultz & Young, 2014). One such provision provides support for cultural competence training of
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healthcare professionals (KFF, 2013a). However, additional cultural competency training is
needed as several investigators reported deficiencies in this area (Diehl et al., 2011; O’Brien et
al., 2006). Lack of researcher training in communication techniques that are culturally
appropriate is a known barrier to recruitment (Baquet, Commiskey, Mullins, & Mishra, 2006),
yet Boden-Albala et al. (2015) found that only 36% of investigators required cultural
competency training for staff as part of their strategy to adhere to the NIH’s minority inclusion
policy.
Cultural, community and site-specific recruitment strategies. Direct community
involvement by researchers who tailor their strategies to align with the culture of the community
have proven to be successful in recruiting minority participants into clinical trials (Duda et al.,
2011; Ejiogu et al., 2011; Etkin, Farran, Barnes, & Shah, 2012; Germino et al., 2011; Wallington
et al., 2016). Germino et al. (2011) described a successful recruitment strategy for recruiting
young African American breast cancer survivors into an interventional study designed to help
women deal with fears and communication issues around their breast cancer and identify positive
directions for their lives. The recruitment strategy involved engaging community stakeholders to
address barriers to recruitment specific to the study population and community. The over-arching
recruitment objectives were focused on increasing familiarity of the study in the targeted
communities through community outreach, partnering with African American churches and
community organizations, increasing the availability and accessibility of study information, and
using cultural brokers to help accomplish their goals. One of the strategies used for increasing
the availability and accessibility of study information included using African American recruiters
who made calls from their homes in the evening so their name appeared on the caller ID rather
than a private or unknown number. They also collected data in the participants’ homes to help
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make participation more convenient. Through the implementation of these culturally informed
strategies by Germino et al. (2011), the recruitment rate of younger African American breast
cancer survivors increased 373% in just under 1 year, with the steepest rise in recruitment
occurring after all strategies were in place and operating simultaneously.
Community involvement by researchers conducting the Telephone Resources and
Assistance for Caregivers (TRAC) study resulted in an exceeded minority enrollment target of
30%. Researchers used social marketing and a community-based approach to develop their
recruitment plan for this interventional study that enrolled sedentary caregivers of patients with
Alzheimer’s disease in an attempt to increase caregiver physical activity. The researchers
collaborated with community leaders and organizations and maintained a strong presence at
community events. They also cast a broad net into the community, making relationships with
senior centers, faith-based organizations and adult day care programs. They attributed their
success in recruiting for this study to the infrastructure and experience of the research center, as
well as the collaborative partnerships and relationships they developed in the community through
their community engagement and giving in the form of educational programs (Etkin, Farran,
Barnes, & Shah, 2012). Similarly, Wallington et al. (2016) conducted community advisory
boards to gain entry into the community and also used the knowledge they gained about the
patients they were targeting and the community they live in to guide their research design. As a
result, they experienced a 62% increase in African American participants across the noninterventional trials they were conducting.
Interestingly, the African American Study of Kidney Disease and Hypertension (AASK)
trial utilized community-based screening and outreach strategies as part of their recruitment
efforts and found it to be ineffective in recruiting African American participants. This may be
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due to a lack of awareness in the community about the relationship between hypertension and
renal dysfunction. Additionally, many people were not aware they have the disease that was
being studied (renal insufficiency due to hypertension) (Phillips et al., 2004). This suggests that
while community-specific recruitment strategies can be successful, their success is dependent on
the disease being studied and cannot be generalized as an effective recruitment strategy across all
studies.
Duda et al. (2011) conducted a study to determine the impact of targeted recruitment
strategies on recruiting minority participants into the National Lung Screening Trial. Seven
institutions from the American College of Radiology Network were selected to be the
intervention sites, which created their own targeted minority recruitment strategies. These seven
sites, which were situated in culturally diverse communities, were selected based on their
performance in overall recruitment and their past success in recruiting minority participants.
Their site-specific recruitment strategies varied from direct mailing, advertising, printed
brochures, disseminating information at community events and enlisting cultural insiders. Of the
18,842 participants enrolled in the study, 1,576 (8.4%) were from racial and ethnic minority
populations. Of the 1,576 minority participants enrolled, 1,223 (77.6%) were from one of the
seven sites that had implemented a targeted minority recruitment strategy. These seven sites with
targeted recruitment strategies enrolled significantly more racial and ethnic minority participants
than those without targeted minority recruitment strategies. Specifically, they enrolled a higher
percentage of African American (9.5% vs. 2.0%), Asian (0.9% vs. 0.3%) and Hispanic (1.7% vs.
0.9%) participants. Duda et al. (2011) found that the rate of minority recruitment increased
quickly after the targeted recruitment strategies were implemented at those seven sites with
dedicated strategies, while the rate of minority recruitment was relatively stable across all other
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sites. Although minority recruitment increased significantly after the targeted recruitment
strategies were implemented, recruitment methods varied and there wasn’t a common strategy
that worked consistently well across all seven sites with targeted recruitment. Additionally, these
seven sites were selected because they were already enrolling minority participants. Therefore,
the impact of their targeted strategies for boosting minority recruitment is speculative and could
be due to characteristics of the site itself.
In a study by Harris et al. (2003), the researchers used both proactive and reactive
recruitment strategies to enroll African American participants into a smoking-cessation clinical
trial, which eventually led to successful recruitment due to their flexibility in changing the
recruitment strategy mid-stream. For the proactive methods, study staff personally recruited
participants from the existing patients and staff at an African American health center in which
the study took place. Reactive strategies consisted of community outreach via a targeted media
campaign and included ads in the form of television, radio and print. Minority recruitment was
considered prior to study design, and many factors were taken into consideration in developing
the study design to increase recruitment of African American participants. For example, all staff
members were African American, the study setting was a health center that was trusted by the
African American community and incentives and reimbursement were offered. Only proactive
strategies were implemented at the start of the study, but since recruitment goals were not being
met, the researchers put reactive strategies in place. Once the reactive strategies were
implemented, recruitment significantly increased and was found to be more successful in
recruiting participants (n = 534) over the proactive strategies (n = 66). Just over one-fourth of all
enrolled participants were recruited on the 5% of screening days in which the media outreach
took place. Additionally, people screened during the reactive phase were more likely to be
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eligible and enroll in the study. Presumably, this was due to those who responded to the media
outreach pre-screening themselves based on their review of the eligibility criteria and who also
were more likely to be ready to quit smoking. After comparing the demographic information
between participants recruited using both methods, Harris et al. (2003) found that participants
recruited in the proactive phase were more socially and economically disadvantaged than those
recruited in the reactive phase. This is likely because the community health center serves an
African American population with a 93% rate of incomes below poverty level, compared with
the metropolitan area surrounding the clinic, in which 28% of the African Americans had
incomes below the poverty level in that year. From this, it may be assumed that proactive
strategies may be more successful in studies looking to recruit lower-income African American
participants. The investigators learned that ensuring the recruitment strategy could remain
flexible when designing the trial was imperative to successful recruitment. When the proactive
recruitment strategies were unsuccessful, alternative methods were used via the reactive
strategies to successfully recruit minority participants (Harris et al., 2003). One difference
between the success reported by Harris et al., (2003) and Williams and Corbie-Smith (2006) in
making midstream modifications to the recruitment strategy is that the smoking-cessation trial
described by Harris et al., (2003) took into consideration a flexible recruitment strategy upfront
when designing the trial.
Brown et al. (2012) conducted a recruitment experiment to determine whether sending
personalized recruitment letters and including ethnic-specific health information in the letter
increased the response rate of minorities recruited for a weight-management trial for obese
women. The response rate was 34.4% higher among the women who received letters that
included health information specific to ethnic minority women than among those women who
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received generic letters. However, personalized letters did not result in a higher response rate. In
this weight management trial, 33.7% were minorities. Of the minority women enrolled in the
trial, 68.9% were recruited using direct mail letters. Of these women, 75.8% were sent a letter
addressed to them and 24.2% were referred into the trial by a family member or friend who
received the letter (Brown et al., 2012). This suggests that direct mail letters are a successful
technique for recruiting minority women into clinical trials.
A personalized letter containing a statement regarding heart disease statistics for the
general American population sent along with a recruitment flyer mailed to Hispanic employees
of Stanford University was found by Kiernan, Phillips, Fair, and King (2000) to result in a
significantly higher response rate (7.8%) to a dietary intervention study than the Hispanic
employees who received only the recruitment flyer without the personalized letter (2.1%). This
study’s findings are in direct conflict with the study findings by Brown et al. (2012) who found
that a personalized solicitation letter did not result in a higher response rate. Kiernan, Phillips,
Fair, and King (2000) have found that a personalized approach to minority recruitment was
successful and employees were four times more likely to respond and be eligible for participation
if they received a flyer along with a personalized letter than those who only received a flyer.
Kiernan et al. (2000) also found that the response rate among Hispanic employees who received
the recruitment flyer in addition to a personalized letter containing heart disease statistics
specific to Hispanics was higher (9.1%) than those who received the flyer with the personalized
letter containing statistics pertaining to the general American population (6.5%). Although this
finding wasn’t significant, it aligns with the finding from Brown et al. (2012) that providing
ethnic-specific disease information yields a higher response rate from minorities.
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The examples of successful minority recruitment that were just discussed are very
specific to the community in which the study was taking place. Additionally, the recruitment
strategies were not consistent across all sites. As demonstrated by the unsuccessful community
outreach strategies described by Phillips et al. (2004), these cultural-, site- and communityspecific strategies employed cannot be generalized across all studies. This leads to a discussion
on the lack of evidence-based minority recruitment strategies.
Lack of evidence-based minority recruitment strategies. There is still a lack of
evidence-based strategies for minority recruitment. The successful examples discussed involved
a combination of several different recruitment strategies. A gap in the evidence remains as to the
effectiveness of any single strategy (Duda et al., 2011; Ejiogu et al., 2011; Etkin, Farran, Barnes,
& Shah, 2012; Germino et al., 2011; Harris et al., 2003). For example, Duda et al. (2011) found
that the site-driven recruitment plans implemented in their study resulted in an increased number
of minority participants enrolled. However, although minority recruitment increased significantly
after the targeted recruitment strategies were implemented, there wasn’t a common strategy that
worked consistently well across all seven sites with targeted recruitment. Additionally, these
seven sites were selected because they were already enrolling minority participants (Duda et al.,
2011). The success that Duda et al. (2011) found may be due to the investigator sites themselves
and their experience rather than an individual recruitment strategy. Their targeted strategies also
required staff to devote a significant amount of time to recruitment efforts, taking away from
their clinic responsibilities. It is also important to note that these sites received infrastructure
support by the NIH for disseminating information in minority communities.
Germino et al. (2011) employed a population-specific approach to recruitment that will
require systematic testing of the strategies implemented in order to know which individual
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strategies were successful in recruiting and retaining younger African American breast cancer
survivors into the study. The researchers’ approach expanded on the existing literature on the
importance of community engagement in research. Through a combination of factors, such as
addressing barriers to research participation, taking into account cultural preferences, as well as
bridging gaps across cultures and communities through the use of cultural brokers, they were
able to successfully recruit African American women into this study. Although the researchers
were successful in recruiting minority women participants, the strategies were very specific to
the community and they can only deduce that the combined strategies were successful. Germino
et al. (2011) did not evaluate the effectiveness of the strategies on an individual level. The
strategies employed also required extra time commitment not typically provided by investigator
sites.
Similarly, a limitation of the study conducted by Harris et al. (2003) is that they did not
systematically test the successful recruitment strategies. The majority of enrolled participants
were recruited through the radio (n = 209), followed by referrals from a friend (n = 152). The
manner in which participants’ friends found out about the study in order to make the referral is
unknown. For instance, study staff members may have approached them during the proactive
stage, or they could have heard about the study through the media campaign. Additionally,
referral by a friend was found to be similar to the reactive strategies in the ability to recruit a
population that was eligible for and more likely to enroll in the study. Although Harris et al.
(2003) demonstrated successful recruitment strategies, it will be important to further test these
strategies to understand which can be attributed to successful recruitment.
Ejiogu et al. (2011) demonstrated how recruiting minority and socioeconomically
disadvantaged participants can be successful by infiltrating the community to better understand
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the needs of the targeted patient population and gaining the support of community stakeholders.
However, they used a combination of several strategies that would need to be evaluated in order
to determine which strategy or strategies were successful in recruiting minority participants.
Their recruitment efforts were directed towards the specific barriers of the targeted population in
that particular community. Specific strategies that are successful in one community may not
work in another because each community and culture has its own unique barriers. Similarly,
Wallington et al. (2016) successfully recruited African American participants into noninterventional cancer clinical trials by employing cultural- and community-specific strategies that
were relevant to a specific population in the Washington, DC metropolitan area. The authors
recognized that strategies might need to vary when recruiting participants from other racial and
ethnic groups and in other geographic locations (Wallington et al., 2016).
While recruitment for the TRAC study was successful in exceeding the minority
recruitment target, it was largely due to the geographical area in which the study was conducted
and the inclusion of a research center that was already well established in the local community.
In fact, the researchers were not successful in recruiting minority participants from communities
in which the center did not already have established relationships (Etkin, Farran, Barnes, & Shah,
2012). The extent of community engagement and involvement that was practiced in this study is
beyond the traditional realm and resources of industry investigators. Likewise, the hands-on
approach discussed by Ejiogu et al. (2011) that involved direct community engagement by the
site staff and PIs, including the creation of a community advisory board, is not common practice
in industry-sponsored studies. Instead, the focus is on reducing R&D costs, while completing a
trial in the shortest amount of time possible to expedite the drug development process (Kermani
& Bonacossa, 2003; National Academies of Sciences, Engineering, and Medicine, 2016;
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USHHS, OIG, 2000). However, this level of involvement greatly contributed to these studies’
minority recruitment successes. The sustainability of this approach is yet to be documented
among industry-funded studies.
Lack of evidence-based minority recruitment strategies in benchmark trials. There are
three benchmark trials that focused specifically on ethnic minority populations: AASK, the
African American Heart Failure Trial (A-HeFT) and ALLHAT (Taylor & Wright, 2005). A brief
description of each follows, as well as a discussion on the lack of evidence-based minority
recruitment strategies or lack of sustainable strategies for these benchmark trials. These
examples provide further evidence of a need to better understand what contributes to
successfully recruiting minority participants into industry-funded clinical trials. Even with these
trials that specifically required a large number of minority participants, variability in recruitment
approaches and success rates among the government-funded trials and lack of information on
recruitment approaches used in the industry-sponsored trial demonstrates that more research is
required in this arena.
AASK. The AASK trial was conducted to compare the effectiveness of different
treatments in African American patients with renal insufficiency due to hypertension. The AASK
trial was funded by the National Institute of Diabetes and Digestive and Kidney Disease, as well
as by NIH grants. Financial support and drug donations were also provided by Pfizer,
AstraZeneca and King Pharmaceuticals (Phillips et al., 2004). Before beginning enrollment into
the AASK study, a pilot study was conducted to determine the feasibility of the proposed
recruitment, retention and data collection procedures. The pilot study enrolled 94 African
American participants, most of whom were recruited through the primary recruitment strategy of
clinic-based chart screening and referrals (67%). Four secondary recruitment strategies were also

84
encouraged: mass mailing campaigns, mass media campaigns, community-based screening and
referrals of relatives and friends of existing patients. The contributions and effectiveness for each
of the secondary recruitment strategies varied widely by research site. Screening through clinical
practice provided only 17% of the participants for pre-screening, yet yielded 67% of the
randomized participants. Mass mailing provided the most interested patients for pre-screen
(44%), but only 15% of the patients recruited through mass mailings were randomized. Of note,
75% of the participants were men (Whelton et al., 1996).
The most-effective recruitment strategy for recruiting patients into the AASK trial was
the same as in the pilot study—screening patients in clinical practice. This included preidentifying prospective patients through chart reviews, as well as primary care provider referrals.
Eight-three percent of patients were recruited for a screening visit through this method and
provided 58% of the randomized patients. However, this required a total of 558,295 chart
reviews to randomize 635 patients, requiring a tremendous amount of resources from the clinics.
The number of chart reviews per randomized patient varied widely among the 21 clinics, ranging
from 42 to 6,381 charts reviewed per site, averaging 879 charts reviewed per randomized patient.
This was a much less effective strategy in the full trial than in the pilot study and also not likely
to be feasible from a resource perspective in an industry-sponsored study without additional
support. Similar to the pilot study, there was variability in the use and effectiveness of the other
recruitment strategies across the 21 clinic sites. As previously discussed, community recruitment
was not an effective strategy for this study. This was likely because patients with hypertension
and renal dysfunction are asymptomatic with low awareness of these diseases in the community.
This suggests that community-based approaches are dependent on the disease being studied and
cannot be generalized as being effective in all populations, diseases or communities. Recruitment
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in general proved to be challenging and the recruitment period was extended by 1 year in order
to meet the recruitment goal (Phillips et al., 2004).
The African American Heart Failure Trial (A-HeFT). Another benchmark trial focusing
on minorities was A-HeFT. A-HeFT was sponsored by NitroMed, Inc., a privately held
pharmaceutical company that is no longer in existence (businesswire, 2008; Mitchell et al.,
2011). Amid much controversy, the first race-specific drug, BiDil, was approved by the FDA in
2005 based on the results of A-HeFT. BiDil was approved for the treatment of heart failure in
African American patients when added to standard therapy. It was approved after demonstrating
effectiveness and showing a mortality benefit in African American patients during A-HeFT,
which recruited over 1,000 African American participants (Brody & Hunt, 2006). The decision
to conduct the study only in African American participants was justified by both NitroMed and
the FDA due to the fact that the post hoc subgroup analyses from two similar studies conducted
previously indicated that African American and white patients had a different response to BiDil.
There was an effect in treatment in African American patients, yet little or no effect in white
patients using the fixed-dose combination of two generic drugs to study the effects against
placebo and an existing treatment. Based on this fact, the FDA had reason to believe that a large
study that included both African American and white participants wouldn’t detect a treatment
effect in white patients. Coupled with the well-known disparities in heart failure rates that
African American patients suffer from more so their white counterparts and the infeasibility of a
mixed-race study that would be too large and take too long to conduct (from a cost and time
perspective to get a needed drug to market), the decision to only include African American
participants was made (Temple & Stockbridge, 2007). An abundance of literature discusses AHEFT, including the controversy the study sparked over the rationale for including only African

86
American participants and using race and ethnicity to categorize participants to test response to
drugs. However, no literature discussed the recruitment strategies employed to recruit the 1,050
African American participants. This is likely due to the fact that this was an industry-sponsored
study and not supported by NIH grants. However, this important study provides more evidence
on the genetic differences in response to different treatments and, therefore, reinforces the
importance of clinical trial participation parity.
ALLHAT. The third benchmark trial, ALLHAT, was funded by the NHLBI. Financial
support was also provided by Pfizer to provide additional recruitment resources to study sites.
The study medications were supplied by three pharmaceutical manufacturers: Pfizer,
AstraZeneca, and Bristol-Myers Squibb (Wright et al., 2001). The primary goal of ALLHAT was
to evaluate different treatment regimens to examine the reduction of CVD incidence between the
different treatment arms in 40,000 patients with hypertension aged 55 or older in a racially
diverse group, 55% of which needed to be African American (Wright et al., 2001). Initial
recruitment strategies implemented by the Recruitment and Eligibility Subcommittee included
mass mailings, as well as encouraging sites to conduct chart reviews, obtain physician referrals
and conduct community screening activities. Some sites also advertised locally. Enrollment into
ALLHAT was slower than projected, which resulted in several study design and recruitment
strategy changes being implemented in an effort to recruit the required 40,000 patients. These
changes included increasing the number of sites from 270 to 600, including expanding the
geographic region to Canada and Puerto Rico; extending the recruitment period by 1½ years
(which resulted in extending the follow-up period by an additional year in order to achieve
sufficient power); opening up the eligibility criteria to also include smokers and reducing the
minimum age requirement from 60 to 55 years; increasing site reimbursement for patient
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enrollment; providing funding for additional site resources; and instituting a national advertising
campaign (radio, print and direct mail letters). Similar to what was reported by Harris et al.
(2003), a flexible approach is sometimes required. These changes all ultimately led to the
successful recruitment of 42,419 participants, 54% of whom were minorities. African Americans
represented 36% of the study participants; however, the goal of recruiting at least 55% African
American participants was not achieved. As demonstrated by Durant et al. (2007), recruitment
goals set for African Americans are not likely to be achieved.
Minority participation in ALLHAT is still considerably higher than most studies, but,
unfortunately, an analysis of effective strategies specific to recruiting minority participants was
not conducted. Since it was a practice-based study and nearly all of the participating patients
were from the practices that were involved in the study, it is expected that the minority
participants primarily were recruited because sites with a large minority patient group were
selected. For example, the addition of Puerto Rican sites also yielded a high number of minority
participants (Pressel et al., 2001). However, the ALLHAT sites with a high African American
patient population recruited at the same rate as those sites recruiting other populations. Wright et
al. (2001) contributed the parity in recruitment rates to investigator motivation, training and
existence of a trusting relationship between investigators and their patients, instead of on the
diverse demographic patient population of these sites. While this is promising, it contributes to
the fact that not only is there a lack of understanding of evidence-based minority recruitment
strategies, but also a lack of understanding of the interacting components and characteristics that
may contribute to an investigator site successfully enrolling minority participants.
Lack of evidence-based minority recruitment strategies summary. In summary, many
studies in the literature focus on the barriers to minority participation in clinical trials and not the
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successful strategies. The successful examples of minority recruitment discussed in the literature
involved government-funded studies and employed strategies that not only would be costly and
difficult for industry to adopt without a system change but also vary across different studies,
sites, patient populations and communities. Even the benchmark studies that specifically required
minority participation reinforce the fact that there is a lack of evidence-based minority
recruitment strategies.
Summary of the Literature
Disparities exist in clinical trial participation, with racial and ethnic minority populations
underrepresented in most studies (Diehl et al., 2011; Duda et al., 2011; Killien et al., 2000;
Martin, Negron, Balbierz, Bickell, & Howell, 2013; Murthy, Krumholz, & Gross, 2004; The
Society for Women’s Health Research & FDA, 2011). There are many reasons for this disparity
as many barriers have been identified that preclude minorities from participating in clinical
research studies. Some of these barriers include individual patient beliefs and concerns about
participating in research; lack of awareness of clinical trials; lack of trust in the healthcare
system; cultural differences between researchers and patients; as well as doctor-patient
communication barriers (Ejiogu et al., 2011; Ford et al., 2012; Ford et al., 2013; Swanson &
Ward, 1995; Williams & Corbie-Smith, 2006). However, minorities are interested in learning
about clinical trials and tend to enroll when they are given the opportunity (Diehl et al., 2011;
Jimenez et al., 2013; Markman, Petersen, & Montgomery, 2008; Simon et al., 2004; Wendler et
al., 2006). Research sites may be better equipped to provide greater access to clinical trials to
minority populations when they follow guidance suggested for delivering culturally competent
healthcare services and exhibit culturally competent techniques (Brach and Fraserirector, 2000;
Purnell et al., 2011).
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Based on findings from a prior study, another area that could help to improve access and
provide minorities with opportunities to enroll is working toward increasing the value
investigators place on minority clinical trial participation, since this has been found to play a role
in the success of recruiting minority participants into clinical trials (Williams & Corbie-Smith,
2006). This is important because minorities are less likely to be offered a clinical trial than their
white counterparts (Baquet, Commiskey, Mullins, & Mishra, 2006; Diehl et al., 2011; Simon et
al., 2004). It has been found by some researchers that PIs’ perceptions of minority patients being
ineligible, noncompliant or disinterested provide explanation for this disparity in recruitment
practices (Durant et al., 2007; Eggly, Barton, Winckles, Penner, & Albrecht, 2015; Howerton et
al., 2007; Simon et al., 2004). Furthermore, many PIs, including those receiving NIH-funding, do
not set minority recruitment goals (Boden-Albala et al., 2015; Durant et al., 2007). While the
literature describes PI attitudes and perceptions in relation to minority recruitment, it is also
important to understand characteristics and perceptions of other research site staff members who
often play a critical role in clinical trial recruitment. This is an area in which there is an
opportunity for contribution to the literature.
Research center infrastructure and experience has also been found to impact the
successful enrollment of minority participants (Etkin, Farran, Barnes, & Shah, 2012; Joseph &
Dohan, 2009). For example, study site staff inexperience with the recruitment of minorities is a
barrier to minority recruitment, as is clinical research sites inability to address the health literacy
needs of patients (Ejiogu et al., 2011; Livaudais-Toman et al., 2014; Williams & Corbie-Smith,
2006). Many organizations, even those receiving NIH-funding, are limited in their focus on
minority recruitment because of infrastructure barriers and the additional cost of translating
materials (Durant et al., 2014; Joseph & Dohan, 2009).
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Existing literature suggests that characteristics related to both specific research sites and
individual investigators may have contributed to their successful enrollment of minorities into
clinical trials (Boden-Albala, 2015; Duda et al., 2011; Jimenez et al., 2013; Joseph & Dohan,
2009; Williams & Corbie-Smith, 2006; Wright et al., 2001). More research is needed in this area
to determine what those specific characteristics may be, including site staff perspectives and
characteristics and how they may play a role in minority recruitment. For example, cultural,
community and site-specific minority recruitment strategies have proven successful in NIHfunded trials (Duda et al., 2011; Ejiogu et al., 2011; Etkin, Farran, Barnes, & Shah, 2012;
Germino et al., 2011; Wallington et al., 2016). There still remains a lack of evidence on what
specifically contributes to successful minority recruitment because while success has been
experienced, it was the result of a combination of several strategies. These strategies were also
specific to the local communities in which the studies were being conducted and may or may not
be generalizable to other geographic areas. Success also may have been due to characteristics of
specific research sites and/or researchers themselves, leading to an unclear explanation as to
what the specific elements are that led to their success (Duda et al., 2011; Ejiogu et al., 2011;
Etkin, Farran, Barnes, & Shah, 2012; Germino et al., 2011; Harris et al., 2003; Wallington et al.,
2016). Additionally, as the examples discussed were from NIH-funded studies, they have a
minimum requirement for enrolling racial and ethnic minority participants as a stipulation of
receiving funding (USHHS, NIH, 2001). Hence, these successful examples discussed could be
due to additional funding and support sites received to amplify their recruitment efforts.
Exploring environmental elements that may be involved with minority recruitment
holistically, including research site staff perceptions and organizational characteristics, among
other factors from an ecological perspective, will contribute to filling these gaps in the literature
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and facilitate a more comprehensive understanding of what specific elements are involved in the
active recruitment of minority participants into industry-funded clinical trials. This will also
provide a significant contribution to the literature since the existing peer-reviewed literature
describing minority clinical trial recruitment is solely related to NIH-funded trials. Additionally,
it offers a wide view for understanding environmental factors more wholly from the perspective
of healthcare professionals involved in clinical research. Once these factors are better
understood, industry stakeholders involved with clinical research can better support minority
recruitment initiatives.
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Chapter III
METHODOLOGY
The purpose of this study was to understand the socio-ecological elements that are
involved in the active implementation of racial and ethnic minority recruitment practices for
biopharmaceutical-funded trials in the United States. A qualitative design was selected utilizing
semi-structured, in-depth interviews in order to allow participants to “express their own
understandings in their own terms” to appropriately capture their perceptions and experiences
(Patton, 2002, p. 348).
Study Design
The study design is a descriptive, exploratory, general qualitative study. A general
qualitative study “involves collection of data in an effort to characterize human experience as it
occurs naturally” to capture participants’ perspectives (Portney & Watkins, 2000, pp. 14-15).
When conducting qualitative research, the researcher is the key instrument and attempts to
identify the complex interactions of factors within the context of the data to gain an in-depth
understanding of how a phenomenon is experienced by individuals (Creswell, 2013). The study
is descriptive in that it involves describing what is prevalent regarding a phenomenon as it
naturally occurs to create a better understanding (Bickman & Rog, 2008; Kumar, 2011; Portney
& Watkins, 2000). This research is also exploratory as it involves examining a phenomenon in
which little is known and “explores its dimensions, including how it relates to other factors”
(Kumar, 2011; Patton, 2002; Portney & Watkins, 2000, p. 14). This design was selected to study
this topic because of the gap in the literature on the specific elements involved when a research
site is actively focused on minority recruitment, including site staff member and organizational
characteristics. This understanding is best achieved when participants are allowed to express
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their own perspectives and experiences rather than fitting them into the researcher’s pre-defined
categories (Patton, 2002). This study design allowed for gaining insight into the personal
perceptions, experiences and behaviors of individuals who work at a clinical research site
regarding trial recruitment and what factors play a role in their actions regarding minority
recruitment. Semi-structured, in-depth interviews were conducted to achieve this.
Research questions. Since this research study utilized a qualitative design, there are no
hypotheses accompanying the research questions. One overarching research question guided the
study:
•

What are the socio-ecological elements that are involved in the active implementation of
racial and ethnic minority recruitment practices for biopharmaceutical-funded trials in the
United States?

This research question is important because it addresses the gap in the literature on what specific
elements contribute to successfully recruiting minority participants into industry-funded clinical
trials from a socio-ecological perspective. To support the overarching research question, five
primary research questions guided the study:
1. How are intrapersonal site staff elements involved in the active implementation of
minority recruitment practices for biopharmaceutical-funded trials in the United States?
2. How are interpersonal site staff elements involved in the active implementation of
minority recruitment practices for biopharmaceutical-funded trials in the United States?
3. How are organizational elements involved in the active implementation of minority
recruitment practices for biopharmaceutical-funded trials in the United States?
4. How are community elements involved in the active implementation of minority
recruitment practices for biopharmaceutical-funded trials in the United States?
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5. How are policy elements involved in the active implementation of minority recruitment
practices for biopharmaceutical-funded trials in the United States?
These five primary research questions address different components of the socio-ecological
model, the conceptual framework that guides this study. The exploratory and descriptive nature
of the overarching research question fit the exploratory and descriptive study design and the
qualitative data analysis methodology as discussed in the literature and that was utilized to
analyze the data in this study.
Sample Selection
Purposive sampling was used to identify potential participants based on the inclusion and
exclusion criteria. In qualitative research, information-rich samples are typically selected
purposefully by the researcher on the basis of specific criteria that will allow for studying this
topic in-depth to learn about issues of central importance to the purpose of the study (Patton,
2002; Portney & Watkins, 2000). Snowball sampling was also utilized. It was suggested that
those individuals contacted may pass along the study solicitation to other potential candidates
who are involved with minority recruitment for clinical trials (Patton, 2002; Portney & Watkins,
2000). In this research study, participants were involved with actively recruiting racial or ethnic
minorities for biopharmaceutical-sponsored clinical trials. As this study was bound to be USspecific, participants needed to reside in the United States. Other inclusion criteria included
being 18 years of age or above and having the ability to understand and speak English.
The sample frame from which to recruit was established from publicly available data that
identifies clinical trial research staff based on the medical conditions in which they specialize, as
well as geographic location. The PI used the publicly available data to create a targeted
recruitment list inclusive of clinical trial research staff located in geographic areas of the United
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States with a large ethnically diverse population, as well as those involved with clinical trials in
disease areas that disproportionately affect racial and ethnic minority populations.
Sample size. The study required a sample size of 15 individuals who provided their
insights on and experiences with recruiting minority participants into clinical trials. These 15
individuals provided adequate information to “elucidate the particular” in reaching an
understanding (Creswell, 2013, p. 157). G*Power is not used to calculate sample size in
qualitative studies. Instead, data are collected until the categories and themes become saturated,
meaning that fresh data no longer gleans new insights (Creswell, 2014). As such, there are no
sample size limitations in qualitative inquiry and, instead, participants should be selected to
provide information-richness to the study findings (Patton, 2002). Patton (2002) recommends
specifying minimum samples “based on expected reasonable coverage of the phenomenon” (p.
246). The goal is to fulfill the intent of qualitative research to explain the particular in depth, and
not to generalize (Creswell, 2013; Merriam, 1998). Typically, a sample size between 10 and 15
individuals provides in-depth coverage of the phenomenon to reach redundancy in qualitative
research (Creswell, 2013; Lincoln & Guba, 1985). According to Guest, Bunce and Johnson
(2006), interviewing 12 participants is sufficient when it is a relatively homogeneous group and
the goal is to describe a shared perception or behavior. Therefore, as this was a qualitative study
utilizing interviews, inclusion of 15 participants is in accordance with guidance that has been
established by qualitative experts. Additionally, data saturation was achieved during this study as
these 15 individuals provided adequate information to reasonably describe the elements of
actively implementing minority recruitment practices in order to reach an understanding.
Sampling Procedure. As previously mentioned, the PI used publicly available data to
create a targeted recruitment list. Upon Institutional Review Board approval, the PI emailed the
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Study Solicitation to individuals on the target recruitment list. The Study Solicitation provided
instructions for individuals interested in participating to confirm their interest, as well as offer
the opportunity to pass along the invitation to other individuals who may qualify for
participation. Individuals confirmed their interest in participating by clicking on a hyperlink that
was provided in the Study Solicitation that directed interested individuals to a registration form
for them to indicate that they would like to be contacted by the PI for study participation, provide
preferred contact details and answer an eligibility screening question. If interested individuals
met the online eligibility criteria, they were contacted by the PI to further confirm eligibility and
to schedule a date and time to participate in a telephone interview. The PI re-contacted
individuals who did not respond to the Study Solicitation after 1 week by sending a solicitation
reminder via email and/or placing a telephone call. A last reminder for any remaining individuals
who did not respond took place 3 weeks following the initial Study Solicitation. Prior to the
telephone interview taking place, the PI emailed the participant the Informed Consent Form (see
Appendix B) and provided a personal fax number for returning the signed consent form prior to
the start of the interview.
The recruitment period was 5 months in duration, during which time a total of 165
individuals were invited for study participation. Of those 165 individuals, 25 declined
participation; three accepted and then were no longer reachable; six had incorrect contact details
listed in the publicly available data and were not reachable; two accepted but were ineligible; 94
did not respond; and the maximum number of follow-up attempts were reached for 20
individuals. Following this recruitment process, 15 individuals participated in this study.
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Data Collection
Data was collected using semi-structured, in-depth telephone interviews. A semistructured interview format was used to allow respondents to more freely share their perceptions
and experiences, while still allowing flexibility for probing for additional information as needed.
Specific interview questions were used as a guide to interview the participants (see Appendix A).
While the development of the interview guide was informed by the socio-ecological model, the
questions were constructed to be broad to allow for more freedom of response by the
participants. Certain steps were taken for the conduct of the interviews, as described next.
Interview process—before the interview. In qualitative research, the researcher is the
instrument. Therefore, it is important that the researcher is attentive to and discloses his or her
personal perspectives and experiences with the phenomenon under study that may affect data
collection, analysis and interpretation (Lincoln & Guba, 1985; Merriam, 1998; Patton, 2002). In
this study, the credibility of the researcher was substantiated through the PI’s
reflexivity/positioning statement (see Appendix C) indicating her position in terms of her
experiences with the topic being explored in this study prior to conducting any interviews.
Reflexivity is when qualitative researchers position themselves by becoming self-aware of the
origin of their perspective. This involves becoming conscious of the biases, values and
experiences that they bring with them, including how that shapes data collection and
interpretations of the data (Creswell, 2013; Patton, 2002). Prior to conducting each telephone
interview, the PI assigned the individual a participant number to be used to identify the
participant during the transcription and data analysis phase to maintain confidentiality. As
previously mentioned, the PI obtained a signed informed consent from each participant prior to
the start of the interview.
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Immediately before the interview started, the PI explained the goals of the research,
assured the interviewee that responses would remain confidential and asked for permission to
audio record the interview.
Interview process—during the interview. Upon permission, the telephone interviews
were recorded utilizing the audio recording functionality from freeconferencecall.com. An
Olympus Digital Voice Recorder model number WS-853 was used to serve as a back-up
recording mechanism. Interview questions were asked one at a time using the interview guide,
asking probing questions as relevant and providing transitions between major topics. The PI tried
to remain neutral and unbiased and took brief notes during each interview. Each interview was
approximately 1 hour in duration.
Interview process—after the interview. Due to the nature of the topic being studied,
questions related to the study participant’s demographic characteristics, as well as characteristics
related the organization in which he or she worked at the time of the interview, were asked at the
end of the interview (see Appendix A). After the interview, the researcher took notes regarding
the interview.
Data Analysis
While data collection and data analysis are simultaneous processes in qualitative
research, formal data analysis commenced once data saturation had been reached (Creswell,
2014; Merriam, 1998). Data analysis for this study was conducted as follows.
Transcription. Each recorded interview was transcribed verbatim, increasing reliability.
A transcription key was used to capture voice inflection and emphasis participants placed on
their words. All personally identifiable information was removed and confidentiality of the
participants was maintained by referring to each participant only by his or her participant
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number. After transcription, the transcripts were checked to make sure no obvious mistakes were
made during the transcription by playing the recording back and ensuring that it matched the
transcription.
Organizing the Data. The raw data was organized by creating a “database” in which to
store all information collected. This included interview transcripts, participant demographic
information and any researcher notes or reflections on the interviews (Creswell, 2013; Merriam,
1998). Atlas.ti data analysis software was utilized for this purpose (Friese, 2019).
Reading and Memoing. The PI immersed in the data by reading transcripts in their
entirety and reviewing all data collected, writing notes in the margins as applicable (Creswell,
2013; Merriam, 1998; Patton, 2002). This process allows the researcher to get a general sense of
the information collected and reflect on the overall meaning (Creswell, 2014).
Coding and Categorizing. The next step was coding and categorizing. First, the PI
formed codes by assigning a label to meaningful, recurrent segments of data (Patton, 2002).
Codes were formed inductively based on information that emerged from the data (Creswell,
2013; Patton, 2002). The socio-ecological model was then used to categorize codes by each level
of the model. All of the data for three interview transcripts were coded initially in order to
develop a preliminary codebook that included definitions and examples for all of the codes
created. A codebook is a set of codes with accompanying definitions and examples in order to
guide data analysis and maintain consistency when coding the data (DeCuir-Gunby, Marshall, &
McCulloch, 2011; Miles & Huberman, 1994). According to Creswell (2013), it is recommended
to develop a codebook from three interview transcripts prior to obtaining inter-coder agreement.
Prior to obtaining inter-coder agreement, intra-coder agreement was achieved by the PI re-coding
a portion of an interview transcript and comparing it with the previously coded portion to assess
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the level of consistency in coding (Miles & Huberman, 1994). Inter-coder agreement was then
established by having an independent reviewer with expertise in qualitative data analysis audit
the codes by coding data from a portion of a transcript independently, using the preliminary
codebook that was developed. The independent reviewer and PI met to compare their analyses,
discuss discrepancies and come to a consensus (Miles & Huberman, 1994). Both intra- and intercoder agreements were achieved within the recommended ranges, which are between 80% and
90% (Creswell, 2013; Miles & Huberman, 2014). The codebook was refined based on the intercoder review process and was then used as a guide for assigning codes to the data for the
remaining transcripts (Creswell, 2013). The codes were continuously reviewed and defined
throughout the coding process (Miles & Huberman, 1994). After all of the data were coded,
major categories were developed based on patterns that emerged from the coded data (Creswell,
2013). As with the codes, the categories were classified by the socio-ecological model levels.
Establish Themes. Overarching themes were developed by further classifying several
categories that formed a common idea and analyzing them to look for consistency and repetition
in order to establish patterns and create the overarching themes (Creswell, 2013). The themes
were categorized by each of the socio-ecological model levels.
Interpretation. Lastly, the PI interpreted, or made sense of, the data using themes to
explain findings (Taylor-Powell & Renner, 2003). The socio-ecological model was used as a lens
to interpret findings and explain the results. The interpretation was grounded in the larger
research literature on this topic (Creswell, 2013).
Trustworthiness
Validity and reliability are specific to quantitative studies. As this is a qualitative study,
trustworthiness standards need to be achieved instead. Trustworthiness demonstrates rigorous
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methods were used for doing fieldwork in an attempt to assess the accuracy of findings as best
described by the researcher and participants (Creswell, 2013; Patton, 2002). In other words,
trustworthiness demonstrates that the researcher followed protocol and standards for conducting
qualitative research such that the findings reported by the researcher accurately describe what the
participants shared. According to Lincoln and Guba (1985), the criteria for establishing
trustworthiness in qualitative studies are through establishing credibility, transferability,
dependability and confirmability. Each of these concepts is described next.
Credibility. Credibility in qualitative research is the equivalent to internal validity in
quantitative research and demonstrates that findings are worth paying attention to, based on
establishing confidence in the truth of the findings (Lincoln & Guba, 1985). Credibility was
achieved in this study through the following courses of action:
•

Member checking was used during the telephone interviews to ensure the PI accurately
interpreted the interviewee’s statements (Creswell, 2013; Lincoln & Guba, 1985;
Merriam, 1998)

•

Independent reviewer examination was conducted to audit findings (Merriam, 1998)

•

In addition to the themes that were formed, discrepant information that ran counter to the
themes was also presented (Creswell, 2014)
Transferability. Transferability in qualitative research is the equivalent to external

validity in quantitative research and refers to the extent to which findings have applicability in
other contexts (Lincoln & Guba, 1985). Transferability was achieved in this study through the
following course of action:
•

Rich, thick description was provided when conveying the findings in order to make
transferability judgments possible for the reader (Creswell, 2013; Lincoln & Guba, 1985).
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Direct quotations from the interview data have been shared in Chapter IV to provide
context to the themes that were derived from the data.
Dependability. Dependability in qualitative research is the equivalent to
reliability in quantitative research and demonstrates that findings would be repeated if the
inquiry were replicated (Lincoln & Guba, 1985). Dependability was achieved in this study
through the following courses of action:
•

Data collection procedures were guided by the study design, research questions and
interview guide

•

The interviews were recorded and transcribed verbatim (Creswell, 2013)

•

Findings and interpretations were supported by the data collected (Lincoln & Guba,
1985; Merriam, 1998)

•

A study database was developed to store all raw data (Creswell, 2013; Merriam, 1998)

•

An audit trail maintained a chain of evidence that demonstrated how data were collected,
how categories were derived and how decisions were made in deriving study findings
(Lincoln & Guba, 1985; Merriam, 1998)

•

A codebook was created to maintain consistency when coding the data (Creswell, 2014;
Miles & Huberman, 1994)

•

Inter-coder agreement was established by using an independent reviewer to analyze and
code transcripts, as well as to audit the creation of categories (Creswell, 2013)
Confirmability. Confirmability in qualitative research is the equivalent to objectivity in

quantitative research and refers to the degree to which findings are determined by the
respondent’s and not the researcher’s biases (Lincoln & Guba, 1985). Confirmability was
achieved in this study through the following courses of action:
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•

An audit trail maintained a chain of evidence that allowed data to be traced back to its
original source (Lincoln & Guba, 1985; Merriam, 1998)

•

Credibility of the researcher was maintained through reflexivity/positioning, becoming
self-aware of personal bias (Creswell, 2013; Lincoln & Guba, 1985; Merriam, 1998;
Patton, 2002)

104
Chapter IV
RESULTS
The results will be presented in two sections. At the end of each interview, several
demographic questions related to characteristics of the interview participants, as well as the
organization in which he or she worked at the time of the interview, were asked. Those results
will be shared first. Second, the themes involved with active minority recruitment practices that
emerged for each level of the socio-ecological model will be shared.
Demographics
The participants in this study were asked 19 demographic questions following the
telephone interview. Table 1 provides a summary of the results related to characteristics of the
interview participants.
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Table 1
Interview Participant Demographics
Participant Characteristics

n

%

1-5 years

1

7%

6-10 years

2

13%

11-15 years

5

33%

16-20 years

3

20%

Over 20 years

4

27%

1-5 years

4

27%

6-10 years

1

7%

11-15 years

6

40%

16-20 years

4

27%

Over 20 years

0

0%

1-5 years

3

20%

6-10 years

4

27%

11-15 years

6

40%

16-20 years

1

7%

Over 20 years

1

7%

Ownera

3

20%

Principal Investigatora

3

20%

Research/Recruitment Lead

10

67%

Executive Director

1

7%

Clinical Research Experience

Minority Recruitment Experience

Duration at Site

Current Role
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Interview Participant Demographics
Participant Characteristics

n

%

Yes

14

93%

No

1

7%

Yes

6

40%

No

9

60%

Spanish

2

13%

French

1

7%

Russian

1

7%

Chinese

1

7%

German

3

20%

Male

8

53%

Female

7

47%

Hispanic, Latino or Spanish origin

2

13%

Not Hispanic, Latino or Spanish origin

13

87%

Patient-Facing Role

Spoken Language other than English

Spoken Language Other than English

Gender

Ethnicity
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Interview Participant Demographics
Participant Characteristics

n

%

White

9

60%

Black or African American

3

20%

Asian

2

13%

Native Hawaiian or Other Pacific Islander

0

0%

American Indian or Alaska Native

0

0%

Mixed

1

7%

Race

a

Some participants indicated they are both an owner and Principal Investigator.
The majority of participants (33%) have between 11 and 15 years of clinical research

experience, as well as minority recruitment experience (40%). Forty percent of participants also
indicated that they have been with their current organization between 11 and 15 years. However,
it is important to note that of the participants who responded that his or her clinical research
experience, minority recruitment experience or duration at his or her organization was between
11 and 15 years, it was not consistently 11-15 years across all three responses. Some participants
focused on minority recruitment for longer than they have been with their current organization,
for example.
The current role of the interview participants is as follows:
•

Three participants own their organization that they opened specifically to improve
access to clinical trials to minority patients—two own dedicated research institutions
and one owns a community physician practice

•

Three are PIs, two of which are also owners

108
•

The majority of participants (10 out of 15) are responsible for overseeing recruitment
activities within their organizations

•

One participant is an executive director

Only one participant is not in a patient-facing role. During analysis, it became evident
that this participant’s responses did not consistently fit with the themes emerging for the other
roles.
Six participants speak a language other than English fluently. These languages include
Spanish, French, Russian, Chinese and German.
There were nearly as many female participants (47%) as male participants (53%), which
is the exact same overall percentage of trial participants by gender in industry-funded trials
reported by CISCRP (2017).
Participants were also asked if they consider themselves to be of Hispanic ethnicity, as
well as which racial designation best describes them. Questions were asked in alignment with the
FDA’s guidance for industry on collecting race and ethnicity information in clinical trials
(USHHS, FDA, 2016). Since respondents were asked to respond to both the race and ethnicity
questions, some respondents indicated that they are of Hispanic ethnicity and white race. Figure
2 provides an overall representation of race and ethnicity in the study. Minority representation is
53%, considerably higher than the minority population in the United States, as well as
representation in clinical trials (CISCRP, 2017; US Census Bureau, 2019). This may be
explained by the fact that participants are researchers themselves focusing on minority
recruitment and, therefore, likely interested in the topic of this study.
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Figure 2. This bar chart illustrates the representation of race and ethnicity in the study.
Participants were asked to provide a response to both race and ethnicity questions.
Table 2 provides a summary of the results related to characteristics of the organizations in
which interview participants worked at the time of the interview.
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Table 2
Organizational Demographics
Organizational Characteristics
Type of Organization
Dedicated research institution
Academic medical center
Community physician/medical practice
Public hospital
Geographical Area of Clinical Trial Setting
Urban
Suburban
Rural
Trial Fundinga
Biopharmaceutical Sponsors
NIH
Therapeutic Area/Disease State of Trialsa
Cardiovascular
Diabetes
Neurology
Oncology
Urology
Multi-therapeutic
Racial/Ethnic Minorities Included on Research Teama,b
Principal Investigator
Sub-Investigator
Recruiter
Study Coordinator
Study Nurse
Minority Recruitment Goal Setting
Yes
No
Cultural Competency Training Required
Yes
No
% Minority Participation in Trials
10% or less
11-25%
26-40%
41-55%
56-70%
71-85%
86-100%

n

%

8
2
3
2

53%
13%
20%
13%

8
7
0

53%
47%
0%

15
3

100%
20%

6
7
5
5
3
4

40%
47%
33%
33%
20%
27%

10
10
14
11
9

67%
67%
93%
73%
60%

6
7

40%
47%

6
8

40%
53%

3
2
3
1
2
0
3

20%
13%
20%
7%
13%
0%
20%
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Organizational Demographics
Organizational Characteristics

n

%

% Minority Participation Representation of
Community Demographics
Less
4
27%
Same
6
40%
More
4
27%
Note. Due to missing responses, n values may not sum to 15 and percentages may not equal 100.
a
Due to multiple responses per participant, n values may exceed 15 and percentages may exceed
100.
b
Recruiter, Study Coordinator and Study Nurse are the same role in some organizations.
More than half of the interview participants (53%) work for dedicated research
institutions, 20% of participants work for a community physician/medical practice, 13% of
participants work for an academic medical center and 13% work for a public hospital. This
reflects the trend with the investigator site landscape for industry-sponsored studies, which has
shifted away from academic medical centers toward private practice or dedicated research sites
used exclusively for research (USHHS, OIG, 2000; IOM, 2012). Private-practice community
physicians and research institutes have replaced academic medical centers as the majority of
industry-sponsored sites, increasing from 37% in 1994 to 74% in 2004 (Steinbrook, 2005).
Increasingly, however, there has become a significant shortage of community physicians
conducting clinical trials since 2009, moving towards an ever-increasing number of research
institutions conducting industry-sponsored clinical trials. Part of the reason for this is the
increasing complexity of procedures included in trial design, making conducting the study within
the trial infrastructure a burden for community physicians and academic medical centers (IOM,
2012).
The geographic area of each organization’s clinical trial setting is either urban (53%) or
suburban (47%). None of the participants reported having a clinical trial setting in a rural area.
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As part of the eligibility criteria, all participants need to be recruiting racial or ethnic
minorities for clinical trials in which biopharmaceutical sponsors are the funding source. Three
participants work for organizations that also receive NIH funding in addition to
biopharmaceutical funding for the trials that their organizations conduct.
The therapeutic areas and/or disease states of trials that the participating organizations
conduct include cardiovascular, diabetes, neurology, oncology, urology and multi-therapeutic,
meaning that they conduct trials across a multitude of indications. The clinical trial experience of
participating organizations in these disease areas is to be expected since minority patients are
disproportionately affected by CVD, diabetes, Alzheimer’s disease, cancer and urologic
conditions, such as prostate cancer (Alzheimer’s Association, 2020; USHHS, CDC, 2013a;
USHHS, NIH, NCI, 2019).
The majority of study sites (93%) have included members of racial and ethnic minorities
as part of their research teams. Only one participant responded that minority staff are not part of
the research team; however, minority staff are part of the regular practice at that organization.
Recommendations from the literature indicate that important components for overcoming distrust
are ensuring research staff are the same race or ethnicity and speak the same language as the
patients they are trying to recruit (Germino et al., 2011; Ford et al., 2013; Hinton et al., 2010).
While 93% of the participants reported their organizations have minority recruiters, a lower
number reported having minority PIs or Sub-Investigators (67%). Although some minority
patients prefer to be treated by physicians of similar racial or ethnic backgrounds, minority
recruiters also have been found to contribute to the successful enrollment of minority participants
(Cook, Kosoko-Lasaki, & O’Brien, 2005; Ejiogu et al., 2011; Germino et al., 2011). In fact,
Williams and Corbie-Smith (2006) found that the inclusion of minority recruiters, not PIs, was
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associated with reported success of minority recruitment. This suggests that while including
racial and ethnic diversity on the research team is important, the race of the PI alone may not be
an essential component.
Nearly half of the organizations that participants work for do not set recruitment goals for
racial and ethnic minority groups (47%), a finding that corroborates with the existing literature.
In fact, recruitment goals for individual minority groups are not often set, even for NIH-funded
studies (Boden-Albala et al., 2015; Durant et al., 2007).
More than half of the organizations (53%) do not require staff to take cultural
competency training. Ensuring researchers are culturally sensitive has been found to be a
contributing factor in the successful recruitment of minorities (Ejiogu et al., 2011). Although
cultural competency is not often instituted as a training requirement among PIs conducting NIHfunded trials, it has been recommended as a best practice for minority recruitment by these
researchers (Boden-Albala et al., 2015). When asked if staff members are required to take
cultural competency training, a couple of study participants indicated that may be something they
may incorporate in the future. Participant #3 said:
No but that’s something I would like to do… that’s a good question…as of today – no but
that is something that I have considered to incorporate into my research uh process and
it’s a good question actually…
Participant #13 also shared:
No? No, it’s a good idea though. That’s not really been um an issue that’s arisen but that
would be a good idea ‘cuz I never I mean I understand my competency on to other
backgrounds but I haven’t really evaluated any others. There’s never really been a reason
to…but it makes sense. Ya, I’m gonna write that down.
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Eight participants reported that the percentage of minorities who participate in trials
conducted by their organizations is 40% or above. This is unique among industry-funded
research sites in that minority recruitment is on par with minority representation in the US
population, which is currently 39% (US Census Bureau, 2019). This finding indicates that these
participants recruit considerably more minorities than other organizations conducting industryfunded trials, since overall only 17% of trial participants in industry-sponsored studies are
minorities (CISCRP, 2017). Four of these participants went on to report that they recruit more
minority participants in their studies on average than the population demographics of their
nearby community. This could be another indicator that researcher and organizational
characteristics may play a role in recruiting minorities.
Themes
The second part of the results that will be discussed are the themes involved with active
minority recruitment practices that emerged for each level of the socio-ecological model during
the data analysis process.
First, the application of the socio-ecological model used for this study is explained.
Because the study explored how the behavior and practices of individuals involved in clinical
research who actively recruit minority participants are influenced by and influence
environmental elements, this puts the research site staff at the intrapersonal level of the model.
Therefore, the intrapersonal level encompasses characteristics of the study participants only,
including their knowledge, attitudes, perceptions, behavior and demographics.
The interpersonal level is related to the interpersonal relationships of the
study participants. The interpersonal level includes characteristics or interactions related to the
interview participants’ co-workers, colleagues and social networks.
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The organizational level is defined as the research sites in which the study
participants belong. This includes organizational characteristics such as policies, culture,
processes, structure and mission.
Community is related to the community surrounding the study participants’ research
sites. The community level encompasses information related to patients; patients’ social
networks; local community stakeholders or organizations; and any outreach efforts conducted by
the study participant or his or her research site that took place in the community.
Policy is related to national, state or local laws, as well as clinical trial policies. The
policy level includes items such as government regulations on clinical trials; federal guidance
related to clinical trial conduct; regulations, policies or expectations set forth by the trial funder
(i.e. NIH or pharmaceutical sponsor); and the healthcare system.
In addition, because the study was designed to better understand perceptions and
experiences of research site staff, most of the discussions and subsequent themes from data
analysis were related to the intrapersonal and organizational levels of the socio-ecological model.
Therefore, results are presented in the order of the socio-ecological model levels in which more
themes emerged. First, findings in response to Research Question #1 are shared related to
intrapersonal site staff elements involved in the active implementation of minority recruitment
practices for biopharmaceutical-funded trials in the United States. Second, organizational
findings related to Research Question #3 at the organizational level of the socio-ecological
model are discussed. Next, community elements in response to Research Question #4 related to
the community level of the socio-ecological model are discussed. Research Question #2 related
to interpersonal site staff elements at the interpersonal level of the socio-ecological model is
addressed next. Lastly, policy elements related to Research Question #5 are discussed.
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There are 20 overarching themes that emerged from the interview data during the data
analysis process. Table 3 provides an overview of these themes involved with active minority
recruitment practices, along with corresponding levels of the socio-ecological model and
corresponding research questions that are addressed.
Table 3
20 Themes Involved with the Active Implementation of Minority Recruitment Practices Emerged
During Data Analysis that Represent Each Level of the Socio-Ecological Model
Research
Question
#1

Socio-Ecological
Model Level
Intrapersonal

Theme

#1

Intrapersonal

Important to increase minority participation in
clinical trials

#1

Intrapersonal

Frustration with barriers to recruiting minority
participants

#1

Intrapersonal

Personal commitment to recruiting minority
participants

#1

Intrapersonal

Satisfying work

#1

Intrapersonal

Evolving personally

#3

Organizational

Mission related to improving healthcare through
clinical research

#3

Organizational

Mission guides recruitment efforts

#3

Organizational

Organizational commitment to minority
recruitment related to providing community
education

#3

Organizational

Organizational commitment to minority
recruitment related to organizational structure

#3

Organizational

Culture of inclusion

#3

Organizational

Minority recruitment practices evolving based
on learning

Research is important
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20 Themes Involved with the Active Implementation of Minority Recruitment Practices
Emerged During Data Analysis that Represent Each Level of the Socio-Ecological Model
Research
Question
#4

Socio-Ecological
Model Level
Community

Theme

#4

Community

Efforts to instill trust

#4

Community

Cultural sensitivity

#4

Community

Encouraging active role in healthcare and trial
participation

#2

Interpersonal

Teamwork

#2

Interpersonal

No peer influence

#5

Policy

Lack of diversity emphasis

#5

Policy

Diversity emphasis attempts

Should have access but don’t: not just about
location

Six intrapersonal themes that are involved with the active implementation of
minority recruitment practices.
Research is important. The first theme at the intrapersonal level is research is important.
Participants shared their personal point of view related to his or her perspective that clinical
research is important. As participant #16 said:
… if research is done well it it’s a win-win-win for everybody. It’s a win for the patient,
it’s a win for the research team, and it’s a win for...the pharmaceutical company that’s
sponsoring it and for the public in general.
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In addition, participant #12 shared, “I think it’s a positive thing. I encourage everyone to do a
research study…I really do, I think you get great…care…you’re helping out society…it’s all
good.”
Participants also discussed how research is important in the context of believing what
they do is important. Participant #3 shared, “I think what…I do is important. You know I think
it’s important for the value of…the scientific validity of new drugs and uh new drug
development…”
Important to increase minority participation in clinical trials. The second theme at the
intrapersonal level is that participants not only believe that research is important, but they also
believe that it is important to increase minority participation in clinical trials. Participants
discussed this in relation to why they feel minority inclusion is important, including for
generating generalizable knowledge in understanding if a drug is safe and effective in different
populations. Participant #1 said:
Research for me is that you know we’re here to seek generalizable knowledge that’s what
we’re trying to learn how this medication or medications or device works and we need
more you know minorities to participate.
In addition, participant #3 shared:
…it’s important to understand…if we can extrapolate the data to… the general practice I
think as a physician and I don’t think a lot of physicians think about this but you know I
thought about it for a long time…when I’m looking at a drug you know for example
when I’m looking at a blood thinner right an anticoagulant you know I’m looking at the
studies that were done and you know that only had a few if any minority participation,
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how can I say that this drug is safe? How can I say it’s effective? You can’t say that until
the only way that’s going to change is to to get more representation in trials.
Participant #2 expanded on this by sharing:
... like I said we wanna start looking at precision medicine and how medication helps a
person, people with the same indication but of different genders, races, age groups, you
know it’s very, very important that we include all people… in those studies...
Having equitable access to treatment options available in clinical research was also
discussed as a reason why participants feel it is important to increase minority participation in
trials. Participant #2 went on to say, “I also think it’s extremely important for the patients in our
health system to have access to the clinical innovations, the research innovations that are there.”
Frustration with barriers to recruiting minority participants. The next theme is
frustration with barriers to recruiting minority participants. Participant #7 said:
I really wanna see um basically effort at the end of the day…we are smaller companies
and… we really wanna see industry-wide more…towards this and giving more help and
support to encourage minority…group to participate in…pharmaceutical trials…but it
just I feels like it’s more frustration from my end… I wanna encourage them but I don’t
have the enough energy and effort…I’m too small… to change the whole
big…picture…so that’s just my frustration…I feel personally it’s important to cover…all
the diversity group, majority or minority, but um big picture wise, industry wise, it seems
that they all ignore that part.
Frustration with barriers related to study design or lack of supportive materials that
prevent access were also discussed. Participant #14 shared:
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…this is a big issue, all of our trial materials need to be translated into different
languages. And the fact that these consents for the most part are not translated routinely
into Spanish, into other languages, is ridiculous…it should be a knee-jerk thing. You
have a Spanish version, you have an English version, you have a Spanish version, you
have an English and it’s really only based on a lot of the sites depending where they are,
maybe you know we’ll we’ll only do it then. Well if you know you have a… urban site
like Chicago where you want to go ahead and do a trial and you have nothing translated
in Spanish, you’re not gonna do it because…you’re then asking only for English
speakers, ok and I think this is something that we have to really understand. You are
excluding people because you will not…go ahead and translate a consent into the
language and/or the study materials and/or the study questions...
Additionally, participants discussed communication barriers with patients, as well as
expressed frustration with barriers preventing appropriate communication with patients.
Participant #14 shared:
I think there’s a lack of understanding from the investigators um to understand the culture
and the community itself and you know I have I have heard investigators say that’s not
my job that is my study team’s job, that’s the nurse’s job, it’s the social worker’s job, it’s
the researcher’s assistant’s job, and I would argue and say no, actually it’s your job. Um
you are the PI and you are the person conducting the trial and if you have no interest or to
even understand how the community operates - what are some of the barriers they face,
um what their world looks like then you really shouldn’t be doing a lot of these trials um
that require um you know you actively recruiting… and I see this consistently where the
community feels this. And the community is very smart and the community will say you
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know the investigator never even came over here. You know, the study team only came.
Or the investigator didn’t have time to talk about results or midway…or…anything about
the disease that’s being studied and I think that’s really sad and I think that’s the reason
why a lot of our minority recruitment is hurting. Um because the investigators itself and
again I mean the PI um needs to be much more engaged in understanding his or her
community in a real way, not just from what his people tell him or her about the
community.
Personal commitment to recruiting minority participants. The fourth theme at the
intrapersonal level is personal commitment to recruiting minority participants. Participants in this
study demonstrated having a personal commitment to minority recruitment by initiating selfdirected action for this purpose. Participant #3 said:
…about 14 years ago I went out in private practice and started my own research company
and…I was focused primarily on recruiting uh patients from…racial minority ethnic
communities uh then trying to improve outcomes in clinical research, participation of
research…
In addition to initiating self-directed action, participants also demonstrated commitment
by displaying determination or dedication towards recruiting minority participants. Participant
#10 said:
I believe in medicine that works for everyone…I’ve made a commitment to…try and
make that happen by hiring um people A) who are from the communities that we’re
trying to reach and B) who have a real desire to work in those communities and get those
individuals engaged with science.
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Participant #5 also discussed this idea:
A lot of people the moment I tell them um I’m in clinical research they say “oh how
many people died in a study?” At the beginning it was for me shocking that people would
even ask because for me it was a given that everybody out there knows that nobody
actually nobody should die in a clinical trial, right? Uh and that’s why we have all those
regulatory authorities and all of this but guess what? People do not know and there is still
this mentality in particular uh nowadays with… technology and social media if
something bad happens it’s immediately spread all over the world but all the good things
that happened are not out there so therefore we have to fight against this myth that
clinical research is something very bad… there are people that abuse the system and then
its it’s a slap in the face for the entire clinical research community trying to do our best
because they did not play by the rules so we go back to the starting point and have to
explain that the moment it’s it’s properly done the entire system tries to keep everybody
volunteering in the system as safe as we can. We are not careless in this industry and this
is something we have to explain there. And I will not give up doing this.
Satisfying work. The fifth theme at the intrapersonal level is satisfying work. Participant
#15 shared:
I mean, it’s kinda funny um maybe I’m telling you too much but… I’m 65 and I um
everybody says to me “are you, when are you gonna retire?” …I’m not ready to retire, yet
I think about it because you know of course it’s I can think about it but…I enjoy research
and I enjoy this job…
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Participants shared their job satisfaction in relation to having positive feelings from
helping patients. For example, participant #16 said, “…you know the whole idea is to help
people. I mean I love what I do.”
In addition to being satisfied with their jobs, participants feel rewarded by their efforts
that help patients. Participant #13 said:
I think it’s very exciting…because it’s something that you’re actually able to possibly
help somebody with as well as help a lot of other people with it. You know it’s really
rewarding experience just to be part of that. Um especially whenever you can talk to
somebody who you know that could possibly benefit from this trial ‘cuz…it’d be better
for them ….. I’ve met this fellow...he was supposed to be taking metformin every day
twice a day. He was taking it once a week, he was borrowing it from his neighbor….I
said listen, you need to come in and meet this doctor. Also I have some trials you might
be good for. He didn’t qualify for the trials ‘cuz of his his hemoglobin A1c was way too
high ‘cuz he wasn’t treated. Uh but the doctor was actually able to get him samples of
the..medicine he needed uh to the point to where he was to actually able to get in to the
the threshold of what the study fit... What if I wasn’t out there that day?...I’m not saying
I’m the direct…reason but…the rewarding part of it is is I know because I had the
opportunity to talk with him, he was actually able to take some action…and find a way to
help himself…
Participant #3 also shared:
…it always makes me happy to you know I see a patient who may have had some
reservations earlier on who have come in for their study visits, who are interested, who
want to know the laboratory data, want to know how they’re doing in the research
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program... it makes me smile, it makes me happy that uh that we have not only educated
a patient, patient who is had some reservations now patient is engaged, fully
engaged…they’re joining their follow-up visits uh and and you know at the end of the
day I can sit down at my desk and say well I think we’ve made…a significant impact on
this patient life…and just it’s a good feeling for me.
Evolving personally. The sixth theme at the intrapersonal level is evolving personally. As
previously mentioned, the responses for the one participant in the non–patient-facing role did not
consistently fit with all of the themes that emerged from the data at the intrapersonal level. This
is one example in which that participant’s responses did not align. Aside from that individual,
personal growth was a common theme that was discussed, with participant #3 saying:
…my feeling when I in participating in trials has made it really I think has made me a
better physician, uh it’s made me a better physician for my patients…in understanding
their disease process, what they go through and how we can impact that in in clinical
trials…
Evolving by changing perspectives was discussed in relation to becoming more sensitive to other
cultures and cultural preferences. Participant #16 said:
I think I’ve um become just a little bit more knowledgeable and sensitive to the situations
that different uh minority populations are in. Um I think over time I’ve learned more and
so I think I’m just a little bit more sensitive to it now than I I was previously. I think
that’s kind of a continuous process.
In addition to changing perspectives, participants also discussed behaviors they have adapted in
order to develop skills for interacting across cultures. Participant #5 shared:
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I can give you a very real example. I needed to be exposed I’m a Caucasian through and
through…so I have never dealt with the African American community besides having
some friends and coworkers. So I personally even started…mingling this um community
in a completely different way in my private time simply to learn more about the thinking
and the culture of this particular group so I ended up line dancing sounds weird
now…with a group of black women at the church. Why did I do this? I want to learn
more about their culture and what kind of triggers them and what what they think about
certain things. That’s why I um even made the step into my private life um investing and
learning and it’s actually it it embraces my life.
Six organizational themes that are involved with the active implementation of
minority recruitment practices.
Mission related to improving healthcare through clinical research. The first theme at
the organizational level is having an organizational mission related to improving healthcare
through clinical research. This includes healthcare for overall society, as well as at an individual
patient level, by improving access to treatment options available in clinical trials. When asked to
share his organization’s mission, Participant #10 said, “to…treat and prevent Alzheimer’s
basically…we’re being seen as a brand uh in the community that can deliver care…at a highlevel and provide research opportunities at a high-level.” Participant #3 also shared:
…when I developed it many years ago…my mission was to… recruit and to improve
minority participation in clinical trials uh with the ideal to dispel misconceptions, to
dispel myths, to improve outcomes in healthcare through participation in community–
based research...
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Mission guides recruitment efforts. The next theme at the organizational level is that the
organization’s mission guides recruitment efforts. Participant #10 said:
So…that idea that we have a mission to prevent and treat is is part of what we market and
what we for lack of a better word sell to people that that being active in research is part of
that ongoing process of treatment or prevention…whether you get better…or not it’s part
of the hope and the… intrinsic value…as a human being that…if you…have dementia for
example being part of the solution ultimately.
In addition, participant #3 shared the following when asked about team members, indicating that
the organization’s mission is prevalent in the ways of working across the organization:
… they’re engaged…they understand what our mission is and they’re engaged… as
engaged and as I am in in getting patients involved in studies, getting the patients
engaged…”
Organizational commitment to minority recruitment related to providing community
education. The third theme at the organizational level is organizational commitment to minority
recruitment related to providing community education. Disease and general clinical trial
education needs to be provided to minority communities prior to presenting a specific trial
opportunity. As participant #14 said:
We’ve always talked about wellness first and we’ve always talked about how do we
maintain where we’re at so we so the decline that we know can happen can be lessened.
So it’s educating first. That then is built on, once we have that established, then we build
on discussing recruitment into trials for specific…trials. This trial is for memory decline,
this trial is for Alzheimer’s, this trial is for stroke, this trial is for Parkinson’s. Then we
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start to build on that but the foundation always is how do we understand aging, how do
we prevent the declines that we know can happen…
Additionally, the education needs to be culturally appropriate. Participant #10 shared:
...somewhere along the way we decided we needed to make that much more culturally
appropriate um it had been uh developed basically with a bunch of rich older white um
folks…in these sort of relatively affluent…retirement communities. And when we were
talking with various community groups and other people we were realizing this didn’t
make any sense for um other groups and we wanted to ask those groups…what they
wanted to learn about and how-what was the best way to deliver that? So we started… to
try this in some black churches um and we…asked them, “…what of these pieces of
[[Alzheimer’s Disease prevention disease education]] do you want to learn, are there
anything different?” um and then we also went into uh a couple of Latino serving
organizations and asked them to help us refine it as well. And we got very different
answers from each group... So we we took [[Alzheimer’s Disease prevention disease
education]] and we modified it to meet those um different demands…and then um uh
started delivering that in those communities um as a first entry point to get people to
know us as a center and build a little bit of trust by delivering some um education and
service maybe connecting people with um resources in that area um off-line or things like
that. So it was it was very little about recruitment and very much about exposure in the
community.
Building on the needs to provide culturally appropriate disease and general clinical trial
education prior to presenting a specific study opportunity, this requires a long-term investment.
As participant #6 said:
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…and this is where many people make a mistake you know how do you recruit patients
for a trial? You recruit patients for a trial, this…particular demographic by first educating
them. By offering them something valuable that they can use without the pressure of or
without the you know the pressure or the um the need to even have to discuss a study.
You know…when you do this in in an effective manner, it means that you have to put up
a lot of resources and quite honestly, many businesses are not willing to invest over the
long term and this is where they go wrong. People want to see numbers on a spreadsheet
and that’s just not the case…when you’re dealing with a certain demographic you cannot
be there for that trial for just that study, your investment has to go beyond that, beyond
the study number one and then before the study even starts, … there’s an initial
investment that you have to make long before that so you can’t look at numbers on a
spreadsheet to determine that you know that that piece of advertisement worked – it
doesn’t work that way. Not…for the kinds of patients that we see.
Organizational commitment to minority recruitment related to organizational
structure. The fourth theme at the organizational level is organizational commitment to minority
recruitment related to organizational structure, which needs to be made conducive for recruiting
minority participants. This includes hiring diverse staff from the local community, ensuring that
staff members are able to speak the same language of the patients that are being recruited and
adjusting hours of operation. Participant #10 said:
…we do make an effort to have people um who uh have comfort and knowledge uh of
the communities we’re trying to…recruit from um so you know for lack of a better way
to say it this is sort of how the field says it - you want to have people in your organization
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who look like the people you’re trying to recruit right and who sound like the people
you’re trying to recruit and who grew up in the neighborhoods and…places.
While participants discussed their organization’s commitment to creating an
organizational structure in order to be better at recruiting minority participants, they also
recognized room for improvement. Participant #10 went on to say:
…who could uh provide the full infrastructure that’s needed it’s not just recruitment I’ve
gotta have um a a doctor to do physical exams who um can speak Spanish for
example,…a Study Coordinator who uh can explain all of the procedures and do help
with all the scheduling um who speak Spanish if that’s the only language… I can make
small investments for recruitment but to really fully get people into trials it is a very
there’s a critical mass…of investment…the center has to make um across the board in in
all aspects of what we do…I can’t just piece meal it 10% here, 10% there, for a 10%
Latino population. I’ve gotta have a full-time person who can do uh who can do that,
multiple full-time people who can serve that whenever we need it. And that’s that’s hard.
Surprisingly, participants discussed their organization’s commitment towards overcoming
barriers to making structural changes just as often as discussing barriers that prevent their
organizations making structural enhancements. Participant #6 said:
And so a couple of years ago you know we made the investment of opening up our clinic
on Saturday, which was a hard thing for us to do because you know from a business
perspective it’s an expensive thing to do Saturdays. You know additional staffing,
physician time, you know you have limitations in terms of how…late you can see
patients because of courier issues, I mean there’s just a multitude of things and so it
requires an up-front investment and a continued sustained approach…
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Culture of inclusion. The fifth theme at the organizational level is culture of inclusion
with regards to diverse inclusivity in clinical research, as participant #5 said:
So you know living in an area here where we have um a population heavily mixed with
minority groups we have all of those people here and the kind of uh communication we
have even on our lunch breaks or whatever now, it’s different. We are listening to each
other to learn about each other and our cultural backgrounds. That hopefully helps us to
understand the motivation of minority groups better um to possibly being a part of
clinical research.
Some participants discussed having a culture of inclusion derived from leadership support or
directive. Participant #2 shared:
I think one of the more important things the aspects of how we recruit is that everyone is
should have access to clinical research within our health system. It is imperative that
everyone have an opportunity to take advantage of health alternatives and that’s just a
thought from um the top of the administration down to you know the clinical research
program.
Additionally, participant #15 shared:
…our hospital system I mean…their whole mission is to serve anyone that comes
through the doors…that kinda drives how you know research mindset is that everybody
qualifies for a study and we don’t care you know.
Minority recruitment practices evolving based on learning. The final theme at the
organizational level is minority recruitment practices evolving based on learning. Participants
discussed how their research organization’s approach to minority recruitment evolves based on
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lessons learned. Participant #3 said, “…you know we’re continually evolving and uh trying to
get understanding of what would help more…” Participant #6 also discussed this idea:
Well it’s changed over time. You know, it’s evolved over time and part of…that is
because you know we don’t have um how can I explain it – it’s changed over time
because as you start to gain the confidence and you start to to learn more about you know
what what people want and what they respond to, you have to kind of customize as you
go along.
Past experiences shape future recruitment approaches. As participant #5 said:
We were supposed as many other sites worldwide this year to enroll in a
pharmaceutical…study uh to enroll people with a different uh ethnical background so um
we were looking for Hispanics, for Asians and for African Americans. Um we thought
living in a hot spot of a very mixed culture here um around San Diego would make it
easier and boy did we learn that it has nothing to do with the statistics of the population
but it has more to do with I come back to the basis with trust. Cuz people of different um
ethnical backgrounds have a different culture and they trust their own but not so much the
rest of the world and therefore if you are not deeply rooted and have have earned your
trust in this community already before you are looking for um volunteers for a clinical
trial um you might not be successful and uh unfortunately this entire project has been
pulled by the by the uh pharmaceutical sponsor because uh the entire world suffered the
same. So what we learned as a team is uh the entire clinical research industry invested in
some education of the public over the last four decades but this education was mainly
targeting Caucasian people – nobody else. And that bites us a little bit in our behind now
because uh we dropped all those other people uh and they need to be educated now that
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we we go to the same level of trust and have a chance to attract them volunteering in
clinical research. So we adjust. So our work now with uh ethnical different communities
changed dramatically so we reprioritized our efforts...
Four community themes that are involved with the active implementation of
minority recruitment practices.
Should have access but don’t: not just about location. The first theme at the community
level is should have access but don’t: not just about location. Clinical research sites do not
always have access to minority patients for trials, despite having physical access based on
geography. As participant #4 said, “…but if you start the trial just because uh doctor say yes yes
yes I have the patient population – 80% of the time uh that means failure.” This is because of the
multitude of barriers to minority participation, which were previously discussed. Participant #2
said:
…and then when I got this position here where our demographic is 88% you know
African American little bit easier to have – ‘cuz you have that population but the
difficulties are still the same because you still have more opportunities for education,
more opportunities for…well more opportunities for continuous education.
Mistrust of research among minority patients was prominent in the discussions during the
telephone interviews, as shared by participant #12:
…minority you just really have to I mean they still have I can’t tell you how many
minority men have you know come have mentioned the [Tuskegee] um incident and you
know “are you using me as a guinea pig?”... probably like one out of every three brings
that up to me.
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Also mentioned earlier as a past experience shaping recruitment approaches, Participant #5
expanded on mistrust as a learning experience that demonstrates it takes much more to being
successful with recruiting minority populations than just having physical access:
We were supposed as many other sites worldwide this year to enroll
in a pharmaceutical…study uh to enroll people with a different uh ethnical background so
um we were looking for Hispanics, for Asians and for African Americans. Um we
thought living in a hot spot of a very mixed culture here um around San Diego would
make it easier and boy did we learn that it has nothing to do with the statistics of the
population but it has more to do with I come back to the basis with trust. ‘Cuz people of
different um ethnical backgrounds have a different culture and they trust their own but
not so much the rest of the world…
Efforts to instill trust. The second theme at the community level is efforts to instill trust.
Many efforts are taken by the study participants and their organizations to establish trust with
minority patients. These efforts are divided into two subthemes: site staff interpersonal
interactions with patients and leveraging a patient’s social network.
Site staff interpersonal interactions with patients. There are several different ways in
which trust is developed with minority patients that relate to research site staff interpersonal
interactions with those patients. First of all, it’s important to give back to the community without
asking for anything in return. As participant #6 said:
We have more traction in terms of recruitment just from word of mouth because we’re
not seen as somebody who just takes. You know if you just take, take, take, it’s gonna
become apparent. You can’t just target people for a study. You know you don’t, you
don’t build trust that way. And so we’ve had to give, give, give, and our return quite
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honestly has been ten-fold. But we haven’t changed that. We put an investment into the
give, give, give, first.
A way to give back to the community and establish trust is to provide personalized education to
help patients understand their disease and how to manage it. Participant #6 shared:
So many of the things that we did to gain their trust first of all you know revolved around
more um humanitarian kind of services so you know one of the things that um that I
learned early on is that um you know people…have a sense and a fear of of the unknown
and when it comes to their…own condition or disease um many of them just don’t have
an understanding. So one of the things that we decided early on is you know rather than
to approach um people with you know with studies why don’t we just dedicate the time
and resources to be able to educate people on what it is that they have…
Having personal interactions with minority patients is important for instilling trust. As
shared by participant #5
…the direct face to face contact with those who might to be impacted by themselves or
take care of somebody who is affected. The face to face um opportunity to meet people
and discuss things is the most important thing um to build the trust for sure…
Another important component for developing trust is for research staff to have a
commonality with patients. This helps with making patients feel comfortable, as well as indicates
to them that the trial is important, when there is someone from the same racial or ethnic
background as part of the study team. Participant #3 shared:
…you know patients trust me and uh that’s important…they’re able to to look at me, I’m
African American and I’m coming from an African American population…so you know
in contrast to an academic center where they’re looking at an Investigator who may not
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reflect um you know their racial or social sensitivities where I may and and so there’s
some commonality and that that helps a lot in terms of recruiting…
Communication techniques are also important for developing trusting relationships. As
Participant #12 said:
…being a good listener…taking our time - if we have to repeat things multiple times, we
repeat them. Um you know just really um if you say you’re gonna call them back, even if
you don’t have the answer yet, you call them back. You have to…you have to build trust
you have to…you just have to do that…and once they start trusting you then it’s great.
You know, there’s no hiding. Like you just gotta make sure they know that nothing,
there’s nothing hidden – there’s no hidden agenda, there’s no we are here for you, and
you know and I think once they meet us and they realize all the stuff we do for them…
In fact, participant #12 went on to share, “…these people become like family. Our
patients, I mean I have so many um you know to be able to help them and you know I’m part of
their lives.”
Developing trust occurs over time and needs to be nurtured. It is also crucial that the PI is
engaged. As participant #14 said:
…the last piece is um you know there has to be a (community) involved with in some
way to ask people to come into a trial and if you don’t give the education and the results
back of what previous trials have shown and explain it, you’re not going to get continued
people to even consider coming in a trial. And that’s very big in our minority populations
where you know it’s you you continue to see it. You know, investigators have come in
and done some work and then they the community never hears from them again…, they
don’t talk about the results, whatever’s been gleaned, and it’s just moving on to the next
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project. And the community’s like wondering well what happened. So I think that’s really
key um especially in our minority populations.
Patient interpersonal influence: social network. There are a couple of ways in which trust
is developed with minority patients by leveraging their social networks. First, participants
discussed how patients’ social networks, such as friends or family members, may refer them for
a trial if they themselves are supportive or had a good experience with a trial. Some participants
discussed the importance of engaging the family in recruitment and consent discussions.
Participant #12 said:
…we really encourage um the wives a lot of times are very mistrusting of us…and uh so
getting um getting them to come in…when their husbands are there with us and actually
talking it out all of us together um helps a lot…
Second, partnering with community stakeholders that serve as existing trusted sources of patients
is a critical component for establishing trust and gaining access to minority communities. As
participant #6 said:
You know…it evolved over time and really what looking back now it was a process of
gaining trust…if I could target those people that were most influential – pastors,…priests
within congregations, if I could get gain their trust and they in turn could introduce me to
people and if I could gain their trust, then I was kind of one step closer to to being able
to…draw them in...
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Cultural sensitivity. The third theme at the community level is cultural sensitivity. Being
aware of and respectful that cultural differences may exist is an important component when
recruiting diverse populations. Participant #16 shared:
…every population is different and you have to really understand what their concerns are,
and and their culture, and and try to…bridge the gap in an individual manner. I mean first
of all, I I think you’ve just gotta respect each individual first of all. First you can’t draw
any conclusions you deal with that person directly and individually. Then if you’re gonna
try to reach out to African Americans or to Hispanics then you you have to understand
how they typically view research…
Participant #14 discussed the negative impact of not recognizing or addressing the
specific needs of cultural groups by stating:
…the other issue we’re facing is because we are trying to recruit ethnically diverse
people, and it goes back to understanding the community but it’s really going back to
understanding the culture. And I have seen this multiple times…if you’re a PI and if you
do not understand the culture and the history of this ethnic group and racial group either
in the city you’re in, the town you’re in, or from the native country about some of the
things that are very important to the group and some of the medical issues that may have
happened with the group, then you’re in trouble and um people sense it and they
understand that…you don’t know of this atrocity that may have happened to to
my…people. That you know typically is said – my people. You don’t know about this
therefore why would…I let you do something to me if you don’t even know that this
happened to our group in this trial…
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It goes beyond recognizing the existence of cultural differences to also understanding
cultural preferences in order to effectively communicate with patients across cultures. As
participant #5 said:
That hopefully helps us to understand the motivation of minority groups better um to
possibly being a part of clinical research. The moment we we understand minority groups
better we have a chance to target and approach them in a different way because we are
thinking more out of their head then out of our head. And that makes a difference...
Participant #4 expanded on this by discussing how everyone who works for him must
learn to work with different cultures:
…forget about your belief um because this trial is not about you…let’s concentrate on the
belief of that minority, let’s try to understand their needs, let’s try let’s try to understand
their culture…let’s try to understand how can we make it better for them… let’s try to to
be educative as possible, let’s try to find new ways to send a very strong message to
them, um let’s learn about them, that’s my message um if you if you work for me…you
have to to learn how to um work with different cultures…and leave your perception out
because it’s not about you. It’s about the patients, it’s about the different cultures.
Encouraging active role in healthcare and trial participation. The fourth theme at the
community level is encouraging an active role in healthcare and trial participation. Participants
discussed how they encourage patients to be engaged and take an active role in managing their
health by educating them so they understand their disease and how to manage treatment options.
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Participant #6 said,
…take for example a diabetic, what we found is that people…could have been diabetic
for 20 years but they really do not understand what is occurring within their own bodies.
And so the first challenge is to really help them understand…
In addition, encouraging patients to take an active role in trial participation is also important, as
stated by participant #1:
…I believe what works for me is give the patient enough time to go over the informed
consent, let them read it, tell the patient, “look you know I need you to ask questions. I
don’t just want you to sign a document, I want you to ask me questions about particular
adverse events. Would this happen? What is the likelihood? What’s the percentage? What
happened?” I mean I need this information because it keeps ME fresh as well too so I like
to have the patient ENGAGED in terms of the studies that they may or may not
participate in.
Participants in this study also shared how minority patients are interested in receiving
disease and general trial education and understanding what it means to them, as shared by
participant #14:
…the foundation always is how do we understand aging, how do we prevent the declines
that we know can happen, and of late we have been focusing on racial differences that we
see…and trying to understand what those racial differences are between Blacks and
Whites and uh Hispanics and hopefully soon Asians…this kind of discussion is very
important in the community. People want to hear it and people are very interested and
wanting to know why are these differences there, what are you thinking, and how are you
designing trials to address those differences…
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Two interpersonal themes that are involved with the active implementation of
minority recruitment practices.
Teamwork. The first theme at the interpersonal level is teamwork. Participants discussed
working together as a team as a standard way of working. Participant #15 said:
I have various teams and…one person comes in…in the morning, also you have to set
your roles and your schedule so that everybody’s agreeable. But one person comes in in
the morning and starts recruitment um starts screening every morning. Um and when she
gets aggravated by doing all that, then you know then I say to the other person, “well, you
know either get in a little bit earlier or as soon as you get here start doing it so that the
other person the first person could do the regulatory today or do something else.” Um so I
think the team effort…
Several different aspects of teamwork were discussed, including taking a proactive, team
approach to recruitment planning as well as involving the PI in recruitment discussions with
team members. Participant #2 discussed both of these ideas:
…ya so it’s it’s developing a recruitment plan uh before we even start we sit down with
the Principal Investigator, develop a recruitment plan on um how we’re gonna chart
review in our electronic medical records, the…physician’s schedule um they are really
involved in looking at their schedule to see if the patients…fit inclusion exclusion
criteria…
Participants described learning as a team within their organizations, as shared by
participant #9, “…well the first few times that we go through the process everybody learns, we
definitely learn something...”
Problem solving as a team was also discussed, as shared by participant #16:
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…if things aren’t going well…we’re just trying to work together to solve the problem so
um I would say I other than maybe some disappointment when things don’t go exactly
according to plan we we’re really just troubleshooting.
Effective communication across teams and between team members is important in order
to be effective at recruitment, as mentioned by participant #16, “…we’re very much a team
and…we’re all in the same room so…there’s really kinda no barriers to conversation between
us.”
Participants also discussed having a team spirit, or camaraderie, as shared by participant
#14:
Assuming you have people that like what they do, love being out there…have a team
supporting them and then you know it’s a very enjoyable experience…for everybody
involved but for especially for them they feel a sense of accomplishment. They feel a
sense of the giving back. They feel that this project is not just let’s say your project, it’s
the team’s project. It’s a win-win.
No peer influence. The second theme at the interpersonal level is no peer influence.
Participants indicated that their colleagues or peers do not influence them with regard to minority
recruitment when asked one of these two questions during the interview, “what types of
discussions are happening among your colleagues with regards to minority recruitment?” or
“Can you share an example of when one of your colleagues encouraged you to focus on minority
recruitment?” Participant #16 responded, “Hmmmm. You know most of my… physician
colleagues are…White, mostly male…” Participant #13 provided a similar response:
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…not a lot to be honest with you…I do talk with other people in the country – I’ve a
friend over in California, I have some friends down in South Florida…they run research
sites and um there’s not really a lot of talk about that…
In fact, some participants shared how they are the ones actively attempting to influence
others with regards to minority recruitment, as mentioned by participant #14, “…um I’m trying
to think I mean it’s often the opposite…It’s me telling somebody else that they better you know
get this thing going here…”
Two policy themes that are involved with the active implementation of minority
recruitment practices.
Lack of diversity emphasis. The first theme at the policy level is lack of diversity
emphasis by the trial sponsor or governing body. Participant #7 shared:
…I feel horrible…because for years I still don’t see…I was always curious as a
researcher background before, I…always ask questions…why uh does no one see it? Is
this really doesn’t matter or it’s like it does matter it’s also difficult for organization like
FDA you know or like pharmaceutical company perspective is this really hard for them to
encourage minority group to participate uh that’s why they just ignore it, they don’t even
put a policy on it or any do anything about it, give any…additional support to the site to
cover it?
Participant #2 expanded on this by stating:
… pharma companies allow too…much control from the individual sites meaning that
hey if I don’t get minorities I don’t get minorities but I…fulfilled my recruitment goal.
You know, in the long run that looks great on the site and it may look great for the
pharmaceutical company but actually is that the best medicine that could be provided
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for…the patient…for the population? … there’s an area of…opportunity there that I
believe um the pharma company can can kind of control a little bit more um you know
they can put regulations…
Participants in this study discussed how either they themselves, their colleagues and/or
organizations are motivated to meet the enrollment goal commitment made to the study sponsor.
This essentially results in a lack of diversity focus, as participant #10 shared:
But at the end of the day, I am judged by how many what my n is…not my n solely of
you know well you you needed 20 and you only got four, but all four were AfricanAmerican…that’s okay but that means I only got paid for four people. Not 20 people.
There was one participant who was an outlier regarding this topic. Participant #3 was
motivated by making a difference to a patient’s life and not necessarily by the numbers:
...these are lives that it’s I think its very powerful…you may have one patient you know
we’ve had trials where I only had one patient and involved in the trial but that one
patient did well. That one patient had a positive outcome and a that one patient had a
positive experience and that one patient comes back and and asks us if there’s other trials
that that she can participate in. You know so you know that that you know that for a
physician I I think that’s important a lot of times we get you know we get sort of bogged
down in in you know even in research we look at the numbers…
Some participants also discussed the lack of diversity focus during site selection, as
participant #3 said, “…when I go to…Investigator Meetings… if there are a hundred
investigators at the meeting there may be 2 or 3 minority investigators…in a clinical trial…”
Surprisingly, participants in the study who work for organizations that also receive NIH
funding shared examples demonstrating a lack of diversity focus that still occurs at the NIH
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level, despite the policy that has been instituted as part of the NIH Revitalization Act of 1993
(USHHS, NIH, 2001; USHHS, NHLBI, 2011). Participant #10 shared:
I’ve never heard of a trial being pulled ‘cuz you didn’t meet your underrepresented
minority uh goal, right? Um nobody ever pulls a trial or scolds you or holds you
accountable to those things.
Diversity emphasis attempts. The second theme at the policy level is diversity emphasis
attempts made by either the trial sponsor or governing body. Participants discussed a recent shift
in the trial landscape with the trial sponsor or FDA emphasizing diversity. This was discussed in
relation to both the NIH and pharmaceutical organizations as the trial sponsor, as shared by
participant #10:
I don’t know if…that’s gonna continue over the next five years. I really feel like at least
at the NIH level there is beginning to be a, “this is not lip service this is important” um
kind of sense…to what I’m hearing. I also think that Pharma truly has an interest in
having their drug um tested in in all types… but…I don’t know if they’re gonna start you
know really holding people accountable…I think there might be…a shift
in…accountability uh beginning just now…just in the last maybe year or so.
Participant #4 discussed this recent shift to a diversity emphasis solely in the context of
pharmaceutical sponsors:
I think right now there’s a small uh shift and I think they’re realizing this now and we’re
seeing more and more feasibility questionnaires um, “hey where is your access to this
specific population or ethnicity group?” um I’m seeing this more on the uh mid-size,
small biopharma companies but in the huge pharma companies I still haven’t seen that
yet…
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When requirements or expectations related to diversity are put in place, this influences
research sites to focus on diverse recruitment, as described by participant #5:
…from a researcher point of view and knowing that the treatment in in the indication we
are operating is heavily impacted by ethnical background, so by genes, the FDA, they
started already requiring not only certain age groups but certain minority groups as well
because the simply the treatment of the same condition is different for different ethnical
groups so therefore…there is no way around this there will be more and more protocols
that will require this targeted population. It’s a requirement so and therefore we have to
be prepared that we have access to those uh minority groups.
Summary of Findings
In summary, several themes emerged during the data analysis process that answered the
research questions, providing an explanation for the elements involved with active minority
recruitment practices. Each research question represented a different component of the socioecological model.
Research question one: how are intrapersonal site staff elements involved in the
active implementation of minority recruitment practices for biopharmaceutical-funded
trials in the United States? Individuals who participated in this study believe that research is
important. They also believe that it is important to increase minority participation in clinical
trials and shared their frustration with barriers preventing that from happening. Participants in
this study are personally committed to providing access to clinical trials to minority participants,
which may be fueled by the satisfaction they receive from their recruitment efforts and their
personal beliefs. Finally, participants discussed examples in which they have personally evolved
through these efforts.
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Research question two: how are interpersonal site staff elements involved in the
active implementation of minority recruitment practices for biopharmaceutical-funded
trials in the United States? At the interpersonal level, participants discussed several aspects of
working as a team towards their recruitment goals. While participants in this study are not
influenced by their colleagues to focus on minority recruitment, there is a social norm within
their organizations of working as a team on their minority recruitment initiatives.
Research question three: how are organizational elements involved in the active
implementation of minority recruitment practices for biopharmaceutical-funded trials in
the United States? Participants work for organizations that have a strong sense of mission
related to improving healthcare through clinical research. A commitment to minority inclusion is
demonstrated by efforts made to provide culturally appropriate, general disease and clinical trial
education to the community with an organizational structure conducive for minority recruitment.
Participants represent organizations that demonstrate a culture of inclusion and continued
learning for further refinement of minority recruitment practices based on learning.
Research question four: how are community elements involved in the active
implementation of minority recruitment practices for biopharmaceutical-funded trials in
the United States? Participants also discussed community elements related to how although they
may have physical access to minority populations to recruit into clinical trials, factors such as
mistrust and lack of awareness come into play that hinder participation. As such, several efforts
are taken by participants and their co-workers to instill trust in the research process and between
patients and site staff, including being sensitive to and understanding cultural preferences, as
well as empowering patients to take an active role in managing their disease through education.
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Research question five: how are policy elements involved in the active
implementation of minority recruitment practices for biopharmaceutical-funded trials in
the United States? Participants in this study are not often influenced by public policy or
expectations of pharmaceutical sponsors to focus on minority recruitment. A strong sense of
commitment to meeting enrollment goals contributes to a study-level focus in expediting
recruitment. At the same time, participants are making long-term preparations for improving
access to minority groups, which also prepares them for the cohort-specific expectations from the
FDA and/or pharmaceutical sponsors that participants discussed are becoming more prevalent.
The next chapter will discuss the meaning of these findings by first comparing and
contrasting with existing literature, then by using the socio-ecological model as a lens to interpret
these findings, and lastly by suggesting recommendations for practice based on these findings
from the data analysis.
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Chapter V
DISCUSSION, RECOMMENDATIONS AND CONCLUSIONS
This qualitative study was designed to understand the socio-ecological elements involved
in the active implementation of minority recruitment practices for biopharmaceutical-sponsored
clinical trials. The socio-ecological model guided this study, and 20 themes emerged from the
data analysis and were categorized across the socio-ecological model levels.
The following section interprets the emerging themes in relation to the literature. The
meaning of these findings is then discussed in relation to the socio-ecological model.
Implications for practice that have been guided by an ecological perspective and derived from
the findings are provided to offer guidance and suggestions for enabling clinical research sites to
effectively create an environment for recruiting minority participants. In conclusion, suggestions
for future research are provided.
The literature on the topic of minority recruitment in clinical trials is in the context of
NIH-funded trials, so these findings offer a new contribution to the literature related to industryfunded trials. In addition, it is important to differentiate between the support and resources that
are provided to sites conducting NIH-funded studies versus those provided to industry-funded
studies. In addition to individual study support, the NIH oftentimes provides funding for research
activity infrastructure at sites. This includes providing strategic guidance, placing resources at
sites or providing funding for hiring and training minority staff to support recruitment and
educational activities (Duda et al., 2011; Cook et al., 2005; Hinton et al., 2010). The discussion
that follows will focus on areas in which the study findings are similar and divergent from
existing literature, outside of these differences discussed relating to the literature and support
provided for NIH-funded trials.
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Themes Interpreted with Literature
As previously discussed, the themes that emerged have been categorized across the socioecological model levels, with themes representing the “intrapersonal” and “organizational” levels
found to be more prominent in this study. A reason why these two levels were more prevalent in
this study is likely a result of the study design and interview questions that captured a better
understanding of research site staffs’ perceptions and experiences within their organizations
related to minority recruitment. Interestingly, attitudes and other intrapersonal elements
regarding minority inclusion in clinical trials from a healthcare professional perspective are not
widely explored in the existing literature and are limited to PI and physician attitudes, perception
of barriers and extent of or lack of focus by virtue of setting and measuring progress toward
minority enrollment targets (Boden-Albala et al., 2015; Durant et al., 2007; Eggly, Barton,
Winckles, Penner, & Albrecht, 2015; Howerton et al., 2007; Simon et al., 2004; Williams &
Corbie-Smith, 2006).
From an organizational perspective, infrastructure barriers to minority recruitment, such
as inexperience and limited funding, are discussed in the literature (Durant et al., 2014; Joseph &
Dohan, 2009; Williams & Corbie-Smith, 2006). However, outside of the importance of hiring a
diverse research staff, organizational contextual characteristics in relation to successful minority
recruitment practices are not widely described in the literature (Etkin, Farran, Barnes, & Shah,
2012; Ford et al., 2013; The Society for Women’s Health Research & FDA, 2011; Williams &
Corbie-Smith, 2006). Existing literature suggests that characteristics related to research sites may
have contributed to the successful enrollment of minorities into clinical trials (Duda et al., 2011;
Jimenez et al., 2013; Wright et al., 2001). Participants in this study have provided context for
specific organizational characteristics that contribute toward the active implementation of
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minority recruitment practices, including incorporating improving access to clinical research in
an organization’s mission statement and nurturing a culture of inclusion.
Although the data that emerged from this study were not as prominent on the community
level as the intrapersonal and organizational levels, there was still an abundance of data
representing the community level of the socio-ecological model. These data were provided from
the perspective of the individuals who participated in this study and was primarily related to
efforts they take to engage with their local communities in efforts to build trust. Most of the
literature related to minority recruitment is specific to the community level of the socioecological model. Many of the examples discussed in the literature share cultural or communityspecific recruitment strategies that involved engaging with the local community and building
trust (Ejiogu et al., 2011; Etkin, Farran, Barnes, & Shah, 2012; Germino et al., 2011; Wallington
et al., 2016). The literature also provides minority patient perspectives, including motivators and
barriers to clinical trial participation (Ejiogu et al., 2011; Ford et al., 2012; Ford et al., 2013;
Markman, Petersen, & Montgomery, 2008; Salihu, Wilson, King, Marty, & Whiteman, 2015;
Wells & Zebrack, 2008). In this study, participants discussed patient motivators and barriers to
trial participation. Although this information was not collected directly from patients, the
perceptions shared by this study’s participants corroborates with existing literature describing
minority patient perspectives regarding clinical trials. In addition to information reported in the
literature, the participants in this study provided context surrounding minority patient interest in
receiving disease education and learning about clinical trials. Participants discussed building
long-term trusting relationships with minority communities by providing education and
empowering patients to take an active role in managing their disease. Study participants also
shared their experiences related to learning about other cultures through face-to-face interactions.
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At the interpersonal level, only two themes emerged from this study – teamwork and no
peer influence. The existing literature related to minority recruitment in clinical trials is not
inclusive of the interpersonal level of the socio-ecological model from a research provider
perspective. Instead, the socio-ecological model has been used in the literature for categorizing
barriers to minority participation in clinical trials and describes influencers of patients’
interpersonal relationships as opposed to researchers’ interpersonal relationships (Salihu, Wilson,
King, Marty, & Whiteman, 2015; Wells & Zebrack, 2008). Thus, the themes at the interpersonal
level provide new contributions to the literature.
Similarly, two themes emerged that represent the policy level of the socio-ecological
model. These two themes are lack of diversity emphasis and diversity emphasis attempts made
by either the trial sponsor or governing body. Due to the application of the socio-ecological
model for this study, the policy level was defined to represent both public policy and clinical trial
policy or expectations set forth by trial sponsors. Therefore, any expectations or lack of
expectations regarding minority enrollment on behalf of the pharmaceutical sponsor was
categorized under the policy level, which broadened the opportunity for representation of this
level. The clinical trial literature is not heavily saturated with policy-level representation related
to minority recruitment. An abundance of literature discusses minority recruitment strategies
utilized for NIH-funded studies; however, the focus of the literature is on describing the
strategies used and not policy implications related to these studies having a minimum
requirement for enrolling racial and ethnic minority participants as a stipulation of receiving
funding (USHHS, NIH, 2001). However, some of the strategies utilized in the literature that were
discussed may have been made possible due to additional funding and support. There is also
literature regarding the low uptake of planning for the NIH’s mandate for minority inclusion with
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regards to setting minority enrollment goals, requiring cultural competency training and
translating study materials (Boden-Albala et al., 2015; Durant et al., 2007; Durant et al., 2014;
USHHS, NIH, 2001). Finally, lack of access to healthcare or not having health insurance are
discussed as barriers to minority participation in clinical trials (IOM, 2003; Swanson & Ward,
1995; USHHS, CDC, 2011a). While not a dominant theme, participants in this study discussed
lack of access to healthcare as being both a barrier and an enabling factor toward minority
participation in clinical trials.
Intrapersonal themes interpreted with literature. Participants in this study
demonstrated their personal commitment to minority recruitment by initiating self-directed
action for this purpose. Based on the literature, underlying factors contribute to active minority
recruitment efforts, specifically actively offering a trial to minority patients. For example,
researcher perception of barriers influence whether or not minorities are offered trial
participation (Durant et al., 2007; Simon et al., 2004; Stone, Mauch, & Steger, 1998; Williams &
Corbie-Smith, 2006). PI motivation also is believed to play a role in successfully recruiting
minority participants (Wright et al., 2001). Researcher attitudes influence success with minority
recruitment, likely because those with positive attitudes toward minority inclusion are more
active in enrolling patients (Williams & Corbie-Smith, 2006). Participants in this study not only
believe that clinical research is important, but also that it is important to increase minority
participation in clinical trials. Participants discussed their frustration with barriers to recruiting
minority participants. Based on the findings of this study, participants’ positive attitudes toward
minority inclusion are fueled by their desire to ensure equitable access to treatment options
available in clinical research and their frustration with barriers. These factors likely contribute to
participants in this study taking an active role in minority recruitment. In addition, participants
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shared their experiences that go beyond merely offering a trial and shared examples detailing
ways in which they are personally committed and determined to improve minority participation
in clinical trials. Participants discussed feeling satisfied with and rewarded by their jobs, more so
than the industry trends reporting job satisfaction levels of clinical research professionals
(Korieth and Anderson, 2015). The participants also discussed personal growth as they undergo a
continuous process of learning through their recruitment efforts. By better understanding their
patients’ needs and perspectives, participants are better able to be effective at communicating
cross-culturally. Existing literature does not discuss personal growth or change among clinical
research staff. For participants in this study, continuous learning is important to being more
effective in minority recruitment.
The limited literature discussing intrapersonal elements from a research professional
perspective is confined to PI and physician attitudes and perceptions regarding clinical research
or minority inclusion in clinical research. This study offers perspectives from other research
professionals related to minority inclusion in clinical trials, outside of PIs. The majority of
participants in this study have responsibility for recruitment within their organizations. They
have positive perceptions regarding the importance of diversity inclusion in clinical research and
are personally committed to actively implementing minority recruitment efforts. For research
organizations focusing on minority recruitment, taking perspectives regarding diversity inclusion
into account is an important consideration when making hiring decisions. When organizations
focus on minority recruitment, hiring considerations for recruitment staff should include those
who believe minority inclusion to be important and thus contribute to a culture of inclusivity
within the organization.

154
Organizational themes interpreted with literature. One of the key elements to
successfully recruiting minority participants, which is supported by the literature, is education of
minority communities through providing disease and general clinical trial education prior to
presenting a specific trial opportunity (Etkin, Farran, Barnes, & Shah, 2012; Regnante et al.,
2019; The Society for Women’s Health Research & FDA, 2011). Despite recognition of the
importance of minority community education prior to study-level recruitment activities, such
action is not being taken ahead of study recruitment activities nor is providing community
education a common practice at the site level (Livaudais-Toman, Burke, Napoles, & Kaplan,
2014). Those research sites that are engaged in educating their local communities are providing
education at the same time as trial recruitment, even when receiving NIH funding or resources
(Aponte-Rivera et al., 2014; Cook et al., 2005; Germino et al., 2011; Hinton et al., 2010;
Sturgeon et al., 2018). The success and sustainability of this approach to providing education to
minority communities is yet to be documented among industry-funded studies. However, NIH
National Institute on Aging Alzheimer’s Disease Research Centers (ADRCs) and NCIdesignated comprehensive cancer centers provide community education to minority communities
prior to introducing a clinical trial opportunity in partial fulfillment of the requirements for being
recognized as a federally designated center and maintaining federal designation status (American
Cancer Society, 2014; Etkin, Farran, Barnes, & Shah, 2012; USHHS, NIH, 2018, January;
Regnante et al., 2019).
Surprisingly, participants in this study discussed how their organizations have made the
commitment to invest in providing general disease education to minority communities prior to
discussing a study, despite the fact that this is not common practice even for NIH-funded
institutions (other than the federally designed ADRCs and NCI comprehensive cancer centers
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that are stipulated to do so). Educational events are costly and they yield few participants
(Sturgeon et al., 2018). Additionally, pharmaceutical sponsors are focusing on expediting trial
enrollment (USHHS, OIG, 2000). Sponsors provide centralized recruitment support on a studyby-study basis, leaving it up to the research sites to establish a long-term commitment to
community education, should they wish to do so. The extent of community education being
provided by sites that conduct industry-sponsored trials is unknown, though presumed scarce or
non-existent based on the literature that depicts NIH-funded research institutions as not initiating
community education at all, let alone as a long-term investment (Livaudais-Toman, Burke,
Napoles, & Kaplan, 2014). This clearly differentiates the participants in this study from research
staff in both NIH and industry-sponsored sites. Industry stakeholders who attended a recent
workshop acknowledged that although recommended, community education prior to focusing on
study recruitment is not occurring with industry-sponsored studies (The Society for Women’s
Health Research & FDA, 2011). Some interview respondents discussed how this concept was
fairly new to them as they recently learned about the importance of community education when
they started focusing on minority recruitment. They ultimately made that change to overcome
barriers and commit to investing in a long-term commitment to educating their local
communities and empowering patients to understand their disease and its potential treatment
options and to be comfortable with the concept of participation in a clinical trial prior to
presenting a specific trial opportunity.
Individuals in this study also discussed how their organization demonstrates its
commitment to minority recruitment by investing in structural enhancements. As described in the
literature, research center infrastructure impacts the successful enrollment of minority
participants, including having the appropriate dedicated staff, resources and structure for
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conducting research activities (Etkin, Farran, Barnes, & Shah, 2012; Ford et al., 2013; Joseph &
Dohan, 2009; Williams & Corbie-Smith, 2006). Even with these investments and having
leadership supportive of clinical research initiatives within their organizations, participants
discussed continuing barriers. Many expressed the need for additional research staff members
and more language capabilities, which are also discussed in the literature as limiting factors for
minority recruitment (Durant et al., 2014; Joseph & Dohan, 2009). However, participants also
shared examples of how their organizations have overcome barriers to improving their research
infrastructures and have enhanced their capabilities to better meet the needs of diverse patients.
Participants also discussed organizational contextual characteristics in relation to
implementation of minority recruitment practices, which are not widely described in the
literature. Participants in this study work for organizations with a mission related to improving
healthcare through clinical research, a finding that is to be expected since these organizations
conduct clinical research. Improving access to clinical research is a component of the
organizational mission for many of the participants’ organizations. While the literature does not
discuss the organizational mission statements of clinical research sites, the authors of one study
reported that research activities are not sufficiently supported when clinical research is not
incorporated into a research organization’s mission statement (Joseph & Dohan, 2009). Findings
from this study suggest that both incorporating clinical research and providing access to clinical
research within a research site’s mission statement are components that promote active minority
recruitment efforts. This finding is supported by the fact that participants in this study discussed
recruitment activities being driven by their mission. Believing in the mission was an important
aspect leading to principles of working in support of carrying out their organization’s mission.
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Regnante et al. (2019) reported that cancer research centers recruiting a high percentage
of minority clinical trial participants demonstrate an inclusive organizational culture by
dedicating leadership roles to diversity and hiring minority staff. In addition to leadership
support deriving a culture of inclusion, the organizational cultures related to this study’s
participants also portray an importance and focus on minority recruitment based on co-worker
attitudes and interactions. Participants’ co-workers help to create an inclusive organizational
culture that is prevalent across the organization.
Another characteristic unique about the participating organizations is that they have
processes that are flexible. This allows their minority recruitment approaches to change based on
learnings from past experience, as individuals and their co-workers gain a better understanding
of the patients being recruited and how to better adapt to those patients’ cultural preferences and
needs. Crosson, Lane, and White (1999) discussed how organizational learning provides a
competitive advantage. Individuals who participated in this study discussed the enhancements
that were made based on organizational learning that improved their organizations’ competencies
and allowed them to improve their recruitment of minority trial participants.
Community themes interpreted with literature. Although organizations conducting
clinical research may be located in diverse communities or have a high percentage of diverse
patients they manage in clinical practice, this does not equate to having access to these diverse
patients for clinical research. While physical access based on geography may be apparent, many
barriers preclude research organizations from the successful enrollment of minority patients into
clinical trials. For example, according to one study, organizational structural barriers prevented
minority enrollment into clinical research within a safety net hospital that serves a high
percentage of minority patients (Joseph & Dohan, 2009). Mistrust in the healthcare system
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and/or clinical research also has prevented clinical research organizations from enrolling
minority patients into trials (Corbie-Smith, Thomas, Williams, & Moody-Ayers, 1999; Durant et
al., 2014; Ejiogu et al., 2011; Ford et al., 2013; Roberson, 1994; Swanson & Ward, 1995).
Similarly, individuals in this study discussed how factors such as mistrust or a lack of
understanding related to clinical trials come into play that prevent them from enrolling minority
patients into trials, despite having physical access to patients based on geography. Despite
geographical location, it still takes time and a concerted effort to overcome the multitude of
barriers that prevent successful enrollment of minority participants into clinical trials.
As mistrust is a prominent barrier, participants in this study discussed the many efforts
they have taken to instill trust in clinical research, as well as a relationship of trust between
research staff and minority patients. Participants discussed the need for developing and fostering
long-term, trusting community relationships that start prior to and extend beyond a specific study
opportunity, and this is facilitated through education. Participants and their research
organizations engage in these activities despite existing literature indicating that building trusting
relationships through community education is not common practice outside of the federally
designated ADRCs and NCI comprehensive cancer centers, as discussed previously (Etkin,
Farran, Barnes, & Shah, 2012; Livaudais-Toman, Burke, Napoles, & Kaplan, 2014; National
Academies of Sciences, Engineering, and Medicine, 2016; Regnante et al., 2019). Providing
general and personalized disease education, coupled with health screenings, is a way to establish
trust by giving back to the community without asking for anything in return. Participants
discussed how their immediate motivation behind community education efforts is related to
developing trust. Recruitment may be their ultimate goal in the future, but their immediate goal
is to build trust with minority communities. This concept is not widely practiced and is one area
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in which the participants in this study display an exceptional practice that is unique compared
with other clinical research sites.
Research stakeholders have indicated that disease education is important to minority
patients (The Society for Women’s Health Research & FDA, 2011). Participants in this study
further validated this and shared that their efforts to empower patients with knowledge and selfefficacy for managing their diseases was of interest to minority patients. In fact, when discussing
patient factors that impact access to clinical trials, participants discussed how patients’
engagement with managing their health positively impacts their access to trials more than being
disengaged negatively impacts access. Participants rarely discussed minority patient interest in
trials in relation to personal benefit, which may suggest that patients aren’t as motivated by
financial incentives as by becoming engaged with managing their disease. However, one of the
barriers is access to information. Patients have to first be made aware of details about their
disease and clinical trials as a potential option to be able to benefit from participation.
Participants also discussed the role a commonality between research staff and patients
plays in developing trust. Ensuring research staff are the same race or ethnicity and speak the
same language as the patients being recruited is recommended for building trust and has been
successful for enrolling minorities in past studies (Germino et al., 2011; Ford, 2013; Hinton et
al., 2010; National Academies of Sciences, Engineering, and Medicine, 2016). Also, participants
emphasized that the PI needs to be involved with recruitment activities. Regnante et al. (2019)
reported that a physician’s role is important in influencing a patient’s willingness to participate in
clinical research. Further, trusting relationships between a physician and a patient, as well as
between a physician and the patient’s family members, contribute toward successfully enrolling
minority patients in clinical research (Regnante et al., 2019; Wright et al., 2001). Leveraging a
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patient’s social network is a tactic participants discussed that helps instill trust in clinical
research. Many of the successful examples of recruiting minorities that have been discussed in
the literature involve developing community partnerships with key stakeholders as a necessary
component for building trust among minority communities (Germino et al., 2011; Ejiogu et al.,
2011; Regnante et al., 2019). Participants in this study shared that they partner with community
stakeholders that have already been established as trusted sources within minority communities,
such as pastors and minority association leaders. Some participants discussed this approach as
being their first step in gaining access to minority communities. Interestingly, while this was
discussed as an important component among participants in this study, as well as reported by
some of the literature reporting on NIH-funded studies, this approach does not appear to be
prevalent among industry-funded clinical research sites. According to a white paper published by
a trade organization representing clinical research sites, the Society for Clinical Research Sites,
only half of individuals representing research sites that responded to a survey related to success
factors in recruiting diverse patient populations in clinical studies indicated that they had
community connections. Yet, individuals representing sites with more community connections
self-reported more success with enrolling diverse patients into clinical trials than the individuals
from sites without community connections (Pierre, 2018). Mistrust or disapproval of clinical
research by a patient’s social network is a known barrier to minority recruitment (Ford et al.,
2008; Swanson & Ward, 1995). Therefore, it would be prudent for researchers to educate and
build trust among a patient’s social network, including leveraging already trusted sources. One
way participants mentioned that this is achieved is by including family members in recruitment
and consent discussions.
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Finally, culturally sensitive researchers provide a valuable role in the successful
enrollment of minorities in clinical trials, especially since cultural differences have an effect on
the communication and understanding of health information (Ejiogu et al., 2011; Ingram, 2012;
IOM, 2004). However, formalized cultural sensitivity or cultural competency training is not
always instituted (Boden-Albala et al., 2015). Only six of the 15 participants in this study
reported having formal cultural competency training requirements at their organizations.
Participants, however, discussed their personal and organizational commitments to actively
implementing minority recruitment practices regardless of whether or not formal cultural
competency training was a requirement within their organizations. Furthermore, formalized
cultural competency training was not a factor in recruiting minorities in equal or greater
proportion to the US population in this study. This is in discordance with the findings of the
author of a recent industry white paper who reported that cultural competency training was a
contributing factor that enabled sites to have more success with enrolling diverse participants.
The author also reported that those research sites in which none to most of the staff were
culturally competent had less success with recruiting diverse patient populations (Pierre, 2018).
As a measure of ensuring that staff members are culturally competent, research sites may want to
consider integrating cultural brokers into their research teams. Serving as a connecting link
between research staff and the communities they serve, this strategy has been found to enhance
trust, promote cultural understanding among team members and ultimately improve access to
minority populations (Germino et al., 2011). Rather than discussing formalized cultural
competency training, participants in this study discussed how understanding and being sensitive
to other cultures does not necessarily come from institutionalized training. Instead, they
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discussed the importance of face-to-face interaction with community members and being
immersed in their culture.
Interpersonal themes interpreted with literature. Ejiogu et al. (2011) described
empowering research staff members to take an active role in study-related decision-making by
soliciting opinions from staff members to inform strategy decisions. This way of working that
was implemented by the study’s PIs motivated research staff to engage in study activities and
also promoted staff retention. It was one of many components that led to the successful
implementation of this longitudinal study in which racially and socioeconomically diverse
participants were recruited. While not an overarching theme, some participants in this study
discussed team member satisfaction in relation to being provided autonomy in decision-making.
The importance of working as a team was a key theme that was divergent from the existing
literature. Many different aspects of teamwork were discussed, including proactive team
planning, involving the PI in recruitment activities, learning and problem solving as a team,
having effective communication across and among teams, as well as having team camaraderie.
These characteristics of participants’ interpersonal relationships and interactions among their coworkers provided insight into their organizational cultures and the high regard placed on working
as a team. Teamwork was important for informing the implementation and refinement of
minority recruitment practices in this study.
Individuals in this study conveyed their personal beliefs in the importance of increasing
minority participation in clinical trials. Through the efforts they take, they also demonstrate a
personal commitment to providing minority populations with greater access to clinical trials.
Peer influence is not a factor in these actions that individuals in this study take to promote
diverse inclusion in clinical trials. This finding is unique in that the clinical trial literature related
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to minority recruitment does not discuss social influence on minority recruitment efforts.
Additionally, the clinical trial literature related to the socio-ecological model is primarily
categorizing motivators and barriers to minority recruitment by providing insights related to a
patient’s intrapersonal perspectives and interpersonal influences, and not perspectives and
interpersonal influences among research staff (Frew et al., 2014; Salihu, Wilson, King, Marty, &
Whiteman, 2015; Wells & Zebrack, 2008). The finding that individuals in this study are not
influenced by their peers with regard to their efforts taken to actively recruit minority trial
participants demonstrates that the commitment of these individuals may be due to personal
attitudes and enabled by organizational contextual factors and teamwork. Although social
influence related to colleagues external from participants’ organizations was not prevalent,
participants’ co-workers within their research organizations contribute to a culture of inclusion.
A combination of the study participant’s attitudes and their co-worker attitudes contribute to a
social norm within their organization of focusing on minority recruitment.
While external social influence is not a factor in promoting active minority recruitment
efforts, participants with a role of PI and/or owner of a research site instead discussed actions
they take in attempts to encourage their peers in relation to minority recruitment. Interestingly,
these individuals discussed providing education to their colleagues on clinical research and the
importance of having diverse representation in clinical trials. Education is also a key practice
among study participants in their efforts to improve minority participation in trials and build
trust. As previously mentioned, the clinical trial literature does not cover social influence on
minority recruitment efforts, so this finding suggests a new contribution to the literature as an
area for future research with a larger sample size.
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Given the lack of influence or even discussions taking place among the participants’
peers, it is evident that clinical research professionals are not widely focusing on minority
recruitment. Additionally, according to the literature, many minority physicians do not view
clinical research as beneficial (Ramirez et al., 2008). PIs and/or owners of a research site
initiated individual efforts to educate colleagues. This finding provides an opportunity by
leveraging the finding that social relationships affect behavior (McLeroy, Bibeau, Stecker, &
Glanz, 1988). Clinical trial stakeholders, such as sponsors, clinical research organizations and
federal agencies, may want to consider attempting to influence social norms by launching
education programs targeted toward the healthcare provider community to raise awareness of the
critical need to improve access to clinical trials among minority populations and to enhance the
belief in the research process among potential referring physicians.
Policy themes interpreted with literature. There was a strong sense of obligation
within participants’ organizations to meet their committed enrollment goals. Participants
discussed minority enrollment expectations only in the context of study-specific racial or ethnic
subgroup enrollment numbers required by either the study sponsor or the FDA. In this study, the
intermittent minority enrollment requirements discussed by participants is to be expected
because of the focus on expediting trial recruitment and lack of policy mandating enrollment of
clinically relevant populations in industry-funded trials (USHHS, FDA, 2014; USHHS, FDA,
2016; USHHS, OIG, 2000). These findings result in a reduced focus on inclusion of diverse
populations that for some trickles down to the site’s activities where striving to meet enrollment
targets on a study level becomes a top priority. Rather than enact federal policy, pharmaceutical
sponsors could start to hold research sites accountable or incorporate minority enrollment targets
into site contracts that are based on disease prevalence in those populations. This may encourage
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research sites to focus more on minority recruitment, especially since participants in this study
discussed the need to meet established enrollment goals as motivation behind fulfilling this
commitment. In addition, the pressure to meet enrollment goals shifts priorities within
participating organizations. Although they still engage in actively pursuing efforts to increase
access to clinical trials among minorities, at a study level, they may need to shift focus to fulfill
the study requirements. This may also be partly due to the paradigm described by study
participants in that they take broader efforts to provide education and build trust to encourage
minority participation, while their goals on a study level are to fulfill the need for enrollment in
the trial. A shortage of educational campaigns nationwide also may contribute to the efforts
taken by participants in this study to raise general awareness of clinical trials within minority
communities. Various resources are available, such as the free “AWARE for All” clinical
research educational programs held by the non-profit organization “The Center for Information
and Study on Clinical Research Participation (CISCRP)” (CISCRP, 2020). It is apparent there is
a need to increase these efforts since lack of awareness of clinical research is a known barrier to
minority participation in clinical trials (Ejiogu et al., 2011; Ford et al., 2008; Leiter, Diefenbach,
Doucette, Oh, & Galsky, 2015; Ramirez et al., 2008; Roberson, 1994; Simon et al., 2004).
On an ad hoc level, expectations and requirements set forth by the trial sponsor or FDA
to recruit a certain proportion of diverse participants for specific studies influenced minority
recruitment practices within the participants’ research organizations in this study. If trial
sponsors expand these expectations beyond select protocols, it may motivate more research sites
to enhance their capabilities and efforts in recruiting diverse participants. Participants discussed a
recent shift in the trial landscape with more emphasis being placed on diversity in areas such as
site selection and expanding the number of protocols with minority enrollment requirements, for
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example. However, the fact that the participants in this study actively recruit minorities already
could partially explain the increased focus they reported seeing with trial sponsors.
Participants discussed barriers to access related to location of research sites and lack of
diverse healthcare professionals conducting research. Efforts to promote a diverse workforce
with the skills and interest in conducting clinical research may improve minority participation, as
a known barrier to minority recruitment is a disparity of minority physicians involved in clinical
research (Ramirez et al., 2008). This also may contribute towards the availability of known
research sites with patient demographic populations that represent the prevalence of a disease.
In spite of strides the NIH has taken to enhance the diversity of clinical trial populations,
it is evident that more work is required, since disparities in trial participation still exist for NIHfunded studies (National Academies of Sciences, Engineering, and Medicine, 2016). While the
sample size was small, participants in this study working for research organizations that also
receive NIH funding provided examples that support this. Surprisingly, for example, informed
consent forms are not always translated into Spanish, despite conducting a trial in locations with
a large Spanish-speaking population. The literature supports that there is still a lack of focus in
that recruitment goals for individual minority groups are not always set, consent forms and
recruitment materials often are not translated and cultural competency training is not often
required for site staff conducting NIH-funded studies (Boden-Albala et al., 2015; Durant et al.,
2007; Durant et al., 2014). It is evident that the NIH may need to provide additional funding and
support to research sites to enable adherence to and accountability for their policy on achieving
proportionate trial representation (USHHS, NIH, 2001).
Unfortunately, the participants discussed that some of the attempts made by trial sponsors
to stipulate demographic cohort requirements failed. For example, several participants discussed
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trials with mandated minority cohort enrollment requirements that were canceled because none
of the sites could recruit the needed numbers. One participant mentioned minority lack of trust
and a need for education as barriers to recruitment, while another participant discussed study
design barriers. These examples demonstrate that a concerted effort is needed to enhance
understanding of successful minority recruitment practices that can be shared with research
stakeholders across the nation. Pharmaceutical sponsors and contract research organizations need
to plan for diversity upfront in considering the target demographic representative of the disease
prevalence and then design the protocol and select research sites in accordance with the target
patient population. They then need to develop a diversity recruitment strategy and provide
funding to support these initiatives. Research sites implement minority recruitment practices at a
local level, and it is critical that they are equipped with the skills and resources to be able to do
so effectively.
Consideration of the Socio-Ecological Model
As discussed, the socio-ecological model guided this study and themes emerged at each
level of the model that provided explanation for elements involved in the active implementation
of minority recruitment practices. When reviewing the findings that represent each level of the
model, more themes emerged for the intrapersonal and organizational levels of the model. A
substantial number of findings emerged for the community level of the model. Fewer findings
emerged that relate to the interpersonal and policy levels of the model. There are two points to
note in relation to the model and its utility for providing a lens to answer the research questions.
First, participants in this study represented the intrapersonal level of the model and spoke mainly
to intrapersonal and organizational components. That is to be expected given the design of the
study and the interview guide. Had other stakeholders, such as minority patients, participants’
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co-workers and pharmaceutical sponsor representatives, also been included in this study, then it
is anticipated that a substantial amount of additional information would have emerged at the
community, interpersonal and policy levels. The information shared by participants offered
unique contributions to the literature at each level of the socio-ecological model, even though
data were collected from an intrapersonal perspective. Second, while looking at the findings that
emerged at each level of the socio-ecological model individually offers unique insights, this
approach also provides a fragmented view of elements involved in active minority recruitment
practices. Instead, a comprehensive and holistic view facilitating the understanding of effective
minority recruitment practices is offered when considering the findings at multiple levels in
relation to one another. This is further explained in the next section discussing the theoretical
implications for the utilization of the socio-ecological model for this study.
Theoretical Implication: Interaction of Socio-Ecological Elements Explain the Active
Implementation of Minority Recruitment Practices
The socio-ecological model was used as a conceptual framework guiding this study.
Themes emerged at each level of the model that helped to identify and explain the components
contributing to the active implementation of minority recruitment practices. The premise of the
model is environmental change based on interactions between individuals and their environment
(Bronfenbrenner, 1977; McLeroy, Bibeau, Stecker, & Glanz, 1988). The model further supports
this study’s findings in that the environment plays a role in influencing behavior and vice versa,
behavior influences the environment as it relates to minority recruitment. For example,
participants in this study feel satisfied with their work and rewarded by the positive impact they
make on patients, indicative of a reciprocal relationship with their environment. At an
interpersonal level there is a sense of team spirit. They work for organizations that have an
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inclusive culture. There is a scarcity of efforts at a sponsor or national policy level to educate
minority communities on clinical trials, and study participants recognize a need to overcome
barriers such as mistrust. All of these factors play a role in the commitment and actions
participants take to provide minority patients with access to clinical trials. These results also
suggest that we need to consider the interaction of components at all levels of the socioecological model for minority recruitment. Although more findings emerged for some levels of
the model over others due to the nature of obtaining information from an individual perspective,
it was evident that findings at all levels of the model in combination with each other offer a more
comprehensive explanation of the elements involved in active minority recruitment practices.
Thus, these multi-faceted findings reveal that an ecological perspective offers insight into
improving access to clinical trials and the socio-ecological model provides an opportunity for
improving minority recruitment practices in the future. This is illustrated graphically in Figure 3.

Figure 3. This figure illustrates the interaction of socio-ecological elements in explaining the
active implementation of minority recruitment practices for improving access to clinical trials.
Adapted from McLeroy, K., Bibeau, D., Steckler, A., & Glanz, K. (1988). An ecological
perspective on health promotion programs. Health Education Quarterly, 15(4), 351-377.
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Similar to other health promotion interventions, the socio-ecological model only works
when put into practice. As a means to help facilitate application of findings derived from the
execution of a socio-ecological model, solutions emerged for improving minority recruitment
practices that were guided by the implementation of an ecological perspective. Specifically, a
model for research sites to use to inform the application of minority recruitment practices
emerged from this study’s findings, which demonstrates how a combination of recommendations
interacting at multiple levels of the socio-ecological model can be applied practically.
Practice Implications: Site Action Plan for Making Minority Recruitment a Core
Competency
The model that emerged from this study may provide a more comprehensive guide to
help organizations that conduct clinical research improve their capabilities by creating an
environment effective for recruiting minority study participants. This model was derived from an
ecological perspective, and thus by making minority recruitment a site’s core competency, the
focus is on environmental system change with the ultimate goal of improving minority access to
clinical trials. This model, the “E3 Model”, consists of three components:
•

Establish: Commit to prepare the foundation

•

Engage: Invest in partnering with the community

•

Execute: Prepare to deliver, refine, repeat
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Figure 4. This figure illustrates the E3 Model site action plan for making
minority recruitment a core competency.
Establish: Commit to prepare the foundation.
Commitment. First, it became evident that sites need to establish themselves internally.
They need to make the commitment to prepare a foundation for minority recruitment within their
organizations. For example, they need to articulate and gain buy-in for the value proposition
across the board from leadership to front-line staff. It cannot just be the top executives who
believe that minority recruitment is important. Research and diversity need to be incorporated
into the organization’s mission and the ways of working need to support that mission, including
recruiting people who believe in and can help foster a culture of inclusivity. Appropriate training
measures need to be in place to promote effective communication with patients, as well as with
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other staff members internally. An illustration depicting the required measures for establishing
the foundation is represented in Figure 5.

Figure 5. This figure illustrates the “Establish” component of the E3 Model site action plan
for making minority recruitment a core competency.
Only after the foundation is established will sites be ready to engage with the community.
Engage: Invest in partnering with the community.
Long-term investment with developing community relationships. The next component
of the E3 Model is to engage in investing in partnerships with the community. This requires two
main actions. First, listen and understand and second, educate and build trust. Figure 6 illustrates
the engagement component of the E3 Model.
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Figure 6. This figure illustrates the “Engage” component of the E3 Model site action
plan for making minority recruitment a core competency.
Listen and understand. The first step in partnering with the community to develop longterm relationships is to obtain an understanding of the preferences and culture of the local
community. This is done by being immersed in an attempt to appreciate and learn other cultures,
as well as by soliciting input directly from community members.
Educate and build trust. Once an understanding has been established, the second step in
partnering with the community to develop long-term relationships is to start building trust and
forming relationships by providing education, leveraging existing trusted sources as a catalyst for
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delivery. This education needs to be personalized. For example, high blood pressure and diabetes
are asymptomatic diseases and people with these conditions may be asymptomatic. The first step
should be to educate people on the importance of screening and what each individual’s results
mean and tie it back to the importance of why that should matter to each individual. One critical
success factor for this component is that recruitment is not the primary focus at this stage. The
primary focus is empowering patients and their families with the knowledge and self-efficacy to
understand and manage their disease and treatment options, including clinical trials as a potential
option.
Execute: Prepare to deliver, refine, repeat.
Putting preparation to work. The next component of the E3 Model is to execute and
prepare to deliver, refine and repeat. Once the foundational core has been established and
research sites are actively engaged in developing relationships with the community, only at this
point is it time to put preparations to work and focus on recruitment for a specific study. At this
point, when research professionals are out in the community educating on management for a
specific disease, the notion of a clinical trial has already been discussed as a potential option for
consideration. For example, the assessments that are required have been discussed and
community member feedback and questions have already been solicited and responded to. At
this point, a relationship and basic understanding has been established and discussions about the
potential for enrollment in a specific trial can be offered. It’s also important that an ongoing
communication across teams and with the community is maintained in order to refine and
leverage learning for future success as an ongoing process. Figure 7 illustrates the components
for the execution phase of the E3 Model.
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Figure 7. This figure illustrates the “Execute” component of the E3 Model site action
plan for making minority recruitment a core competency.
While future research is required to assess the impact of the E3 Model, the shared goals
with successfully implementing the E3 Model into practice include site staff satisfaction and
growth, improved sponsor success, improved community and population health, greater trial
generalizability, business growth and future funding.
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Figure 8. This figure illustrates the E3 Model site action plan for making minority
recruitment a core competency.
Limitations
There are limitations to this study. First, the sample is a convenience sample, identified
from publicly available data. For this reason, there is a potential for self-selection bias from
participants interested in this topic. Also, data collected from the interviews reflect self-reported
perceptions regarding organizational, community, interpersonal and policy elements. Finally, as
this is a qualitative study, the results are not generalizable and an assumption was made that
study participants honestly conveyed their experiences and perspectives. Participants did
represent various roles across the full spectrum of clinical research organizational settings in
both rural and urban areas, offered trials across a variety of therapeutic areas and had differing
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historical performance in minority enrollment. This allowed for obtaining a broad range of
perspectives from research stakeholders who were able to provide their first-hand experiences in
recruiting minorities. However, the small sample size selected through purposeful sampling
limits transferability of findings. Instead, readers will be able to apply findings to their own
unique situations to make transferability judgments on their own.
Future Research
There are several opportunities for future research that emerged during data analysis.
While not a dominant theme, participants discussed the importance of recruiters having certain
personality characteristics in relation to minority recruitment. They also discussed being
passionate about what they do and going “above and beyond.” Future research could be designed
to better understand how personality characteristics contribute to recruitment efforts and job
satisfaction as an implication for future hiring decisions.
As the findings in this study are based solely on the interview respondent’s perceptions,
future research could involve additional stakeholders to represent direct perspectives at each of
the socio-ecological model levels. For example, minority patient preferences were conveyed as
experienced by the interview respondents. Although perspectives shared, such as mistrust of
research and interest in learning about clinical trials, are similarly documented in the literature,
obtaining direct input from minority community members would offer a more comprehensive
view of community factors, for example.
The themes presented at the intrapersonal level were consistent across the participants
that represented various roles within their organizations, except for several occurrences in which
the responses from the participant in a non-patient role varied. However, there was also an
apparent difference in responses between roles with regards to other information shared at the

178
intrapersonal level that was not considered an overarching theme. The PIs’ and owners’
responses were consistent with one another, yet varied with the recruitment leads’ responses in
some areas. This also occurred at the interpersonal level as it relates to peer influence regarding
minority recruitment with the PIs and owners actively encouraging others. Future research could
explore these differences in responses between roles.
This study was bound by recruitment practices and, therefore, retention of minority
participants was not incorporated into the interview guide and thus not a main focus for the
study. As these participants shared their gainful knowledge and perspectives related to minority
recruitment, future research could be conducted to understand how these participants promote
retention.
Finally, while many participants in this study recruit a high percentage of minority
clinical trial participants, this was not a specification in the eligibility criteria for study
participation. Participants representing organizations with lower historical minority recruitment
performance still offered indistinguishable insights related to their minority recruitment
commitment and practices. For this reason, future research could focus on success not by
excluding individuals that have not historically recruited a high number of minority trial
participants and instead conduct a focus group or survey with these same participants to establish
the E3 Model as a model for success.
Conclusion
In conclusion, guided by the socio-ecological model, the results of this research
demonstrate that environmental change can provide a premise for improving access to clinical
trials among minority populations. This research also provides practical guidance for research
sites to implement minority recruitment practices by implementing the E3 Model. To effectively
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implement the E3 Model will require a shift in the standard approach to recruitment by moving
from a study-level recruitment focus to empowering patients and developing trust as the core
focus, which will require environmental change. The participants in this study demonstrated that
it is possible, even with their current resources, to create an environment conducive for
improving minority access to clinical trials.
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APPENDIX A
INTERVIEW GUIDE
1. Tell me about yourself.
a. How did you get into clinical trials?
Transition: First, I want to get a general sense of the wider picture related to recruitment in
terms of the societal and environmental landscape. Please answer this next question considering
this broader aspect.
2. What do you see playing a role in your recruitment efforts?
a. How about with minority recruitment?
b. What concerns do you have with what is happening with healthcare in this
country right now and how that could impact recruitment?
3. Talk to me about your organization’s mission.
4. Walk me through your organization’s approach to recruitment (in general).
a. What’s working? Not working?
b. If your organization had unlimited resources, what would you do differently to
make your organization the best it could possibly be with regards to minority
recruitment?
c. How does your organization engage with the community?
i. How responsive do patients seem to be with your outreach efforts?
ii. How have you changed what you do based on what you’ve learned?
5. What types of discussions are happening amongst your colleagues with regards to minority
recruitment?
a. Can you share an example of when one of your colleagues encouraged you to
focus on minority recruitment?
6. When tasked with recruiting for a new study, what is it like for you?
a. How do you react personally?
b. What about others on the team – what’s it like for them?
7. What are your perceptions with recruiting for clinical trials (in general)?
a. What about with minority recruitment?
8. What additional ideas do you have that we haven’t discussed that will help me better
understand what is involved when you specifically focus on minority recruitment?

201
Demographic Information
1.
2.
3.
4.

How many years of clinical research experience do you have?
How long have you been involved with promoting minority recruitment?
How long have you been with your current organization?
What is your current title?
a. In your role, do you speak directly with potential clinical trial participants?
5. [If answered ‘yes’ to question 4a only] Do you speak a language fluently other than English?
6. [If answered ‘yes’ to question 5 only] What other languages do you speak?
7. What is your gender?
8. From an ethnicity perspective, would you categorize yourself as Hispanic, Latino or Spanish
origin?
9. Which of the following racial designations best describes you? You can select one or more:
a. White
b. Black or African American
c. Asian
d. Native Hawaiian or Other Pacific Islander
e. American Indian or Alaska Native
10. What type of organization do you currently work for:
a. Dedicated research institution
b. Academic medical center/University hospital
c. Community physician/medical practice
11. Which of the following best describes the geographical area of your clinical trial setting?
a. Urban [within city limits of a metropolitan area’s central city]
b. Suburban [part of a metropolitan area that is not in that metropolitan area’s central
city]
c. Rural [not part of a metropolitan area]
12. What other funding outside of biopharmaceutical sponsors do you receive for conducting
clinical trials?
13. What are the therapeutic areas of the trials that you typically conduct?
14. Are racial/ethnic minorities included on your research team, specifically in the following
roles:
[Minority defined as a race and ethnicity other than non-Hispanic White]
a. Principal Investigator
b. Sub Investigator
c. Recruiter
d. Study coordinator
e. Study nurse
15. Is it common practice for minority recruitment goals to be set within your organization?
16. Are staff members required to take cultural competency training?
17. Approximately what percentage of your patients who participate in clinical trials are
minorities?
18. Does this reflect the population demographics in your community?
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APPENDIX C
RESEARCHER POSITIONING STATEMENT
Researchers recognize that their own background shapes their interpretation, and they
“position themselves” in the research to acknowledge how their interpretation flows from
their own personal, cultural, and historical experiences. Thus the researchers make an
interpretation of what they find, an interpretation shaped by their own experiences and
background. The researchers intent, then, is to make sense of the meanings others have
about the world (Creswell, 2013, p. 25).
As a result of being responsible for providing strategic direction or implementation
oversight of patient recruitment programs for pharmaceutical-sponsored clinical trials for more
than 10 years, I have first-hand experience and understanding of the pressures related to meeting
and exceeding recruitment timelines. These pressures are understandable, given the financial
impact tied to recruitment performance for sponsors, contract research organizations and
research sites. In my experience, considerations for inclusion of clinically relevant populations
related to race or ethnicity have historically been limited to a handful of studies in which
demographic-specific cohorts were the result of a mandate by the Food and Drug Administration.
The vast majority of trial participants are non-Hispanic white, even though industry
stakeholders and governmental agencies have recognized a need for greater diversity in
recruitment. More recently, I have engaged in discussions with diversity and inclusion leaders
whose roles are to improve diversity in the pharmaceutical-sponsored clinical trials in which they
participate. Unfortunately, they face some of the same barriers I have encountered when
attempting to implement a diversity strategy plan on a trial level. While they are in alignment on
the necessity of diversity inclusion, there is hesitation regarding the return on investment and the
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potential impact of time and cost on a trial. While that can be frustrating, I have an appreciation
for the difficulties of operationalizing diversity inclusion on a trial level.
I grew up in a non-diverse area and did not appreciate social injustice until becoming an
adult. In addition, my first-hand experiences with people in my life who have different values
and beliefs regarding utilization of the healthcare system from mine opened my eyes to
recognizing cultural and socio-economic differences that may impact their beliefs and attitudes
about healthcare. That is when I began developing a strong interest in how different cultures
assimilate healthcare information, healthcare disparities among minority cultures, and how to
address these disparities by providing culturally relevant education through multi-cultural
marketing initiatives. My professional background in clinical trial recruitment led to combining
my interest in multi-cultural marketing with opportunities for addressing inequalities by focusing
on improving access to clinical trials within diverse populations.
After reading the literature regarding minority recruitment in clinical trials, I was curious
about what motivates researchers who conduct industry-sponsored trials and who actively focus
on recruiting minority trial participants, since these researchers are not mandated to do so. I
assumed that it is not just one reason, but that many different factors could be at play, and the
socio-ecological model allowed for observing many elements in this regard. I did not want to
incorporate my preconceived thoughts into the study as to what the motivation or other elements
may be that are involved when researchers actively recruit minorities when not mandated to do
so. Therefore, the interview guide was carefully designed to be very broad to allow participants
to provide a wide view of their perceptions and experiences on this topic.
My professional background has afforded me experience with developing recruitment
strategies, including strategies specific to recruiting minority populations. I do not have
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experience working at a research site and hope that discussing the practical minority recruitment
experiences of individuals who work at research sites will deepen my knowledge in this area and
give me a better understanding of related activities that take place at a research site level. I would
like to be able to be a part of moving the needle from recognizing the problem, to discussing and
planning for change, to actually implementing a successful change initiative that will result in a
more proportionate demographic representation in biopharmaceutical-sponsored research.
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